Afya Limited
A Brazilian company that trains doctors and builds digital tools for them, from medical school through daily practice. Afya runs medical schools and residency-prep courses, and its apps include Whitebook, a clinical reference used at the bedside, and iClinic, software that manages a doctor's practice. The company formed in 2019 when medical-school group NRE Educacional merged with exam-prep specialist Medcel, and its name is the Swahili word for "health."
20-F · Fiscal year ended Dec 31, 2024 · SEC filing ↗
The original filing sections are available below.
RISK We are exposed to market risks in the ordinary course of our business, including the effects of interest rate changes and foreign currency fluctuations. We monitor market, credit and operational risks in line with the objectives in capital management, supported by the overs…
RISK We are exposed to market risks in the ordinary course of our business, including the effects of interest rate changes and foreign currency fluctuations. We monitor market, credit and operational risks in line with the objectives in capital management, supported by the oversight of our Board of Directors, in decisions related to capital management and to ensure their consistency with our objectives and assessment of risks. Information relating to quantitative and qualitative disclosures about these market risks is described below. 151 Table of Contents Interest Rate Risk Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Our exposure to the risk of changes in market interest rates relates primarily to cash equivalents, loans and financing and accounts payable to selling shareholders with floating interest rates. The following table demonstrates the sensitivity to a reasonably possible change in the current interest rates on cash equivalents, loans and financing and accounts payable to selling shareholders. With all variables held constant, our income before income taxes is affected through the impact on floating interest rate, as follows: Balance as of December 31, 2024 Index Base rate (amounts in R$ thousands, unless otherwise stated) Cash equivalents 883,327 CDI 106,358 Loans and financing (1,341,460) CDI (184,413) Loans and financing (8,209) TJLP (610) Accounts payable to selling shareholders (385,429) CDI (46,766) Accounts payable to selling shareholders (125,276) SELIC (15,221) Net exposure (140,652) Increase in basis points +75 +150 (amounts in R$ thousands, unless otherwise stated) Effect on profit before tax (7,324) (14,648) For further information, see note 12.4.1 to our audited consolidated financial statements included elsewhere in this annual report. Foreign Currency Risk Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. Our exposure to the risk of changes in foreign exchange rates relates to cash and cash equivalents denominated in U.S. dollars in the amount of R$21.6 million as of December 31, 2024. See note 12.4.1 to our audited consolidated financial statements for a sensitivity analysis of the impact of a hypothetical 10% change in the exchange rate variation on our cash and cash equivalents as of December 31, 2024. Credit Risk Credit risk is the risk that a counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. We are exposed to credit risk from its operating activities (primarily trade receivables) and from its financing activities, including cash and cash equivalents. Customer credit risk is managed by us based on the established policy, procedures and control relating to customer credit risk management. Outstanding customer receivables are regularly monitored. Credit risk from balances with banks and financial institutions is managed by the treasury department in accordance with our policy. Investments of surplus funds are made only with approved counterparties and within limits assigned to each counterparty. The carrying amounts of financial assets are the maximum exposure to credit risk for the components of the statements of financial position on December 31, 2024 and 2023. Liquidity Risk Our Management has responsibility for monitoring liquidity risk. In order to achieve the our objective, Management regularly reviews the risk and maintains appropriate reserves, including bank credit facilities with first tier financial institutions. Management also continuously monitors projected and actual cash flows and the combination of the maturity profiles of the financial assets and liabilities. 152 Table of Contents The main requirements for financial resources used by us arise from the need to make payments for suppliers, operating expenses, labor and social obligations, loans and financing and accounts payable to selling shareholders. For more information, see “Item 5. Operating and Financial Review and Prospects—B. Tabular Disclosure of Contractual Obligations.”
A. Reserved B. Capitalization and Indebtedness Not applicable. C. Reasons for the Offer and Use of Proceeds Not applicable. D. Risk Factors Summary of Risk Factors An investment in our Class A common shares is subject to several risks, including risks relating to our business an…
A. Reserved B. Capitalization and Indebtedness Not applicable. C. Reasons for the Offer and Use of Proceeds Not applicable. D. Risk Factors Summary of Risk Factors An investment in our Class A common shares is subject to several risks, including risks relating to our business and industry, risks relating to Brazil and risks relating to our Class A common shares. The following list summarizes some, but not all, of these risks. Please read the information in the section entitled “Risk Factors” for a more thorough description of these and other risks. Certain Risks Relating to Our Business and Industry · We face significant competition in each program we offer. If our competition increases or if we fail to compete efficiently, we may lose market share and our profitability may be adversely affected. We compete with various public and private post-secondary education institutions, including distance learning institutions and remote locations. If our competition increases due to lighter regulatory constraints or otherwise, or if we fail to compete effectively, our business, results of operations and financial condition could be materially affected. 4 Table of Contents · Changes to the rules or delays or suspension of tuition payments made through FIES may adversely affect our cash flows and our business. · If we lose the benefits of federal tax exemptions provided under the PROUNI program, our business, financial condition and results of operations may be materially adversely affected. We may be disqualified from the PROUNI program and lose our tax exemptions if we do not comply with certain requirements. · An increase in delays and/or defaults in the payment of tuition fees may adversely affect our income and cash flows. · We may face challenges in identifying and acquiring new medical higher education institutions, which could hinder our strategic and financial goals. Additionally, difficulties in effectively integrating and managing an increasing number of acquisitions may adversely affect our strategic objectives. We aim to expand our operations by acquiring medical higher education institutions and healthtech companies, including potentially significant and strategically relevant acquisitions. However, we cannot guarantee the identification or acquisition of suitable medical education institutions on favorable terms or at all. Additionally, integrating acquired companies may present challenges, such as managing a larger, geographically dispersed workforce, implementing uniform controls, procedures, and policies, and incurring high or unexpected integration costs. · We may require additional funds to continue our expansion strategy. If we are unable to obtain adequate financing on favorable terms to complete any potential acquisition and implement our expansion plans, our growth strategy may be materially and adversely affected. If adequate funds are unavailable or are not available on acceptable terms, we may be unable to fund our expansion, capitalize on acquisition opportunities, develop or enhance our product and service portfolio, or respond to competitive pressures, which could have a material adverse effect on our business, results of operations and financial condition. · Our revenues are highly concentrated in the tuition fees we charge for our medical courses and other health sciences programs. Any adverse economic, market or regulatory factors affecting such medical courses and health sciences programs could decrease demand, which could materially adversely affect us. Economic, market or regulatory factors affecting either the amount of tuition fees we are able to charge for the medical courses and health sciences programs we offer or the ability of our students to pay such tuition fees could result in significantly decreased demand for our services. Certain Risks Relating to Brazil · The Brazilian federal government has exercised, and continues to exercise, significant influence over the Brazilian economy. This involvement as well as Brazil’s political and economic conditions could harm us and the price of our Class A common shares. The Brazilian government’s actions to control inflation and other policies and regulations have often involved increases or decreases in interest rates, changes in fiscal policies, wage and price controls, currency devaluations, capital controls, import and export restrictions, among others. Uncertainty over whether the Brazilian federal government will implement reforms or changes in policy or regulation affecting these or other factors in the future may affect economic performance and contribute to economic uncertainty in Brazil. · Economic uncertainty and political instability in Brazil may harm our business and the price of our Class A common shares. Political crises have affected and continue to affect the confidence of investors and the general public, which have historically resulted in economic deceleration and heightened volatility in the securities offered by companies with significant operations in Brazil. · Exchange rate instability may have adverse effects on the Brazilian economy, us and the price of our Class A common shares. The Brazilian government has implemented various economic plans and used various exchange rate policies, including sudden devaluations, periodic mini devaluations (during which the frequency of adjustments has ranged from daily to monthly), exchange controls, dual exchange rate markets and a floating exchange rate system. In addition, domestic and international reactions to restrictive economic policies could have a negative impact on the Brazilian economy. 5 Table of Contents · Infrastructure and workforce deficiency in Brazil may impact economic growth and have a material adverse effect on us. Growth is limited by inadequate infrastructure, including potential energy shortages and deficient transportation, logistics and telecommunication sectors, general strikes, the lack of a qualified labor force, and the lack of private and public investments in these areas, which limit productivity and efficiency. Certain Risks Relating to Our Class A Common Shares · An active trading market for our Class A common shares may not be sustainable. If an active trading market is not maintained, investors may not be able to resell their shares and our ability to raise capital in the future may be impaired. Although our Class A common shares are listed and being traded on the Nasdaq Global Select Market, an active trading market for our shares may not be maintained. The stock market in general has experienced substantial price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of particular companies affected. · The concentration of ownership and voting power in Bertelsmann, our controlling shareholder, limits your ability to influence corporate matters. Bertelsmann, our controlling shareholder, owns 77.8% of our outstanding Class B common shares as of the date of this annual report, which, together with its ownership of 57.0% of our outstanding Class A common shares, represent approximately 67.1% of our outstanding share capital and 75.8% of the voting power of our outstanding share capital, and, together with the Esteves Family, controls all matters requiring shareholder approval. This concentration of ownership and voting power limits your ability to influence corporate matters. The decisions of Bertelsmann and the Esteves Family on these matters may be contrary to your expectations or preferences, and they may take actions that could be contrary to your interests. So long as Bertelsmann and the Esteves Family continue to beneficially own a sufficient number of Class B common shares, even if they beneficially own significantly less than 50% of our outstanding share capital, acting together, they will be able to effectively control the outcome of all decisions at our shareholders’ meetings. · Class A common shares eligible for future sale may cause the market price of our Class A common shares to drop significantly. The market price of our Class A common shares may decline as a result of sales of a large number of our Class A common shares in the market (including Class A common shares issuable upon conversion of Class B common shares) or the perception that these sales may occur, including by our controlling shareholder. · There can be no assurance that we will not be a passive foreign investment company, or PFIC, for any taxable year, which could subject United States investors in our Class A common shares to significant adverse U.S. federal income tax consequences. Based on the composition of our income and assets and the value of our assets, including goodwill (the implied value of which we estimate based on the price of our Class A common shares), we believe that we were not a PFIC for the taxable year of 2024. However, because we hold a substantial amount of cash (relative to the assets shown on our balance sheet) and because our PFIC status for any taxable year will depend on the composition of our income and assets and the value of our assets from time to time (which may be determined, in part, by reference to the market price of our Class A common shares, which could be volatile), there can be no assurance that we will not be a PFIC for any taxable year. Certain Risks Relating to Our Business and Industry We face significant competition in each program we offer. If our competition increases or if we fail to compete efficiently, we may lose market share and our profitability may be adversely affected. We compete with various public and private post-secondary education institutions, including distance learning institutions and we expect existing competitors and new entrants to revise and improve their business models constantly in response to challenges from competing businesses, including ours. Our competitors may offer programs or courses similar to or better than those offered by us, have access to more funds, be more prestigious or well-regarded within the academic community, have more conveniently located campuses with better infrastructure, introduce new or improved delivery of online education and technology-enabled services that we cannot match or exceed in a timely or cost-effective manner, or charge lower tuition. In any of these cases, our ability to grow our revenue and achieve profitability could be compromised. 6 Table of Contents Particularly with our Continuing Education segment, we have recently experienced increasing competition from traditional education institutions that previously had been limited to providing undergraduate courses and have since begun to offer graduate programs. Increased competition in the graduate program landscape within our Continuing Education segment may result in pricing pressure for us in terms of the percentage of tuition and fees we are able to negotiate. The competitive landscape may also result in longer and more complex sales cycles with prospective students or a decrease in our market share, any of which could negatively affect our revenue and future operating results and our ability to grow our business. For undergraduate programs, the expansion of medicine courses in Brazil is subject to restrictive requirements, under the “Mais Médicos” program. Among the criteria that support the creation of medical schools seats, two relevant aspects are (i) the importance of these new openings in a specified region, and (ii) the sufficiency of the current medical infrastructure in both public regional hospitals and in the applicant medical institution in order to obtain government authorization. In connection with these requirements, and in order to evaluate the impacts of the opening of medical courses in Brazil, on April 5, 2018, MEC issued Ordinance No. 328/2018, pursuant to which, among other measures, MEC imposed a five-year suspension on the granting of authorizations for the creation of new medical education courses. This ordinance was revoked on April 5, 2023 by MEC through Ordinance No. 650/2023. However, following the enactment of Ordinance No. 328/2018, certain educational institutions began to judicially challenge these restrictions before Brazilian courts and sought to compel MEC to receive and review requests (i) for new medicine courses, not observing the public call requirements set forth in Article 3 of Law No. 12,871/2013, or the “Mais Médicos” Law, and (ii) for an increase in the number of medicine seats for existing undergraduate courses, in each case by alleging that these rules amounted to an undue restriction on freedom of competition. In response to those judicial claims, the Brazilian National Association of Private Universities (Associação Nacional das Universidades Particulares) filed the Declaratory Action of Constitutionality (Ação Declaratória de Constitucionalidade) No. 81 towards the Brazilian Federal Supreme Court (Supremo Tribunal Federal), or the Brazilian Supreme Court, to discuss the constitutionality of Article 3 of the “Mais Médicos” Law. Brazil’s Medicine Federal Council (Conselho Federal de Medicina, or CFM) manifested in the Declaratory Action of Constitutionality No. 81 against the judicial authorization of new medical courses or increase in the number of medicine seats. On August 8, 2023, the Brazilian Supreme Court issued a preliminary ruling affirming the constitutionality of Article 3, which requires new medical courses to adhere to the established public call process. To address numerous administrative proceedings before MEC arising from judicial decisions outside the Mais Médicos program, the Court limited the effects of its ruling, allowing these proceedings to continue under MEC’s review. Specifically, the Court directed MEC to assess cases that have progressed beyond the documentary review phase for compliance with decision-making standards set by the Department of Regulation and Supervision of Higher Education (SERES) under Ordinance No. 531/2023. However, there is a risk that these standards may be relaxed as a result of CNE rulings or future judicial decisions that set aside the applicability of Ordinance No. 531. As of May 9, 2024, the Attorney General’s Office (Advocacia-Geral da União, or AGU) reported that MEC had 206 requests for new courses or increase in the number of medicine seats under analysis, of which 11 proceedings were already suspended pursuant to court decisions, resulting in a total of 195 proceedings pending review. As a result of the foregoing, our revenues and profitability may decrease. We cannot assure you that we will be able to compete successfully against our current or future competitors. If we are unable to maintain our competitive position or otherwise respond to competitive pressures effectively, we may lose our market share, our profits may decrease and we may be adversely affected. For more information, see “Item 4. Information on the Company—Business Overview—Regulatory Overview.” We may not be able to update, improve or offer the content of our existing programs to our students on a cost-effective basis, which may materially and adversely affect our ability to attract and retain students. To differentiate ourselves and remain competitive, we must continually update our courses and develop new educational programs, including through the adoption of new technological tools. We may not be able to introduce new educational programs at the same pace as our competitors or at the pace required by the market. As such, we are subject to significant execution risk given the technological needs, the expectations of our customers and market standards change rapidly, especially with the increasing adoption of artificial intelligence (AI) technologies. Additionally, updates to our current courses and the development of new educational programs may not be readily accepted by our students or by the market. If we do not adequately modify our educational programs in response to market demand, whether due to financial restrictions, unusual technological changes or other factors, or if our students do not respond positively to our innovations, our ability to attract and retain students may be impaired and we may be materially and adversely affected. 7 Table of Contents If we are not able to attract and retain students, or are unable to do so without decreasing our tuition fees, our revenues may decline. The success of our business depends primarily on the number of students enrolled in our programs and the tuition fees that they pay. Our ability to attract and retain students depends mainly on the tuition fees we charge, the convenient locations of our facilities, the infrastructure of our campuses and the quality of our programs as perceived by our existing and potential students. These factors are affected by, among other things, our ability to (i) respond to increasing competitive pressures, (ii) develop our educational systems to address changing market trends and demands from post-secondary education institutions and students, (iii) develop new programs and enhance existing programs to respond to changes in market trends and student demands, (iv) adequately prepare our students for careers in their chosen professional occupations, (v) successfully implement our expansion strategy, (vi) manage our growth while maintaining our teaching quality and (vii) effectively market and sell our programs to a broader base of prospective students. If we are unable to continue to attract new students to enroll in our programs and to retain our current students without significantly decreasing tuition, for example as a result of changes in our students’ preferences due to economic uncertainty or volatility, our revenues and our business may decline and we may be adversely affected. If we fail to maintain the quality of our educational programs, our reputation, student enrollment, and financial performance may suffer. The perceived quality of our medical education programs, including residency preparation, specialization test preparation and graduate courses within our Continuing Education segment, is critical to attracting and retaining students. Any decline in academic standards, deficiencies in faculty expertise, ineffective curriculum design, inadequate infrastructure, or failure to adapt to evolving industry and regulatory requirements could diminish our competitive position. Additionally, as we expand our offerings and delivery methods—including digital and in-person content—ensuring consistency and effectiveness across platforms is essential. Negative student outcomes, such as lower test pass rates or dissatisfaction with career preparedness, could also harm our reputation and reduce demand for our Continuing Education programs. If we are unable to sustain high-quality educational services, student enrollment may decline, adversely impacting our revenues, growth prospects, and overall business. We may be adversely affected if the government changes its investment strategy in education. According to Brazilian Federal Law No. 9,394/1996, as amended, providing education is a duty of the government and of the family, and private education is permitted subject to the terms set forth by the Brazilian Constitution and applicable laws and regulations. Certain public institutions may have certain competitive advantages over us in the admissions process, as they do not charge tuition fees and may be perceived as more prestigious than private institutions. However, the highly limited number of available positions and the intensely competitive nature of the admission process to public institutions significantly restrict student access to these institutions. Nevertheless, the Brazilian government may implement policy changes that heighten the competition by (i) increasing public investment in primary and post-secondary education, expanding available positions and enhancing the quality of education provided by public institutions; and (ii) reallocating resources from centers of excellence and research to public post-secondary education institutions. Additionally, the introduction or expansion of affirmative action admission policies by federal and state institutions, based on socioeconomic status, race or ethnicity, could also further intensify competition in the industry. Any significant policy change that alters the level of public investment in education may adversely affect us. As of the date of this annual report, our management is not aware of any pending policy changes or proposed legislation that would impact public investment in Brazil’s education sector. Changes to the rules or delays or suspension of tuition payments made through FIES may adversely affect our cash flows and our business. Some of our students finance their tuition fees through the Higher Education Student Financing Fund (Fundo de Financiamento ao Estudante do Ensino Superior, or FIES) created by the Brazilian federal government, and operated through the National Fund for Educational Development (Fundo Nacional de Desenvolvimento da Educação, or FNDE), which offers financing to low-income students enrolled in undergraduate programs in private higher education institutions. As of the date of this annual report, we have adhered to FIES as most recently amended by the Brazilian federal government. As revised, FIES provides financial support for low-income students throughout Brazil, in particular in the North, Northeast and Midwest regions. As a result, we have exposure to risks associated with delays in the transfer of monthly tuition payments from the FIES program operated by the Brazilian federal government. 8 Table of Contents Should (i) the Brazilian federal government terminate or reduce the transfer of monthly payments to our institutions that participate in FIES, (ii) we fail to meet the requirements for participation in the programs, or our students benefiting from FIES fail to meet the requirements for enrollment in the programs, or (iii) the Brazilian federal government extends the term to make reimbursements under FIES or adversely change their rules, our results of operations and cash flow may be materially adversely affected. We may also experience a decline in revenues and a decline in the number of students at our campuses from the FIES program. Moreover, recent changes to the rules to renew FIES contracts, as well as the shutdown of the system to enter into new student financing agreements, may negatively affect the number of students enrolled in our courses, causing a reduction in our revenues. For more information regarding the changes to FIES contracts, see “Item 4. Information on the Company—Business Overview—Regulatory Overview.” The taxation system in Brazil may undergo significant changes, including as a result of the upcoming tax reform bill, potentially leading to material changes in taxation of our products and services that could adversely affect our results of operations and financial condition. Taxation in Brazil is complex, with a myriad of regulations, exemptions, and amendments, that make it challenging for businesses to navigate and anticipate their tax obligations. As part of a broad tax reform effort, Constitutional Amendment Proposal No. 45/2020 was approved and subsequently promulgated in Constitutional Amendment No. 132, on December 20, 2023, which proposes a new tax to substitute the Social Contribution Tax on Gross Revenue (Programa de Integração Social, or PIS), and the Social Security Financing Tax on Gross Revenue (Contribuição para o Financiamento da Seguridade Social, or COFINS), (and other state and municipal taxes). In an effort to implement Constitutional Amendment No. 132, the Brazilian government enacted Complementary Law No. 214/2025 on January 16, 2025, sanctioning Complementary Bill No. 68/2024. This law introduced the Goods and Services Tax (Imposto sobre Bens e Serviços, or IBS), the Social Contribution on Goods and Services (Contribuição Social sobre Bens e Serviços, or CBS), and the Selective Tax (Imposto Seletivo, or IS). The CBS replaces PIS and COFINS as part of a broader tax reform. Notably, the CBS maintains a zero rate for educational institutions participating in the PROUNI program, preserving the related tax benefits. Additionally, regarding the IBS, which replaces the current Service Tax (ISS), a 60% reduction in the applicable rate for the education sector has been granted. However, the final rate still depends on regulation by the States and Municipalities, with a reference percentage estimated at 17.7%. It is worth noting that the current average ISS rate is 3%, which could impact the institution’s overall tax burden. Any increase in tax rates could elevate the cost of our products and services, thereby reducing profitability if we could not timely pass these adjustments on to consumers. On the other hand, a decrease in tax rates might positively impact margins, but could also lead to intensified competition as other market players might adjust their own pricing strategies. The effects of these proposed tax reform and any other changes that result from enactment of additional tax reforms have not been, and cannot be, quantified. However, some of these measures, if enacted, may result in increases in our overall tax burden, which could negatively affect our overall financial performance. Moreover, on December 27, 2024, Law 15,079/2024 was enacted, establishing the implementation of the OECD Pillar Two global minimum tax in Brazil, effective as of January 1, 2025. Law 15,079/2024 aligns the Brazilian tax legislation to the OECD’s Global Anti-Base Erosion (GloBE) rules by introducing a minimum effective taxation of 15% through an additional Social Contribution tax on Net Profit (Contribuição Social sobre o Lucro Líquido, or “CSLL”). This regulation applies to multinational groups within the scope of the OECD’s GloBE rules, specifically those whose ultimate parent entity reported annual consolidated revenues of at least €750 million in at least two of the four fiscal years immediately preceding the year under review. 9 Table of Contents The rules are designed to ensure that the additional CSLL qualifies as a Qualified Domestic Minimum Top-up Tax (QDMTT) under the OECD Inclusive Framework, subjecting Brazilian entities to a minimum tax rate of 15%. Although these rules do not apply to the fiscal year ended December 31, 2024, we are currently assessing their potential effects on our consolidated financial statements. However, the implementation of the Pillar Two regulations could result in an increase in our overall tax burden and adversely affect our profitability. In turn, this additional cost may limit our ability to invest in growth initiatives, or require us to raise prices in order to maintain margins, which could affect our competitiveness relative to other market participants who are not subject to the same regulatory framework. As a result, our market position, business, and operating results could be affected. While the financial impact has not yet been quantified, we are taking steps to ensure compliance with the new tax requirements. On March 28, 2025, we filed a writ of mandamus with the Brazilian Federal Courts challenging the enforceability of the newly enacted additional CSLL. The action is grounded on constitutional and statutory arguments, and we are seeking a preliminary injunction in the Federal Court of Appeals of the Sixth Region (TRF6), to prevent the collection of the additional CSLL, which is scheduled to disburse in 2026 with respect to the 2025 fiscal year. If we lose the benefits of federal tax exemptions provided under the PROUNI program, our business, financial condition and results of operations may be materially adversely affected. Some of our students participate in the University for All Program (Programa Universidade para Todos, or PROUNI program). Through the PROUNI program, the Brazilian federal government grants a number of full and partial scholarships to low-income undergraduate students in private higher education institutions. As a result of our participation in the PROUNI program, we benefit from certain federal tax exemptions relating to undergraduate’s and associate’s degree programs, such as (i) income tax, (ii) PIS, (iii) COFINS, and (iv) CSLL, regarding our revenues from undergraduate and associate programs. We may be disqualified from the PROUNI program and lose our tax exemptions if we do not comply with certain requirements, such as providing total or partial scholarships for low-income students eligible for the program, and submitting to MEC semi-annual records of attendance, achievement and dropout of students receiving scholarships, among others. See “Item 4. Information on the Company—Business Overview—Regulatory Overview.” If we lose our tax exemptions or are unable to comply with other, more stringent requirements that may be introduced in the future, our business, financial condition and results of operations could be materially adversely affected. There is a risk that additional changes in tax laws may prohibit, interrupt or modify the use of existing tax exemptions, and we cannot assure you that we will fully maintain such tax and other benefits related to PROUNI in the event the tax laws are amended further. In connection with the broader tax reform in Brazil, Bill No. 3,887/2020, which proposed revoking PROUNI-related exemptions under the previous tax regime, is no longer applicable. However, future regulatory developments or additional legislative changes could still impact the tax benefits available to us under the PROUNI program. Any suspension, accelerated default, repayment or inability to renew our tax exemptions may have an adverse effect on our results of operations. If we lose our tax exemptions and incentives, if we are unable to comply with future requirements or if changes in the law limit our ability to maintain these tax benefits, our business, financial condition and results of operations may be significantly and adversely affected. Any change or review of the tax treatment of our activities, or the loss or reduction in tax benefits on the sale of books (including digital content) may materially adversely affect us. The Brazilian Federal Constitution, in Article 150, grants tax immunity for activities related to the production, sale, and resale of books. In this sense, this activity, previously carried out by Medcel, which was merged by Afya Brazil in 2024, is not taxed by the federal VAT (tax on industrial activity, or “IPI”), the state VAT (tax on sale or resale of products, or “ICMS”) and the municipal VAT (tax on services, or “ISS”). According to Brazilian federal law No. 10,865/2004, the Company also benefited from a zero-tax rate on Federal Social Contributions, PIS and COFINS, which are calculated on gross revenue. The tax reform ensured tax immunity for the taxes provided for in Article 150 of the Federal Constitution, applying exclusively to the IBS. However, no differentiated provisions were established regarding the CBS. Nevertheless, infra-constitutional legislation, particularly Complementary Law No. 214/2025, included the CBS within the scope of the immunity granted by Article 150 of the Federal Constitution, as stated in its Article 9. 10 Table of Contents If the Brazilian government or tax authority or the Brazilian superior courts decide to change or review the tax treatment for the production or sales of books (including digital books and e-readers), and we are unable to pass any cost increase onto our students, our results may be materially adversely affected. We may be held liable for extraordinary events that may occur at our campuses, which may have an adverse effect on our image and, consequently, our results of operations. We may be held liable for the actions or omissions of officers, directors, professors or other employees at our campuses, including allegations of non-compliance with MEC legislation and regulations. Accidents, injuries or other damages affecting students, professors, other employees, or third parties at our campuses could lead to claims of negligence, inadequate supervision, or other liability. Injuries could be caused by or arise from the actions or negligence of our students, employees, contractors or visitors on our premises, including due to failures in our in-access control and security systems or infrastructure issues. If any such event occurs, our facilities may be perceived as unsafe, potentially deterring students from enrolling or attending our schools. We may also face claims alleging that officers, directors, professors or other employees committed moral or sexual harassment or other unlawful acts, and we may be subject to legal proceedings by current and/or former employees alleging breaches of applicable labor laws. Even if unsuccessful, these claims may cause negative publicity, reduce enrollment numbers, increase student attrition rates, entail substantial expenses and divert the time and attention of our management, materially adversely affecting our results of operations and financial condition. Moreover, we operate clinics, outpatient facilities, and laboratories where physicians and students perform procedures. Non-compliance with health and safety standards, regulations, and laws can result in serious consequences, including death or physical injury to physicians, students, patients and other persons on our premises. We cannot assure you that we will be at all times able to comply with all such regulations or guarantee the safety of all persons on our premises, including patients. Additionally, infrastructure vulnerabilities can lead to adverse events with significant impacts on our reputation to the extent that they may expose students and faculty to physical injury. As of the date of this annual report, we have dozens of campuses spread across Brazil, and we cannot assure you that all of them will be adequately conserved and have safety practices that are appropriately observed. Structural problems in any such facilities may include faulty floors and ceilings, premises that are intermittently closed due to lack of safety or appropriate licenses, areas prone to flooding, exposed electrical wiring and other issues that may increase the risk of personal injury to our students, faculty and other persons on our premises. If any such events were to occur, our reputation would be materially and adversely affected, which could cause significant adverse effects on our results of operations and financial condition. Our insurance coverage may not cover certain indemnifications we may be required to pay, be insufficient to cover these types of claims, or may not cover certain acts or events. We may also not be able to renew our current insurance policies under the same terms. Such liability claims may affect our reputation and harm our financial results. See “Item 4. Information on the Company—Business Overview—Insurance.” We cannot guarantee that our suppliers will not engage in improper practices, including inappropriate labor practices. To meet the needs of our students and offer greater comfort and quality in all areas and aspects of our activities, we depend on service providers and suppliers for services such as cleaning, surveillance, telemarketing and security. In the event that our service providers engage in such improper business practices, our customers’ perception of our business may be adversely affected, which may adversely affect our business, results of operations and our reputation. For example, we may be adversely affected if these third-party service providers and suppliers do not meet their obligations under Brazilian labor laws and with the obligations and guidelines established in our Code of Ethics and Conduct and also in our services agreements for providers and suppliers, including with respect to supplying appropriate protective equipment or training to employees that are designated to work on our premises. According to Brazilian labor law, we may be liable to the employees of these service providers and suppliers for labor obligations of these service providers and suppliers to the extent such service providers and suppliers fail to indemnify such employees pursuant to court orders, and we may also be fined by the relevant authorities. This risk is particularly relevant if these suppliers are involved in sensitive labor issues, such as violations of human rights, discriminatory acts, child labor and direct or indirect use of forced labor or modern slavery and for which we may be held liable in civil, labor, criminal and administrative proceedings, including for damages and remediation costs. As a result, we may face difficulties in obtaining or maintaining operating licenses. Any such litigation could impact our customers’ perception of our business, and adverse decisions may compel us to disburse material amounts in connection therewith, which may adversely affect our business, results of operations and our reputation. 11 Table of Contents We are subject to anti-corruption, anti-bribery and anti-money laundering laws and regulations. We operate in jurisdictions that have a high risk for corruption and we are subject to various anti-corruption, anti-bribery and anti-money laundering laws and regulations, including the Brazilian Federal Law No. 12,846/2013, also known as the Clean Company Act (and Decree No. 11,129/2022 that regulates the Clean Company Act), Brazilian Federal Law No. 9,613/1998, as amended by Brazilian Federal Law No. 12,683/2012, and Brazilian Federal Law No. 8,429/1992, as amended by Brazilian Federal Law No. 14,230/2022, in addition to the United States Foreign Corrupt Practices Act of 1977, as amended, or the FCPA. Both the Clean Company Act and the FCPA impose liability against companies who engage in bribery of government officials, either directly or through intermediaries. Anti-corruption laws are interpreted broadly and prohibit us and our collaborators from authorizing, offering, or directly or indirectly providing improper payments or benefits to recipients in the public or private sector. Although we strongly condemn the practice of corruption and bribery by promoting a culture of ethics and through our integrity program as provided for in our Code of Ethics and Conduct and Compliance, Anti-Corruption and Fraud Policy and in the whistleblowing channel, we or our collaborators may have direct and indirect interactions with government agencies and state-affiliated entities and universities in the course of our business. We use third-party collaborators, and strategic partners, law firms, and other representatives for regulatory compliance, patent registration, deregulation advocacy, field testing, and other purposes. We can be held liable for the corrupt or other illegal activities of these third-party collaborators, our employees, representatives, contractors, partners, and agents, even if we do not explicitly authorize such activities. Anti-money laundering, anti-bribery, anti-corruption and sanctions laws and regulations to which we are subject require us, among other things, to conduct full customer due diligence (including sanctions and politically exposed person screening) and to keep our customer, account and transaction information up to date. We have implemented and are in the process of reviewing our policies and procedures detailing what is required from those responsible, but all such policies may not be completed or may not be fully in effect as of the date of this annual report (in particular, our policies relating to sanctions laws and regulations). In addition, we rely heavily on our employees to assist us by spotting such illegal and improper activities and reporting them, and our employees have varying degrees of experience in recognizing criminal tactics and understanding the level of sophistication of criminal organizations. In addition, we rely upon our relevant counterparties to a large degree to maintain and appropriately apply their own appropriate compliance measures, procedures and internal policies. Accordingly, there can be no assurance that all of our employees, representatives, contractors, partners, or agents will comply with these laws at all times. If we are unable to apply the necessary scrutiny and oversight of employees, third parties to whom we outsource certain tasks and processes or counterparties, we increase the risk of regulatory breach. Violations of — or even accusations of or associations with violations of — anti-corruption, anti-bribery and anti-money laundering laws and regulations could result in criminal liability, administrative and civil lawsuits, significant fines and penalties (including being added to “blacklists” that would prohibit certain parties from engaging in transactions with us), forfeiture of significant assets and reputational harm. Non-compliance with these laws could subject us to whistleblower complaints, investigations, sanctions, settlements, prosecution, injunctions, suspension and debarment from contracting with certain governments or other persons, the loss of export privileges, reputational harm, adverse media coverage, and other collateral consequences. If any subpoenas or investigations are launched, or governmental or other sanctions are imposed, or if we do not prevail in any possible civil or criminal litigation, our business, results of operations, and financial condition could be materially harmed. In addition, responding to any action will likely result in a materially significant diversion of management’s attention and resources and significant defense costs and other professional fees. Enforcement actions and sanctions could further harm our reputation, business, results of operations, and financial condition. If any person in the Cayman Islands knows or suspects, or has reasonable grounds for knowing or suspecting that another person is engaged in criminal conduct or money laundering, or is involved with terrorism or terrorist financing and property, and the information for that knowledge or suspicion came to their attention in the course of business in the regulated sector, or other trade, profession, business or employment, the person will be required to report such knowledge or suspicion to (i) the Financial Reporting Authority (“FRA”) of the Cayman Islands, pursuant to the Proceeds of Crime Act (As Revised) of the Cayman Islands, if the disclosure relates to criminal conduct or money laundering, or (ii) a police officer of the rank of constable or higher, or the FRA, pursuant to the Terrorism Act (As Revised) of the Cayman Islands, if the disclosure relates to involvement with terrorism or terrorist financing and property. Such a report shall not be treated as a breach of confidence or of any restriction upon the disclosure of information imposed by any enactment or otherwise. 12 Table of Contents We are subject to environmental laws and regulations, which may become more stringent in the future and increase our obligations and capital expenditures with respect to their compliance. We are subject to several environmental laws and regulations at the municipal, state and federal levels, and noncompliance may result in significant penalties and liabilities. Our operations are subject to extensive environmental laws and regulations enforced by governmental agencies and regulatory bodies, which have the authority to impose administrative, civil and criminal sanctions. Any violations of these laws and regulations could result in the imposition of criminal and administrative sanctions, as well as civil liability, seeking redress for alleged environmental damages and damages to third parties. Environmental infractions may lead to administrative sanctions, including, among other consequences, fines ranging from R$50 to R$50 million, the revocation of our licenses and authorizations, or the temporary or permanent suspension of our activities. There is no statutory limit to the amount courts may award to cover the costs of remediation in the case of civil liability or, if the environmental damage cannot be repaired, the payment of an indemnity. Additionally, claims for environmental damages are not subject to a statute of limitations. The enactment of more stringent laws and regulations or more stringent interpretations of existing laws and regulations may force us to increase our capital expenditures relating to environmental compliance, therefore diverting funds from previously planned investments. These changes could have a material adverse effect on us. Governmental agencies or other authorities may also significantly delay or deny the issuance of permits and authorizations required for our operations, preventing us from making constructions and improvements at our campuses. Additionally, we have environmental compliance obligations under the loan agreement executed with the International Finance Corporation (IFC) and under the debentures’ issuance. Any failure to comply with these obligations could trigger events of default, which may result in the acceleration of these financial agreements, requiring us to make immediate repayments that could materially impact our financial condition. See “Item 5. Operating and Financial Review and Prospects—B. Liquidity and Capital Resources—Indebtedness.” In addition, the improper disposal of solid waste, as well as accidents during waste transportation could also result in administrative, civil and criminal penalties. Under the strict and joint environmental liability framework, we may be held responsible for environmental damages caused by third parties hired for waste collection, transportation and final disposal, even if we comply with contractual and regulatory obligations in outsourcing such services. Furthermore, Brazilian Federal Law No. 8,501, enacted on November 30, 1992, establishes regulations for the use of unclaimed cadavers for educational and scientific purposes by medical institutions. Institutions must comply with documentation and requirements established by the referred law. Noncompliance with these regulations may result in administrative, civil, criminal penalties, and reputational damage. We are subject to supervision by MEC and, consequently, may suffer sanctions as a result of non-compliance with any regulatory requirements. Brazilian Federal Law No. 10,861/2004, regulated by Decree No. 9,235/2017, implemented the activities of supervision of post-secondary education entities and courses in the Brazilian federal education system. MEC’s SERES is responsible for the regular and special supervision of the corresponding courses and programs. Regular supervision derives from complaints and allegations by students, parents and faculty members, as well as by public entities and the press. These complaints and allegations involve specific cases of entities with courses showing evidence of irregularities or deficiencies. We are subject to those complaints and representations. Special supervision, on the other hand, may be commenced by MEC itself, based on its post-secondary education regularity and quality standards, and involves more than one course or entity, grouped according to the criteria chosen for the special supervision. These criteria may include unsatisfactory results in the National Student Performance Exam (Exame Nacional de Desempenho de Estudantes, or ENADE) and the Difference Indicator between Expected and Actual Performance (Indicador de Diferença entre os Desempenhos Observado e Esperado), among other quality indicators, the history of course evaluations by INEP, as well as compliance with specific legal requirements as, for example, the minimum ratio between faculty members with master’s or doctorate degrees or certain mandatory digitization requirements with respect to academic documents for our students under MEC’s recent digital academic collection rules. Administrative irregularities can include, among others: (i) unlicensed or irregular post-secondary courses; (ii) any outsourcing of post-secondary education activities; (iii) the failure to file a re-accreditation or recognition or renewal request with respect to post-secondary education courses within the time periods enacted by MEC pursuant to Decree No. 9,235/2017; (iv) failure to comply with the rules and requirements for maximum occupancy of authorized vacancies approved by MEC; and (v) failure to comply with any penalties imposed by MEC. 13 Table of Contents If MEC concludes, as part of its supervisory activities, that an irregularity constitutes an imminent risk or threat to students or the public interest, it may impose the following measures on the relevant educational institution for a period to be determined by SERES: (i) suspend the admission of new students; (ii) suspend the offering of undergraduate or graduate lato sensu courses; (iii) suspend the institution’s discretionary ability to, among other things, create new post-secondary courses and establish course curricula, if applicable; (iv) suspend the license to establish new distance learning programs; (v) override any ongoing regulatory requests filed by the institution and prohibit new regulatory requests; (vi) suspend participation in FIES; (vii) suspend participation in PROUNI; and (viii) suspend or restrict participation in other federal education programs. The educational institution can contest MEC’s findings by filing motions with MEC or with Brazilian courts. Upon completion of the supervisory process and to the extent MEC concludes that there are administrative irregularities, SERES may apply the penalties provided for by Law No. 9,394/1996, namely (i) discontinue courses; (ii) directly intervene in the educational institution; (iii) temporarily suspend the institution’s discretionary ability to, among other things, create new post-secondary courses and establish course curricula, if applicable; (iv) disqualify the institution as an educational institution; (v) reduce the number of student vacancies; (vi) temporarily suspend new student enrollments; or (vii) temporarily suspend courses. Moreover, we and our subsidiaries face the risk of unintentionally surpassing MEC’s authorized medical or other enrollment limits due to court-mandated student enrollments, which do not count towards our allocated enrollment limit. Inaccurate assessment of these judicial demands, such as misinterpreting obligations like discounts as enrollments under litigation, may result in exceeding our authorized enrollment limits. This breach by us, or by any of the companies that we have acquired or may acquire, could lead to regulatory penalties, reputational harm, and strain our resources, compromising our educational quality. The post-secondary education sector is highly regulated, and our failure to comply with existing or future laws and regulations could significantly impact our business. We are subject to various federal laws and extensive government regulations by MEC, Conselho Nacional de Educação (National Education Council, or CNE), INEP, FIES and the National Post-secondary Education Assessment Commission (Comissão Nacional de Avaliação da Educação Superior, or CONAES), among others, including, but not limited to the “Mais Médicos” Law, which created the “Mais Médicos” program. Brazilian education regulations define three types of post-secondary education institutions: (i) colleges, (ii) university centers and (iii) universities. The three categories depend on previous accreditation by MEC to operate. Colleges differ from the other categories with respect to the programs offered, as colleges depend on previous authorization from MEC to implement new programs, while university centers and universities are not subject to such requirements, except for courses in law, medicine, psychology, nursing and dentistry, which require the prior approval of MEC. All accredited educational institutions require the prior approval of MEC to create campuses outside their headquarters. All post-secondary education programs must be recognized by MEC as a requirement, together with registration of the program, to validate the diplomas issued by them. However, pursuant to article 101 of Ordinance No. 23/2017 of MEC, issued diplomas may be valid even if the program is not formally recognized by MEC, so long as the educational institution has filed the request with MEC to certify the program, and the request is pending formal review and approval by MEC. As a result, any failure to comply with legal and regulatory requirements by post-secondary education entities may result in the imposition of sanctions by MEC, as well as damage to the program’s reputation. MEC must authorize our campuses located outside our headquarters before they can start their operations and programs. For further information, see “Item 4. Information on the Company—Business Overview—Regulatory Overview.” Distance learning programs, as well as on-campus learning, are also subject to strict accreditation requirements for their implementation and operation. We must comply with all such requirements in order to obtain and renew all authorizations. 14 Table of Contents We cannot assure you we will be able to comply with these regulations and maintain the validity of our authorizations, enrollments and accreditations in the future. If we fail to comply with these regulatory requirements, MEC could place limitations on our operations, including cancellation of programs, reduction in the number of positions we offer to students, termination of our ability to issue degrees and certificates and revocation of our accreditation, any of which could adversely affect our financial condition and results of operations. We cannot assure you that we will obtain accreditation or re-accreditation of our post-secondary education institutions, or that our courses will receive authorization or reauthorization as scheduled, or that they will have all of the accreditations, re-accreditations, authorizations and re-authorizations required by MEC. The absence of such accreditations and authorizations from MEC or any delays in obtaining them could adversely affect our financial condition and results of operations. In addition, we may also be adversely affected by any changes in the laws and regulations applicable to post-secondary education institutions, particularly by changes related to: (i) any revocation of accreditation of private educational institutions; (ii) the imposition of controls on monthly tuition payments or restrictions on the profitability of private educational institutions; (iii) faculty credentials; (iv) academic requirements for courses and curricula; (v) infrastructure requirements of campuses, such as libraries, laboratories and administrative support; (vi) the “Mais Médicos” program; and (vii) the promulgation by MEC of new rules and regulations affecting post-secondary education, in particular with respect to distance learning programs. We may be materially adversely affected if we are unable to obtain these authorizations, accreditations, course recognitions, or to comply with changes in the laws and regulations in a timely manner, if we cannot introduce new courses as quickly as our competitors, if we are not able to or do not comply with any new rules or regulations promulgated by MEC, or if laws and regulations are passed adverse to the business and operations of post-secondary education institutions. If we are not able to maintain our current MEC evaluation ratings and the evaluation ratings of our students, we may be adversely affected. We and our students are regularly evaluated and rated by MEC. If our campuses, programs or students receive lower scores from MEC than in previous years in any of its evaluations, including the IGC (Índice Geral de Cursos), and the Student Performance National Exam (Exame Nacional de Desempenho de Estudantes, or ENADE), we may experience a reduction in enrollments and be adversely affected by perceptions of decreased educational quality, which may negatively affect our reputation and, consequently, our results of operations and financial condition. The quality of our academic curricula is also a key element of the quality of the education we provide. In addition, we cannot assure you that we will be able to develop academic curricula for our new programs with the same levels of excellence as existing programs and meet the standards set forth by MEC. In the event that any of our programs receive unsatisfactory evaluations, the post-secondary education institution offering the programs may be required to enter into an agreement with MEC setting forth proposed measures and timetables to improve the program and remedy the unsatisfactory evaluation. Non-compliance with the terms of the agreement may result in additional penalties for the institution. These penalties could include, but are not limited to, suspending our ability to enroll students in our programs, denial of accreditation or re-accreditation of our institutions or prohibiting us from holding regular class sessions, all of which can adversely affect our results of operations and financial condition. We may face restrictions and penalties under the Brazilian Consumer Protection Code in the future. Brazil has a series of strict consumer protection laws, referred to as the Consumer Protection Code (Código de Defesa do Consumidor). These laws apply to all companies in Brazil that supply products or services to Brazilian consumers. They include protection against misleading and deceptive advertising, coercive or unfair business practices and issues in the formation and interpretation of contracts, usually in the form of civil liabilities and administrative penalties for violations. These penalties are often levied by the Brazilian Consumer Protection Agencies (Fundação de Proteção e Defesa do Consumidor, or PROCONs), which oversee consumer issues on a district-by-district basis. Companies operating across Brazil may face penalties from multiple PROCONs, as well as from the National Secretariat for Consumers (Secretaria Nacional do Consumidor, or SENACON). Companies may settle claims made by consumers via PROCONs by paying compensation for violations directly to consumers and through a conduct adjustment agreement (Termo de Ajustamento de Conduta, or TAC). 15 Table of Contents Brazilian public prosecutors may also commence investigations of alleged violations of consumer rights and require companies to enter into TACs. Companies that violate TACs face potential enforcement proceedings and other potential penalties such as fines, as set forth in the relevant TAC. Brazilian public prosecutors may also file public civil actions against companies who violate consumer rights or competition rules, seeking strict adherence to consumer protection laws and compensation for any damages to consumers. In certain cases, we may also face investigations and/or sanctions by the CADE, in the event our business practices are found to affect the competitiveness of the markets in which we operate or the consumers in such markets. We may also be subject to legal proceedings by current and/or former students alleging breaches of rights granted by the Brazilian Consumer Protection Code that, even if unsuccessful, may cause negative publicity, reduce enrollment numbers, increase student attrition rates, entail substantial expenses and divert the time and attention of our management, materially adversely affecting our results of operations and financial condition. Government agencies, MEC and third parties may conduct inspections, file administrative proceedings or initiate litigation against us. Because we operate in a highly regulated industry, government agencies, MEC or third parties may conduct inspections, file administrative proceedings or initiate litigation for non-compliance with regulations against us or the institutions we purchase. If the results of these proceedings or litigations are unfavorable to us, or if we are unable to successfully defend our cases, we may be required to pay monetary damages or be subject to fines, limitations, injunctions or other penalties. Even if we adequately address issues raised by an inspection conducted by an agency or successfully defend our case in an administrative proceeding or court action, we may have to set aside significant financial and management resources to settle issues raised by these proceedings or to those lawsuits or claims. Administrative proceedings or court actions brought against us may damage our reputation, even if such lawsuits or claims are without merit. Failure to obtain or maintain licenses and permits with respect to our real estate or construction projects in a timely manner may result in penalties, including closures of some of our campuses. The use of all our buildings, including operational and administrative facilities, is contingent upon the successful issuance of an occupancy permit (Habite-se) or an equivalent certificate issued by the municipality where the property is located, certifying that the building was constructed in compliance with applicable zoning and municipal regulations. Additionally, non-residential properties must obtain a use and operations license and/or permit from the relevant municipality, as well as a fire department inspection certificate, issued by the fire department, before regular use. We are currently in the process of obtaining and/or renewing these licenses for some of the real estate we use. The absence of such licenses may result in penalties ranging from fines to the forced demolition of non-compliant areas or, in the worst-case scenario, the temporary or permanent closure of the campus or branch lacking the licenses and permits. This could occur if the relevant penalties and fines are not paid, and the licenses and permits are not obtained following notifications from the relevant authorities. Any imposed penalties, particularly the forced closure of any of our campuses or branches, could have a material adverse effect on our business. Furthermore, in the event of any accident at our campuses or branches, the lack of such licenses could result in civil and criminal liability, and the cancellation of insurance policies, if any for the respective campus or branch and could damage our reputation. Additionally, we routinely undertake complex construction, expansion and renovation projects at our campuses, which require additional construction licenses and permits, including environmental licenses for such projects. Failure to obtain or maintain these licenses or permits during these projects may lead to delays to or additional costs (including fines or other penalties imposed by governmental authorities), as well as material adverse effects on our results of operations, financial condition, and reputation. Failure to provide a high-quality customer experience may adversely affect us. Customer experience is fundamental to the success of our institution. Meeting high-quality standards in both in-person and virtual learning is a constant challenge, as customers’ expectations continue to rise. Failure to deliver a valuable learning experience—whether in physical classrooms or online—can lead to student dissatisfaction, ultimately adversely affecting our reputation and our ability to attract and retain students. Factors such as the perceived quality of teaching, institutional credibility, and overall student support play crucial roles in fostering satisfaction and long-term engagement. 16 Table of Contents Delivering a consistently valuable experience requires overcoming several obstacles. In in-person programs, maintaining qualified faculty, ensuring well-equipped facilities, and providing satisfactory administrative support are key concerns. Students expect engaging, practical, and hands-on learning, particularly where clinical training and laboratory access are required. Any shortcomings in these areas can lead to frustration and impact the perceived value of our programs. In virtual programs, the challenges are different but equally significant. Students depend on user-friendly, reliable digital platforms to access course materials, attend live sessions, and engage with instructors. Technical failures, poor user experience, or insufficient student support can result in disengagement and lower retention rates. Additionally, delivering virtual learning programs with the same depth and effectiveness as face-to-face instruction requires continuous innovation in teaching methodologies. Brazil’s geographic and economic diversity adds another layer of complexity. While in some regions, students benefit from robust infrastructure and access to resources, others may struggle with unreliable internet connections, limited access to technology, or logistical barriers to attending in-person classes. These disparities make it difficult to provide a uniform student experience across different locations. Any of these factors could materially affect our business, financial condition, and results of operations. If we continue to grow, we may not be able to appropriately manage the expansion of our business and staff, the increased complexity of our software and platforms, or grow in our addressable market. Additionally, our ability to attract, recruit, retain and develop key personnel and qualified employees is critical to our success and growth. We are currently experiencing significant expansion and facing numerous related issues, such as the acquisition and retention of experienced and talented personnel, cash flow management, corporate culture and effectiveness of internal controls. These challenges, along with the significant time spent addressing them may divert our management’s attention from other business issues and opportunities. Additionally, our current and planned platform and systems, procedures and controls, personnel and third-party relationships may not be adequate to support our future operations. The strain on management and our operational and financial resources is expected to continue, and failure to manage growth effectively could seriously harm our business, results of operations and financial condition. We are also dependent upon the ability and experience of key personnel. Failure to retain or attract senior executives, board members (including those with M&A experience related to our industry), or key managers, could have a material adverse effect on our business, financial condition and results of operations. Our teaching faculty, including teachers and professors at our post-secondary education institutions, is essential for maintaining the quality of our programs and the strength of our brand and reputation. We promote training to ensure our faculty attains and maintains the qualifications we require and stays updated on trends and changes in their areas. Due to shortages in the supply of qualified professors, competition for hiring and retaining qualified professionals has increased substantially. We cannot assure you that we will succeed in retaining our current professors or recruiting or training new professors who meet our quality standards, particularly as we continue to expand our operations. Our corporate culture and values are critical to our success, and failure to preserve them could harm our ability to recruit, retain and develop personnel and implement our strategic plans effectively. We are advancing culture change through the implementation of diversity, equity and inclusion, or DEI initiatives. For example, in 2021, we undertook a public commitment by signing onto the United Nations Global Compact and committing to achieve gender equity by having women occupy half of our managerial positions by 2030. Failure to implement these initiatives successfully could adversely impact our ability to recruit, attract and retain talent, and perceived insufficient commitment to DEI or environmental, social, and governance initiatives, which may adversely affect our reputation and, consequently, our results of operations and financial condition. To successfully compete and grow, we must attract, recruit, retain and develop personnel with the necessary expertise. The competitive market for qualified personnel may hinder our ability to recruit additional personnel or replace key personnel who depart. Our efforts to retain and develop personnel may also result in significant additional expenses, adversely affecting our profitability. We cannot assure you that qualified employees will continue to be employed, that we will manage them successfully, or that, in the future, we will be able to attract qualified personnel with similar skills and expertise at an equivalent cost in the future. 17 Table of Contents To remain competitive, we must constantly update our software, enhance and improve our billing, transaction and other business systems, and add and train new software designers and engineers, as well as other personnel. This process is time-intensive and expensive and may lead to higher costs in the future. Furthermore, managing multiple commercial relationships with strategic partners, online service providers, and other third parties could lead to execution problems affecting current and future revenues and operating margins. We may face challenges in identifying and acquiring new medical higher education institutions, which could hinder our strategic and financial goals. Additionally, difficulties in effectively integrating and managing an increasing number of acquisitions may adversely affect our strategic objectives. We aim to expand our operations by acquiring medical higher education institutions and healthtech companies, including potentially significant and strategically relevant acquisitions. However, we cannot guarantee the identification or acquisition of suitable medical education institutions on favorable terms or at all. Additionally, our previous and any future acquisitions involve several risks and challenges that may have a material adverse effect on our business and results, including the following: · the acquisition may not align with our commercial strategy or institutional image; · future acquisitions may be subject to approval by Brazil’s Administrative Council for Economic Defense (Conselho Administrativo de Defesa Econômica, or CADE) or other regulatory authorities, which may deny approval, or impose conditions or restrictions; · we may face contingent and/or successor liabilities (either currently known or unknown to us) related to judicial and administrative proceedings, financial, reputational and technical issues, including regulatory, tax, labor, social security, environmental, intellectual property, accounting practices, financial disclosures, internal controls, anti-corruption, anti-bribery or anti-money laundering issues, which may not be fully indemnifiable under the relevant acquisition agreement; · the acquisition process may require additional funds and/or may be time-consuming, diverting management’s attention from daily operations; · our investments in acquisitions may not yield expected returns, and we may mismanage administrative and financial resources during integration; · the business model of acquired institutions may differ from ours, and we may be unable to adapt them to our business model or do so efficiently; · we may not be able to integrate efficiently and successfully the operations of the institutions we acquire, including their personnel, financial systems, distribution or operating procedures; · certain acquisitions may impact our financial reporting obligations and delay the preparation of our consolidated financial statements; · the acquisitions may generate goodwill, the impairment of which could reduce our net income, negatively affecting our financial statements; · the transfer of management of the target institution due to a change of control or corporate restructuring must be notified to MEC within 60 days from the consummation of the acquisition, and MEC may impose additional restrictions on its reaccreditation; and · we may be unable to provide the necessary resources to support the acquired company’s operations and failure to meet any applicable reaccreditation requirements may result in additional restrictions or conditions on the reaccreditation imposed by MEC. 18 Table of Contents In addition, we may face significant challenges in the process of integrating the operations of any acquired company with our existing business, such as managing a larger, geographically dispersed workforce, and implementing efficient uniform controls, procedures and policies, along with incurring high or unexpected integration costs. As of the date of this annual report: (i) we have fully integrated the operations of 26 of our acquisitions; and (ii) we are in the process of integrating the operations of Shosp, Cliquefarma, Medical Harbour, Medicinae, iClinic, RX PRO Glic, IBES and SESSA with our existing business. The anticipated benefits of the acquisitions we may pursue will not be achieved unless we successfully and efficiently integrate the acquired companies into our operations and effectively manage, market and apply our business strategy to them. Additionally, we may be unable to integrate faculty and personnel with diverse professional experiences and corporate cultures, potentially impairing our relationship with current and new employees, including professors. Failure to prevent or detect a malicious cyber-attack on our systems and databases could result in a misappropriation of confidential information or access to highly sensitive information. Cyber-attacks are becoming more sophisticated and pervasive. Across our business, we hold large volumes of personally identifiable information, including that of employees, institutions, customers, students and parents, legal guardians, patients, physicians and clients (B2B and B2C). Individuals have tried and may continue to try to gain unauthorized access to our data in order to misappropriate such information for potentially fraudulent purposes, and our security measures may fail to prevent such unauthorized access. A breach of our systems could result in a devastating impact on our reputation, financial condition or student experience. In addition, if we were unable to prove that our systems are properly designed to detect an intrusion, we could be subject to severe penalties and loss of existing or future business. In particular, data protection and privacy laws are developing rapidly to take into account the changes in cultural and consumer attitudes towards the protection of personal data. In operating our business and selling our products and services to customers, we and our subsidiaries collect, use, store, transmit and otherwise process employee and customer data, including sensitive personal data. As a result, we and our subsidiaries are subject to a variety of laws and regulations in Brazil, as well as contractual obligations, regarding data privacy, security and protection. In many cases, these laws and regulations apply not only to third-party transactions, but also to transfers of information between or among us, our subsidiaries and other parties with which we have commercial relationships. Privacy, information security, and data protection are significant issues globally. The regulatory framework governing the collection, processing, storage, use and sharing of certain information, particularly financial and other personal data, is rapidly evolving and is likely to continue to be subject to uncertainty and varying interpretations. The occurrence of unanticipated events and the development of evolving technologies often rapidly drive the adoption of legislation or regulation affecting the use, collection or other processing of data and the manner in which we conduct our business. Any failure or perceived failure by us to comply with our privacy policies or any applicable privacy, security or data protection, information security or consumer protection-related laws, regulations, orders or industry standards in one or more jurisdictions could expose us to costly litigation, significant awards, fines or judgments, civil and criminal penalties or negative publicity, and could materially and adversely affect our business, financial condition and results of operations. Our success depends on our ability to monitor and adapt to technological changes in the education sector and maintain a technological infrastructure that works adequately and without interruption. Information technology is an essential factor for our growth. Our information technology systems and tools may become obsolete or insufficient, or we may have difficulties in following and adapting to technological changes in the education sector, particularly in the distance learning segment where the technological needs and expectations of our customers and market standards change rapidly, especially with the increasing adoption of AI technologies, and we must quickly adapt to new distance learning technology, practices and standards. Moreover, our competitors may introduce better products or service platforms. Our success depends on our ability to efficiently improve our current products while developing and introducing new products that are accepted in the marketplace. Additionally, a failure to upgrade our technology, features, content, security infrastructure, network infrastructure, or other infrastructure associated with our platform could harm our business. Adverse consequences could include unanticipated disruptions, slower response times, bugs, degradation in levels of customer support, impaired quality of users’ experiences of our educational platform and delays in reporting accurate financial information. 19 Table of Contents The efficient operation of our business depends on our information technology systems, particularly our Continuing Education and Medical Practice Solutions segments. If our information technology systems fail to operate as anticipated and without interruptions or do not perform as specified, our services may be interrupted, patient care may be affected, and we may be subject to legal claims, regulatory compliance issues and our reputation may be harmed. Several problems regarding our information technology structure, such as viruses, hackers, system interruptions and technical difficulties regarding our satellite transmissions of data, sound and image, may have a material adverse effect on us and our business. Our information technology systems are also vulnerable to damage or interruption including from fires, floods and other natural disasters; terrorist attacks and attacks by computer viruses or hackers; power losses; and computer systems, or Internet, telecommunications or data network failures and our disaster recovery plans may not be effective. The failure of our information technology systems to perform as we anticipate or our failure to effectively implement new systems could disrupt our entire operation and could result in decreased sales, increased overhead costs, legal and regulatory liability and reputational harm, all of which could have a material adverse effect on our reputation, business, results of operations and financial condition. In addition, we face risks associated with unauthorized access to our systems, including by hackers and due to failures of our electronic security measures. These unauthorized entries into our systems can result in the theft of proprietary or sensitive information, including student information, intellectual property and sensitive data, cause interruptions in the operation of our systems, or hinder our ability to innovate. As a result, we may be forced to incur considerable expenses to protect our systems from electronic security breaches and to mitigate our exposure to technological problems and interruptions. The Internet Act (Law No. 12,965/2014) applies only to personal data collected through the internet, and establishes other principles and rules with respect to the privacy and protection of the personal and behavioral data of internet users. The Internet Act guarantees, among others, the privacy of internet and privately stored communications. Any data processing activity is subject to the data subject’s informed, free and express consent. Decree No. 8,771/2016, which regulates the Internet Act, requires internet app providers to maintain certain security measures in connection with the storage of personal data, including: (i) strict controls on access to personal data; (ii) authentication safeguards; (iii) detailed data inventories (e.g., date, time and duration of access to the data, identity of the employee that accessed the data and the actions taken), and (iv) use of IT solutions to ensure the data is protected (for example, data encryption or other equivalent protective measures). If we fail to comply with the provisions of the Internet Act, we may be subject to sanctions and penalties, including damages, which will be assessed based on the nature and degree of our non-compliance, among other factors. We rely upon a third-party data center service provider to host certain aspects of our platform and content and any disruption to, or interference with, our use of such services could impair our ability to deliver our platform, resulting in customer dissatisfaction, damaging our reputation, and harming our business. We utilize data center hosting facilities from a global third-party service provider to make certain content available on our platform. Our operations depend, in part, on our provider’s ability to protect its facilities against damage or interruption from natural disasters, power or telecommunications failures, criminal acts and similar events. The occurrence of spikes in user volume, traffic, natural disasters, acts of terrorism, vandalism or sabotage, or a decision to close a facility without adequate notice, or other unanticipated problems at our provider’s facilities could result in lengthy interruptions in the availability of our platform, which would adversely affect our business. Some of our systems are not fully redundant, and our disaster recovery planning cannot account for all eventualities. Any problems at our data centers could result in lengthy interruptions in our service. In addition, our products and services are highly technical and complex and may contain errors or vulnerabilities, which could result in interruptions in our services or the failure of our systems. Failure to comply with data privacy regulations could result in reputational damage to our brands and adversely affect our business, financial condition and results of operations. Any perceived or actual unauthorized disclosure of personally identifiable information, whether through a breach of our network by an unauthorized party, employee theft, misuse or error or otherwise, could harm our reputation, impair our ability to attract and retain our customers, or subject us to claims or litigation arising from damages suffered by individuals. Failure to adequately protect personally identifiable information could potentially lead to penalties, significant remediation costs, reputational damage, the cancellation of existing contracts and difficulty in competing for future business. In addition, we could incur significant costs in complying with relevant laws and regulations regarding the unauthorized disclosure of personal information, which may be affected by any changes to data privacy legislation at both the federal and state levels. 20 Table of Contents In particular, on August 14, 2018, the President of Brazil approved the General Personal Data Protection Law (Lei Geral de Proteção de Dados Pessoais, “LGPD,”) which came completely into force on August 1, 2021. The LGPD is a comprehensive data protection law establishing general principles and obligations that apply across multiple economic sectors and contractual relationships. The LGPD applies to individuals or legal, private or government entities, who process personal data in Brazil or collect personal data in Brazil or, further, when the processing activities have the purpose of offering or supplying goods or services to data subjects located in Brazil. The LGPD establishes detailed rules for the collection, use, processing, storage and any operation carried out with personal data (including personal data of clients, suppliers, employees and patients of our medical schools), and affects all economic sectors, including the relationship between customers and suppliers of goods and services, employees and employers and other relationships in which personal data is collected, whether in a digital or physical environment. Specifically, the LGPD establishes, among other things, data subjects’ rights, the legal basis for personal data protection, requirements for obtaining consent from data owners, obligations and requirements related to security incidents, data leaks and international data transfers, as well as the creation of the National Data Protection Authority (Autoridade Nacional de Proteção de Dados, “ANPD”), for the purposes of monitoring, implementing and supervising compliance with the LGPD in Brazil. In the event of non-compliance with the LGPD, we may be subject to penalties, including (1) warnings, with the impositions of a deadline for the adoption of corrective measures; (2) a one-time fine for each violation of up to 2% (subject to an upper limit of R$50,000,000) of our revenue; (3) a daily fine (subject to an upper limit of R$50,000,000); (4) public disclosure of the violation after due investigation and confirmation of its occurrence; (5) the restriction of access to the personal data to which the violation relates, until corrective measures are implemented; (6) deletion of the personal data to which the violation relates; (7) partial suspension of the databases to which the violation relates for up to six months, which can be extended for an equal period until corrective measures are implemented; (8) suspension of the personal data processing activities to which the violation relates for up to 12 months; and (9) partial or full prohibition on personal data processing activities. In addition, the LGPD creates a private cause of action, which means we are subject to both class-based and individual claims for violations of the LGPD. The application of sanctions by the ANPD has been further regulated by the Regulations on the Application of Administrative Sanctions, dated February 27, 2023, as a result of which the ANPD will now be able to apply administrative sanctions based on clearer and more established guidelines and requirements. Data protection is an important issue for us. We consider the LGPD as an opportunity to further develop and continuously improve our data protection processes. Since 2021, we have been offering training on the LGPD on our e-learning platform to teach our employees the principles of data protection. This training is mandatory for all employees, including our management. As part of this development and improvement process, we have also introduced governance models and technical improvements to comply with legal requirements, reduce the risk of data breaches and guarantee the rights of stakeholders with regard to their data security and privacy. While we are in the process of putting in place systems and processes to comply with the LGPD, we cannot assure you that our LGPD compliance efforts will be deemed appropriate or sufficient by regulatory authorities, in particular ANPD, or by courts, such as the Brazilian Public Prosecution Office (Ministério Público). Moreover, as the LGPD requires further regulation from the ANPD regarding several aspects of the law, which are yet unknown, we may have difficulty adapting our systems and processes to the new legislation due to the legislation’s complexity. The changes have impacted, and could further adversely impact, our business by increasing our operational and compliance costs. Any additional privacy laws, rules or regulations enacted or approved in Brazil or in other jurisdictions in which we operate could cause us to incur costs to correct the breaches or failures, expose us to uninsured liability, increase our risk of regulatory scrutiny, subject us to lawsuits and administrative procedures, and result in the imposition of material penalties and fines under state and federal laws or regulations, which could seriously harm our business, financial condition or results of operations. Any failure, real or perceived, by us to comply with our privacy policies or with any regulatory requirements or orders or other local, state, federal or international privacy or consumer protection-related laws and regulations could cause customers to reduce their purchases of our products and services and could materially and adversely affect our business. 21 Table of Contents We face risks relating to our Medical Practice Solutions segment. We may face risks relating to the expansion, including through acquisitions, of our Medical Practice Solutions segment, which provides clinical decisions software, practice management tools and electronic medical records, doctor-patient relationship, telemedicine and digital prescriptions. We are subject to significant execution risk since we are providing new digital features and developing a new market, where the technological needs, the expectations of our customers and market standards change rapidly, especially with the increasing adoption of AI technologies. Our competitors may offer solutions that are similar to or better than those offered by us, have access to more funds, and be more prestigious or well-regarded within the medical community. As such, we may have to quickly modify our products and services to adapt to new digital education technologies, practices and standards. In addition, an error in the design, programming or validation of clinical decisions software could lead to inappropriate assignment or dosing of patients, which could give rise to patient safety issues and/or liability claims against us, amongst other things, any of which could have a material adverse effect on our financial condition, results of operations and reputation. See also “—Our success depends on our ability to monitor and adapt to technological changes in the education sector and maintain a technological infrastructure that works adequately and without interruption.” In addition, the success of our digital solutions depends on the general population having easy and affordable access to the internet, as well as on other technological factors that are outside of our control. If the internet becomes inaccessible or access costs increase to levels higher than current prices, we may be unable to successfully implement our digital solutions strategy, which would have an adverse effect on our growth strategy. Additionally, we may face regulatory risks related to the approval, certification, and compliance requirements applicable to our Medical Practice Solutions segment. Failure to comply with healthcare, medical device, or digital health regulations, including ANVISA (Brazilian Health Agency) requirements, could limit our ability to offer certain products, or result in sanctions, fines, or other penalties, any of which could adversely affect our operations and reputation. Finally, we also face operational risks relating to the integration of any acquired companies to build our ecosystem, including userbase and platform integration risks, among other risks. As a result, any acquisitions we may make in this segment involve several uncertainties, risks and challenges that may have a material adverse effect on our business and results of operations, and result in the risk of impairment. See also “—We may face challenges in identifying and acquiring new medical higher education institutions, which could hinder our strategic and financial goals. Additionally, difficulties in effectively integrating and managing an increasing number of acquisitions may adversely affect our strategic objectives.” Our business depends on the continued success of the brands of each of our institutions, as well as the “Afya” brand, and if we fail to maintain and enhance the recognition of our brands, we may face difficulty enrolling new students and selling educational content and medical practice solutions to new clients, and our reputation and operating results may be harmed. We believe that market awareness of our brands has contributed significantly to the success of our business. Maintaining and enhancing our brands is critical to our efforts to increase student enrollments and expand the selling of educational content and medical practice solutions for new clients. Failure to maintain and enhance our brand recognition could have a material and adverse effect on our business, operating results and financial condition. We have devoted significant resources to our brand promotion in recent years, but we cannot assure you that these efforts will be successful. If we are unable to further enhance our brand recognition, or if we incur excessive marketing and promotion expenses, or if our brand image is negatively impacted by any negative publicity, our business and results of operations may be materially and adversely affected. If we fail to maintain effective internal controls over financial reporting, we may be unable to accurately report our results of operations, meet our reporting obligations or prevent fraud. Disclosure controls and procedures over financial reporting are designed to provide reasonable assurance that information required to be disclosed by the Company is accumulated and communicated to management, and recorded, processed, summarized and reported in accordance with applicable rules. These disclosure controls and procedures have inherent limitations which include the possibility that judgments in decision-making can be faulty and that breakdowns occur because of errors or mistakes. Additionally, controls can be circumvented by any unauthorized management override of controls. Consequently, our businesses are exposed to risk from potential noncompliance with policies, employee misconduct or negligence and fraud, which could result in regulatory sanctions, civil claims and serious reputational or financial harm. It is not always possible to deter employee misconduct and the precautions we take to prevent and detect this activity may not always be effective. And, we may also not be able to adapt the disclosure and internal controls environment of companies that we acquire within the permitted one-year period. Accordingly, because of the inherent limitations in the internal control system, misstatements due to error or fraud may occur and not be detected. For details of the controls mentioned above, see the section of this annual report entitled “Item 15. Controls and Procedures—B. Management’s Annual Report on Internal Control Over Financial Reporting.” 22 Table of Contents We cannot assure that significant deficiencies or material weaknesses in our internal control over financial reporting will not be identified in the future. In addition, if we fail to maintain the adequacy of our internal control over financial reporting, as the laws, regulations and policies standards are modified, supplemented or amended from time to time, we may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002. If we fail to maintain an effective internal control environment, we could suffer material misstatements in our financial statements, fail to meet our reporting obligations or fail to prevent fraud, which would likely cause investors to lose confidence in our reported financial information, the trading price of our Class A common shares could decline, and we could be subject to sanctions or investigations by NASDAQ, the SEC or other regulatory authorities. Failure to remedy any future material weakness in our internal controls over financial reporting, or to implement or maintain other effective control systems required of public companies in the United States, could also restrict our future access to capital markets and reduce or eliminate the trading market for our Class A common shares. Any decrease in the number of customers in our education programs and medical practice solutions may adversely affect our results of operations. We believe that our attrition rates are primarily influenced by the personal motivation and financial circumstances of our current and prospective customers, as well as by socioeconomic conditions in Brazil. Significant changes in future attrition rates and/or failure to re-enroll or re-engage may affect our new customers numbers, particularly in the context of economic uncertainty or volatility, and may have a material adverse effect on our revenues and our results of operations. An increase in delays and/or defaults in the payment of tuition fees or license subscription fees of medical practice solutions may adversely affect our income and cash flows. We depend on the full and timely payment of (i) the tuition we charge our students, including tuition payments we receive through FIES; and (ii) the subscription fees we charge our clients. Adverse changes in the macroeconomic environment and the earnings capacity of our customers, may lead to an increase in payment delinquency or default and negatively impact our ability to collect our accounts receivable. An increase in payment delinquency or default by our customers may have a material adverse effect on our cash flows and our business, including our ability to meet our obligations. Our allowance for expected credit losses expenses as a percentage of our revenue was 1.8%, 2.6% and 1.8% for the years ended December 31, 2024, 2023 and 2022, respectively. There is no guarantee that our allowance for expected credit losses expenses will not increase in the following years. Our inability to collect our accounts receivable on a timely basis, if at all, could cause our allowance for expected credit losses expenses to increase in the future, and materially and adversely affect our financial condition, liquidity and results of operations. Unfavorable decisions in our legal, arbitration or administrative proceedings may adversely affect us. We are, and we, our controlling shareholder, directors or officers may be in the future, party to legal, arbitration and administrative investigations, inspections and proceedings arising from the ordinary course of our business or from nonrecurring corporate, tax, criminal or regulatory events, involving our suppliers, students, faculty members, as well as environmental, competition and tax authorities, especially with respect to civil, tax, criminal and labor claims. We cannot guarantee that the results of these proceedings will be favorable to us or that we have made sufficient provisions for liabilities that may arise as a result of these or other proceedings. Adverse decisions on material legal, arbitration or administrative proceedings may damage our reputation and may adversely affect our results of operations and the price of our Class A common shares. Difficulties in identifying, opening and efficiently managing new campuses or in obtaining regulatory authorizations and accreditations on a timely basis as part of our organic growth strategy may adversely affect our business. Our organic growth strategy includes expanding by opening new campuses and integrating them into our educational network. This growth plan presents significant challenges in terms of maintaining our teaching quality and culture due to the complexity and difficulty of effectively managing a greater number of campuses and programs. If we are unable to maintain our current quality standards, we may lose market share and be adversely affected. 23 Table of Contents Establishing new campuses poses significant challenges and requires substantial investments in infrastructure, marketing, personnel and other pre-operational expenses, primarily in identifying new sites for lease or purchase. We prioritize identifying strategic sites, negotiating the purchase or lease of properties, building or refurbishing facilities (including libraries, laboratories and classrooms), obtaining local permits, hiring and training faculty and staff, and investing in administration and support. We cannot assure you that we will succeed in identifying facilities with adequate infrastructure for our new campuses, develop adequate infrastructure in properties we acquire, or have enough resources to continue expanding through acquisitions or development of new projects. We are also required to register our new campuses with MEC, before opening and operating them, as well as having our new programs accredited by MEC in order to issue official degrees and certificates to our students. If we do not succeed in identifying and establishing our campuses in a cost-effective manner or in obtaining such authorizations or accreditations on a timely basis, or if MEC imposes restrictions or conditions on our accreditation requests for new campuses, our business may be adversely affected. If we fail to develop adequate infrastructure for new programs that meets the requirements imposed by MEC or the standards set forth in our business plan, our ability to offer such programs and expand our business may be limited and our financial condition and results of operations may be adversely impacted. We may not be successful in meeting our environmental, social and corporate governance, or ESG, commitments, which may have a material adverse effect on our business, financial condition, reputation and results of operations. The market is increasingly concerned with how companies assess and manage ESG risks to protect themselves and create opportunities to generate value. As part of this trend, we have made certain ESG commitments, and we strive to maintain socially responsible business practices, including fostering social investments and structuring programs to generate a positive social impact in areas related to our business, such as access to medical care and improvement of health indicators in surrounding communities, employability, education and culture. Failure to meet our ESG commitments or to pursue these socially responsible business practices, partially or at all, may have a material adverse effect on our business, reputation, financial condition and results of operations. There has been an increase in ESG rules and regulations applicable to our business. Given the pace of legislative developments in this area, although we make efforts to follow the best practices, we may not be able to comply with the new regulations in their totality. We are also exposed to the risk that future ESG rules and regulations may adversely affect our ability to conduct our business by requiring us to reduce the value of our assets or reduce their useful life, face increased compliance costs or take other actions that may be adverse to us. Our activities may also impact the lives and socioeconomic dynamics of communities, especially those neighboring our campuses. These impacts may include truck, vehicle and pedestrian traffic, construction, noise and waste generation, and the effects of lower-quality, free services that we may provide to such communities. As a result, there may be stoppages in our operations due to demonstrations in surrounding communities, as well. If we do not establish effective communication channels with such communities, we may face challenges in the operation of educational institutions and project execution, which could jeopardize our reputation and impede the attainment of our strategic objectives. Our holding company structure makes us dependent on the operations of our subsidiaries. We depend on dividend distributions by our subsidiaries, and we may be adversely affected if the performance of our subsidiaries is not positive. We are a Cayman Islands exempted company with limited liability. Our material assets are our direct and indirect equity interests in our subsidiaries. We control a number of subsidiary companies that carry out the business activities of our corporate group. Our ability to comply with our financial obligations and to pay dividends to our shareholders depends on our ability to receive distributions from the companies we control, which in turn depends on the cash flow and profits of those companies. There is no guarantee that the cash flow and profits of our controlled companies will be sufficient for us to comply with our financial obligations and pay dividends to our shareholders. Furthermore, exchange rate fluctuation will affect the U.S. dollar value of any distributions our subsidiaries make with respect to our equity interests in those subsidiaries. 24 Table of Contents In addition, the Brazilian federal government recently stated that the income tax exemption on the distribution of dividends may be repealed, and income tax assessed on the distribution of dividends in the future, and that applicable taxes on the payment of interest on shareholders’ equity may be increased in the future. Any repeal of the income tax exemption on the distribution of dividends and any increase in applicable taxes on the payment of interest on shareholders’ equity may adversely affect us and our financial condition to distribute dividends. Failure to protect or enforce our intellectual property and other proprietary rights could adversely affect our business and financial condition and results of operations. We rely and expect to continue to rely on a combination of trademark, copyright, patent and trade secret protection laws, as well as confidentiality and license agreements with our employees, consultants and third parties with whom we have relationships to protect our intellectual property and proprietary rights. From time to time, we expect to file patent, copyright and trademark applications in Brazil and abroad. Nevertheless, these applications may not be approved or otherwise provide the full protection we seek. Any dismissal of our “AFYA” trademark application may impact our business. Third parties may challenge any patents, copyrights, trademarks and other intellectual property and proprietary rights owned or held by us. Third parties may knowingly or unknowingly infringe, misappropriate or otherwise violate our patents, copyrights, trademarks and other proprietary rights, and we may not be able to prevent infringement, misappropriation or other violation without substantial expense to us. Furthermore, we cannot guarantee that: · our intellectual property and proprietary rights will provide competitive advantages to us; · our competitors or others will not design around our intellectual property or proprietary rights; · our ability to assert or enforce our intellectual property or proprietary rights against potential competitors or to settle current or future disputes will not be limited by our agreements with third parties; · our intellectual property and proprietary rights will be enforced in jurisdictions where competition may be intense or where legal protection may be weak; · any of the patents, trademarks, copyrights, trade secrets or other intellectual property or proprietary rights that we presently employ in our business will not lapse or be invalidated, circumvented, challenged or abandoned; or · we will not lose the ability to assert or enforce our intellectual property or proprietary rights against or to license our intellectual property or proprietary rights to others and collect royalties or other payments. If we pursue litigation to assert or enforce our intellectual property or proprietary rights, an adverse decision in any of these legal actions could limit our ability to assert our intellectual property or proprietary rights, limit the value of our intellectual property or proprietary rights or otherwise negatively impact our business, financial condition and results of operations. If the protection of our intellectual property and proprietary rights is inadequate to prevent use or misappropriation by third parties, the value of our brand and other intangible assets may be diminished, competitors may be able to more effectively mimic our service and methods of operations, the perception of our business and service to customers and potential customers may become confused in the marketplace and our ability to attract customers may be adversely affected. We may in the future be subject to intellectual property claims, which are costly to defend and, if we do not succeed in defending such claims, could harm our business, financial condition and operating results. From time to time, third parties may allege in the future that we or our business infringes, misappropriates or otherwise violates their intellectual property or proprietary rights, including with respect to our publications. Many companies, including various “non-practicing entities” or “patent trolls,” are devoting significant resources to developing or acquiring patents that could potentially affect many aspects of our business. We have not exhaustively searched patents related to our technology. In addition, the publishing industry has been, and we expect in the future will continue to be, the target of counterfeiting and piracy. We may implement measures in an effort to protect against these potential liabilities that could require us to spend substantial resources. Any costs incurred as a result of liability or asserted liability relating to sales of unauthorized or counterfeit educational materials could harm our business, reputation and financial condition. 25 Table of Contents Third parties may initiate litigation against us without warning. Others may send us letters or other communications that make allegations without initiating litigation. We have in the past and may in the future receive such communications, which we assess on a case-by-case basis. We may elect not to respond to the communication if we believe it is without merit or we may attempt to resolve disputes out of court by electing to pay royalties or other fees for licenses. If we are forced to defend ourselves against intellectual property claims, whether they are with or without merit or are determined in our favor, we may face costly litigation, diversion of technical and management personnel, inability to use our current website or inability to market our service or merchandise our products. As a result of a dispute, we may have to develop non-infringing technology, including partially or fully revising any publication that infringes intellectual property rights, enter into licensing agreements, adjust our merchandising or marketing activities or take other action to resolve the claims. These actions, if required, may be unavailable on terms acceptable to us or may be costly or unavailable. If we are unable to obtain sufficient rights or develop non-infringing intellectual property or otherwise alter our business practices, as appropriate, on a timely basis, our reputation or brand, our business and our competitive position may be affected adversely and we may be subject to an injunction or be required to pay or incur substantial damages and/or fees and/or royalties. Most of our services are provided using proprietary software and our software is mainly developed by our employees, who assign to us their copyrights over the software. In this regard, though applicable law establishes that employers shall have full title over rights relating to software developed by their employees, we could be subject to lawsuits by former employees claiming ownership of such software. As a result, we may be required to obtain licenses of such software, incurring costs relating to payments of royalties and/or damages and we may be forced to cease the use of such software. If we are unable to use certain of our proprietary software as a result of any of the foregoing or otherwise, this could have a material adverse effect on our business, financial condition and results of operations. In addition, we use open source software in connection with certain of our products and services. Companies that incorporate open source software into their products have, from time to time, faced claims challenging the ownership of open source software and/or compliance with open source license terms. As a result, we could be subject to suits by parties claiming ownership of what we believe to be open source software or non-compliance with open source licensing terms. Some open source software licenses require users who distribute or use open source software as part of their software to publicly disclose all or part of the source code to such software and/or make available any derivative works of the open source code on unfavorable terms or at no cost. Any requirement to disclose our proprietary source code or pay damages for breach of contract could have a material adverse effect on our business, financial condition and results of operations. Some of the properties that we occupy are owned by companies controlled by one of our significant shareholders. Therefore, we are exposed to conflicts of interest, since the administration of such properties may conflict with our interests, those of such significant shareholder and those of our other shareholders. Some of the properties we occupy, including properties where some of our campuses are located, are owned and operated by companies controlled by one of our significant shareholders. Therefore, the interests of our significant shareholder in the administration of such property may conflict with our interests and those of our other shareholders. For further information, see “Item 7. Major Shareholders and Related Party Transactions—Related Party Transactions” and note 7 to our audited consolidated financial statements. We could be adversely affected if we are unable to pass on increases in our costs and expenses to our students by adjusting our monthly tuition fees. Our primary source of income is the monthly tuition payments we charge to our students. Our payroll costs and expenses account for the majority of the costs of services and selling, general and administrative expenses, or 49.3%, 51.1%, and 53.1% of such costs and expenses for the years ended December 31, 2024, 2023 and 2022, respectively. Our faculty and administrative employees are represented by labor unions in the higher education sector and are covered by collective bargaining agreements or similar arrangements determining the number of working hours, minimum compensation, vacations and fringe benefits, among other terms. These agreements are subject to annual renegotiation and may be so modified. We could also be adversely affected if we fail to achieve and maintain cooperative relationships with our professors’ or administrative employees’ unions or face strikes, stoppages or other labor disruptions by our professors or employees, or if we are unable to pass on any increase in costs arising from the renegotiation of collective bargaining agreements to the monthly tuition fees paid by students, which may have a material adverse effect on our business. 26 Table of Contents In addition, our maintenance expenses and utilities expenses (comprised mainly of water, electricity and telephone expenses) represent 6.6%, 5.9% and 5.7% of our costs of services and selling, general and administrative expenses for the years ended December 31, 2024, 2023 and 2022, respectively. Personnel costs and expenses, lease values and the cost of electricity are adjusted regularly using indices that reflect changes in inflation levels. If we are not able to transfer any increases in our costs and expenses to students by increasing the amounts of their monthly tuition fees, for example as a result of ongoing political and economic instability in Brazil or globally, our operating results may be adversely affected. Climate change can create transition risks, physical risks and other risks that could adversely affect us. Climate risk is a transversal risk that can be an aggravating factor for the types of traditional risks that we manage in the ordinary course of business, including, without limitation, the risks described in this “Risk Factors” section. Based on the classifications used by the Taskforce on Climate-Related Financial Disclosures, we consider that there are two primary sources of climate change-related financial risks: physical and transition. Physical risks resulting from climate change can be event-driven (acute) or long-term shifts (chronic) in climate patterns: · Acute physical risks include increased severity of extreme weather events, such as drought, hurricanes, or floods; · Chronic physical risks include changes in precipitation patterns and extreme variability in weather patterns, rising mean temperatures, chronic heat waves or rising sea levels; The main physical risks that can impact us are acute physical risks that can disrupt our supply chain, or prevent our schools from operating normally. Transition risks refer to actions to address mitigation and adaptation requirements related to climate change, and they can fall into various categories such as market and technology changes: · Market risk may manifest through shifts in supply and demand for certain commodities, products, and services, as climate-related risks and opportunities are increasingly considered. · Technology risk arises from improvements or innovations to support the transition to a lower-carbon, energy-efficient economic system that can have a significant impact on companies to the extent that new technology displaces old systems and disrupts some parts of the existing economic system. One of our strategies to minimize our carbon footprint is to reduce the number of physical pages we print as part of our printed educational materials by making those educational materials available to students digitally on our online platform. Policy actions generally fall into two categories: those that attempt to constrain actions that contribute to the adverse effects of climate change and those that seek to promote adaptation to climate change. The risk associated with, and the financial impact of policy changes depends on the nature and timing of the policy change. Our campuses may be adversely affected by increased regulatory requirements going forward as a result of the increasing importance of environmental matters, which may indirectly affect our business. This and other changes in regulations in Brazil and international markets may expose us to increased compliance costs, limit our ability to pursue certain business opportunities and provide certain products and services, each of which could adversely affect our business, financial condition, and results of operations. 27 Table of Contents The interests of our management team may be focused on the short-term market price of our Class A common shares, which may not align with your interests. Additionally, our shareholders may experience dilution of their interests in our share capital and in the value of their investments due to the issuance of new shares for settlement of our share-based incentive plans. Our directors and officers, among others, own shares issued by us and are beneficiaries under our share-based incentive plans. Our current stock option plan for our managers and employees, approved in August 2019 (and amended in July 2020, July 2022 and July 2023), reserves up to 4% of our common shares at any time (excluding treasury shares) for issuance under this equity incentive plan. In addition, on July 8, 2022, we established a restricted stock units (RSUs) program, reserving up to 1.2% of our common shares at any time for issuance under this plan. Due to the issuance of stock options or RSUs, to members of our management team, a significant portion of their compensation is closely tied to our results of operations and, more specifically to the trading price of our Class A common shares. This may lead such individuals to direct our business and conduct our activities with an emphasis on short-term profit generation. Consequently, the interests of our management team may not align with the interests of our other shareholders that have longer-term investment objectives. Once options have been exercised by the participants and/or the common shares to be issued under the RSUs program have vested, our board of directors will determine whether our capital stock should be increased through the issuance of new shares to be subscribed by participants, or if they will be settled through shares held in treasury. If settlement occurs through the issuance of new shares, our shareholders will experience dilution, of their interests in our share capital and in the value of their investments, up to a maximum of 5.2% of our common shares at any time. Should new stock options or RSUs be granted, whether under existing plans or new plans, our shareholders will be subject to additional dilution. For additional information on our share-based incentive plans, see “Item 6. Directors, Senior Management and Employees—B. Compensation—Long-Term Incentive Plans.” We may not be able to maintain or renew our existing leases. We lease substantially all of the properties on our campuses. According to Brazilian lease laws, a lessee has the right to request judicial renewal of existing non-residential leases for subsequent terms equal to the original term of the lease. In order for a lessee to enforce this right, the following criteria must be met (i) the non-residential lease agreement must have a fixed term equal to or greater than five consecutive years, or, in the event there is more than one agreement or amendment thereto regarding the same real estate, the aggregate term in such agreement or amendment must be greater than five consecutive years (ii) the lessee must have been using the property for the same purpose for a minimum and continuous period of three years and (iii) the lessee must claim the right to judicial renewal at least one year and at most six months prior to the end of the term of the lease agreement. Lease agreements with terms lasting less than five years are not entitled to a right of compulsory renewal and, as a result, the lessor has the right to refuse renewal of the lease upon expiration of its term. Even for lease agreements with terms of five years or more, renewal is not automatic and depends on compliance with the legal requirements for judicial renewal. The lease agreements relating to our campuses generally have terms lasting from five to 30 years and are renewable in accordance with applicable Brazilian lease laws. If we are forced to close any of our campuses due to the termination of a lease agreement and our inability to renew the lease, our business and results of operations may be adversely affected. In addition, most of our lease agreements are not registered with the relevant real estate registries. Although we have a statutory right of first refusal under Brazilian lease laws, the absence of registration prevents us from enforcing this right against third parties. A subsequent purchaser who was not formally notified of our lease and consequent right of first refusal may require that we vacate the property. Our success depends on our ability to operate in strategically located property that is easily accessible by public transportation. We believe that urban mobility, inadequate public transportation systems and high transportation costs in many Brazilian cities make the location and accessibility of campuses a decisive factor for students choosing an educational institution. Therefore, a key component of the success of our business consists in finding, renting and/or buying strategically located property that meets the needs of our students. We cannot guarantee that we will be able to keep our current property or acquire new property that is strategically located in the future. In addition, acquisition costs, costs associated with improvements, construction, and repairs of existing properties, and rental values for the properties we use might increase in the future and could have a material adverse effect on our business. Finally, due to demographic and socioeconomic changes in the regions in which we operate, we cannot guarantee that the location of our campuses will continue to be attractive and convenient to students. 28 Table of Contents Our operations and projects are exposed to occupational health and safety and accident risks. We are subject to laws and regulations governing health and safety matters, protecting both members of the public and their employees and contractors. Some of the tasks undertaken by our employees and contractors, including our maintenance employees, can be inherently dangerous and have the potential to result in serious injury or death. Moreover, in the ordinary course of our business, we undertake complex construction, expansion and renovation projects that may subject our employees or contractors to the risk of harm. Any breach of these obligations, or serious accidents involving our employees, contractors or members of the public could expose us to adverse regulatory consequences, including the forfeit or suspension of operating licenses, potential litigation, claims for material financial compensation, reputational damage, fines or other legislative sanction, all of which have the potential to impact the results of our operating entities and our ability to make distributions. In addition, any insurance coverage that we may have obtained with respect to such obligations may not cover certain indemnifications we may be required to pay, be insufficient to cover these types of claims, or may not cover certain acts or events. We may require additional funds to continue our expansion strategy. If we are unable to obtain adequate financing on favorable terms to complete any potential acquisition and implement our expansion plans, our growth strategy may be materially and adversely affected. In the future, we may need to raise additional capital to fund our expansion (organically or through strategic acquisitions), obtain new licenses, develop or enhance products and services, or respond to competitive pressures. Our ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond our control. For example, financial markets have been negatively impacted by current macroeconomic trends, including high interest rates and rising inflation. Adequate funding may not be available on favorable terms to us or at all, particularly under these conditions. If adequate funds are unavailable or are not available on acceptable terms, we may be unable to fund our expansion, capitalize on acquisition opportunities, develop or enhance our product and service portfolio, or respond to competitive pressures, which could have a material adverse effect on our business, results of operations and financial condition. Raising additional funds through the issuance of equity or convertible debt securities may dilute our shareholders’ interests, and the issued securities may have rights, preferences and privileges senior to those of our shares. Additionally, debt financing may impose restrictive covenants that limit our operational and financial flexibility, including by imposing restrictions on our ability to incur additional indebtedness, create liens, make acquisitions, dispose of assets and make restricted payments, among others. Such indebtedness may also require us to maintain certain financial ratios, potentially limiting our ability to secure future financing, withstand future economic downturns, or conduct necessary corporate activities. A breach of any such covenant would likely result in a default, leading to acceleration of the outstanding indebtedness if not waived. For more information, see “Item 5. Operating and Financial Review and Prospects—B. Liquidity and Capital Resources—Indebtedness.” Our revenues are highly concentrated in the tuition fees we charge for our medical courses and other health sciences programs. Any adverse economic, market or regulatory factors affecting such medical courses and health sciences programs could decrease demand, which could materially adversely affect us. A significant portion of our revenue relating to undergraduate programs is currently concentrated in the tuition fees we charge for our medical courses and other health sciences programs across our network. For the years ended December 31, 2024, 2023 and 2022, 87.1%, 86.7% and 86.9%, respectively, of total undergraduate programs’ revenue were derived from tuition fees we or our subsidiaries charged for medical courses and other health sciences programs. Therefore, economic, market or regulatory factors affecting either the amount of tuition fees we are able to charge for the medical courses and health sciences programs we offer or the ability of our students to pay such tuition fees could result in significantly decreased demand for our services, which could materially adversely affect us. 29 Table of Contents We may not be able to successfully expand our presence and performance in the distance learning business. We may face difficulties in successfully operating and expanding our distance learning program, as well as in implementing and investing in the necessary technologies. The technological needs, the customer expectations and market standards in this sector change rapidly. We must quickly modify our products and services to adapt to new distance learning technologies, practices and standards. Our competitive position may be adversely affected if current or future competitors introduce superior products or service platforms, or if our resources are insufficient to develop and adapt our technological capabilities swiftly enough to maintain our competitive position. Additionally, the success of our distance learning programs depends on the general population having easy and affordable access to the internet, as well as on other technological factors that are beyond our control. If internet access becomes unavailable, access costs increase to levels significantly higher than current prices, or if the number of students interested in distance learning educational methods does not increase, we may be unable to successfully implement our distance learning strategy, which would adversely affect our growth strategy. Acquisitions of educational institutions, in certain circumstances, must be approved by the Administrative Council for Economic Defense. Brazilian legislation provides that acquisitions of educational institutions meeting certain requirements must be approved by Brazil’s Administrative Council for Economic Defense (Conselho Administrativo de Defesa Econômica, or CADE) prior to the completion of the acquisition if one of the companies or group of companies involved has gross annual revenues in Brazil of at least R$750.0 million in the year immediately prior to the acquisition and any other party or group of companies involved has gross income of at least R$75.0 million in that same period. As part of this process, CADE analyzes whether the transaction may substantially lessen competition in the relevant market, create or strengthen a dominant position, or result in the elimination of a significant portion of competition. If CADE determines that the transaction raises competitive concerns, it may impose structural or behavioral remedies, such as requiring the divestiture of assets, imposing restrictions on certain commercial practices, or setting conditions for market access. Failure to obtain approval for future acquisitions or to comply with any remedies imposed as a condition for approval may result in fines or the annulment of the transaction which could adversely affect our results of operations and financial condition. As a result of our growth strategy through acquisitions of new entities, we may need additional funds to implement our strategy. Therefore, if we cannot obtain adequate financing to conclude any potential acquisition and implement our expansion plans, our growth strategy will be affected. See “—We may require additional funds to continue our expansion strategy. If we are unable to obtain adequate financing on favorable terms to complete any potential acquisition and implement our expansion plans, our growth strategy may be materially and adversely affected.” Our Continuing Education segment is subject to seasonal fluctuations, which may cause our operating results to fluctuate from quarter-to-quarter and adversely impact our working capital and liquidity throughout the year, adversely affecting our business, financial condition and results of operations. Continuing Education revenues are mostly related to: (i) monthly intakes and tuition fees on medical education, which generally do not experience significant fluctuations resulting from seasonality and (ii) Medcel’s revenue, derived from the sales of e-books which are recognized at the point in time when control is transferred to the customer, which is generally concentrated in the first and last quarter of the year due to the period of enrollments. Accordingly, we expect quarterly fluctuations in our revenues and operating results to continue. These fluctuations could result in volatility and adversely affect our liquidity and cash flows. As our business grows, these seasonal fluctuations may become more pronounced. As a result, we believe that sequential quarterly comparisons of our financial results may not provide an accurate assessment of our financial position. Additionally, in recent years, the overall macroeconomic environment in Brazil has undergone significant volatility as a result of adverse political and economic pressures. Adverse macroeconomic conditions have led to a contraction in the disposable income of both existing and potential clientele within our Continuing Education segment, prompting a deferral of their intentions to pursue residency and graduate endeavors. Consequently, this resulted in diminished demand for our residency preparatory courses and medical graduate courses during that timeframe and may result in the risk of impairment of goodwill recorded from the acquired companies in our Continuing Education segment. 30 Table of Contents Recent developments in artificial intelligence regulation in Brazil may impose additional compliance costs and operational challenges that could adversely affect our business. In December 2024, the Brazilian Senate approved the regulatory framework for artificial intelligence (AI), known as the “Marco Regulatório da Inteligência Artificial,” which is currently under consideration by the Brazilian House of Representatives. This proposed legislation aims to establish comprehensive rules for the development and use of AI systems across various sectors, including education and healthcare. If enacted, the new regulations may require us to implement additional compliance measures, such as conducting AI impact assessments, enhancing data security and privacy protocols, and strengthening corporate risk management frameworks in accordance with regulatory guidelines. Given our reliance on technology-driven solutions for medical education and digital healthcare services, increased regulatory scrutiny on AI applications could impact our ability to develop, deploy, or improve AI-based tools. Compliance with evolving AI regulations may lead to higher operational costs, delays in innovation, and potential restrictions on certain AI-driven functionalities, which could adversely affect our business, financial condition, and results of operations. Disruption or volatility in global financial and credit markets could adversely affect the financial and economic environment in Brazil, which could materially and adversely affect our business, financial condition and results of operations. Our operations are closely tied to the performance of the Brazilian economy. Volatility in global financial and credit markets, driven by geopolitical conflicts, inflationary pressures, rising interest rates, and protectionist trade policies, can affect investor confidence, capital flows, commodity prices, and exchange rates. These dynamics influence Brazil’s economic stability and, in turn, the financial condition of our customers and counterparties. Geopolitical instability, including the ongoing conflict between Russia and Ukraine and escalating hostilities in the Middle East, particularly in Israel and surrounding areas, has led to increased volatility in global financial and commodity markets. These conflicts have contributed to higher energy and food prices, increased maritime shipping costs, and disrupted global supply chains. Such developments place inflationary pressure on the Brazilian economy, raise import costs, and may compel monetary authorities to adopt tighter policies, which could slow economic growth. In addition, the resulting macroeconomic uncertainty may reduce investor appetite for emerging markets, leading to currency depreciation, lower levels of foreign direct investment, and diminished access to international capital markets for Brazilian companies, including us. Further contributing to global economic uncertainty, in April 2025, the United States announced new trade measures imposing a 10% base tariff on most imports effective April 5, 2025, with higher reciprocal tariffs of up to 50% applying to imports from nearly 60 countries as of April 9, 2025. On April 9, 2025, President Trump announced a pause to individualized higher tariff rates on most countries for 90 days. These and similar measures may result in retaliatory trade policies, lower global trade volumes, and supply chain realignments, which could increase the cost of goods in Brazil and reduce demand for Brazilian exports. A decline in export revenues or an increase in import costs could reduce Brazil’s trade surplus, exert downward pressure on the Brazilian real, and negatively impact domestic investment, inflation, and overall economic activity. These external pressures may reduce liquidity and increase the cost of funding for Brazilian issuers and borrowers, including us. A deterioration in economic conditions could also impair the financial capacity of our students and adversely affect demand for our programs, products and services. Reduced access to capital may limit our ability to pursue growth initiatives or respond effectively to changing market conditions, which could negatively affect our results of operations. Public health outbreaks, epidemics or pandemics have adversely affected and may continue to adversely affect our business. Public health outbreaks, epidemics or pandemics could materially adversely impact our business. Such public health crises may negatively impact the global economy, disrupt supply chains, and create significant volatility in global financial markets. They could also lead to interruptions of our on-campus activities to varying degrees, especially affecting our practical educational activities. The ultimate extent of any such epidemics, pandemics, outbreaks or other public health crises on our business, financial condition and results of operations would depend on future developments, which are highly uncertain and cannot be predicted with any certainty. Such developments could therefore have a material adverse effect on our business, financial condition and results of operations, and it may also have the effect of heightening many of the other risks described in this “Risk Factors” section. 31 Table of Contents Our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. Failure to maintain effective business continuity and disaster recovery plans could materially disrupt our operations and negatively impact our financial performance, reputation, and stakeholder relationships. Our ability to deliver high-quality educational and medical services across our core segments—Undergrad, Continuing Education, and Medical Practice Services—relies on uninterrupted operations. Unexpected events, such as natural disasters, wildfires, public health crises, cyberattacks, technology failures, power outages, or other emergencies, could impair our ability to offer courses, delay student progression and graduation, and lead to financial losses. The continuity of our Undergraduate and Continuing Education programs is critical to preserving student trust and academic partnerships, while any disruption to our Medical Practice Services could directly affect patient care, physician engagement, and relationships with B2B clients, including pharmaceutical companies. If we fail to effectively mitigate or recover from such disruptions, we could face legal liabilities, financial setbacks, and reputational harm that adversely impact our business and growth prospects. Certain Risks Relating to Brazil The Brazilian federal government has exercised, and continues to exercise, significant influence over the Brazilian economy. This involvement as well as Brazil’s political and economic conditions could harm us and the price of our Class A common shares. The Brazilian federal government frequently exercises significant influence over the Brazilian economy and occasionally makes significant changes in policy and regulations. The Brazilian government’s actions to control inflation and other policies and regulations have often involved, among other measures, increases or decreases in interest rates, changes in fiscal policies, wage and price controls, foreign exchange rate controls, blocking access to bank accounts, currency devaluations, capital controls and import and export restrictions. We have no control over and cannot predict what measures or policies the Brazilian government may take in the future. We and the market price of our securities may be harmed by changes in Brazilian government policies, as well as general economic factors, including, without limitation: · growth or downturn of the Brazilian economy; · interest rates and monetary policies; · exchange rates and currency fluctuations; · inflation; · liquidity of the domestic capital and lending markets; · import and export controls; · exchange controls and restrictions on remittances abroad and payments of dividends; · modifications to laws and regulations according to political, social and economic interests; · fiscal policy and changes in tax laws; · economic, political and social instability, including general strikes and mass demonstrations; · the regulatory framework governing the educational industry; · labor and social security regulations; 32 Table of Contents · energy and water shortages and rationing; · commodity prices; · changes in demographics, in particular declining birth rates, which will result in a decrease in the number of enrolled students in education in the future; and · other political, diplomatic, social and economic developments in or affecting Brazil. Uncertainty over whether the Brazilian federal government will implement reforms or changes in policy or regulation affecting these or other factors in the future may affect economic performance and contribute to economic uncertainty in Brazil, which may have an adverse effect on our activities and consequently our operating results, and may also adversely affect the trading price of our Class A common shares. Recent economic and political instability has led to a negative perception of the Brazilian economy and higher volatility in the Brazilian securities markets, which also may adversely affect us and our Class A common shares. See “Item 5. Operating and Financial Review and Prospects—Significant Factors Affecting Our Results of Operations—Brazilian Macroeconomic Environment.” Economic uncertainty and political instability in Brazil may harm our business and the price of our Class A common shares. Brazil’s political environment has historically influenced, and continues to influence, the performance of the country’s economy. Political crises have affected and continue to affect the confidence of investors and the general public, which have historically resulted in economic deceleration and heightened volatility in the securities offered by companies with significant operations in Brazil. The recent economic instability in Brazil has contributed to a decline in market confidence in the Brazilian economy as well as to a deteriorating political environment. Historically, expenditures by the Brazilian federal government have resulted in fiscal deficits, with consecutive deficits recorded from 2014 to 2020. However, in 2022, the federal government achieved a budget surplus, driven in part by rising commodity prices and higher inflation. In 2023, as commodity prices stabilized, inflation eased, and economic activity slowed, government revenues declined while expenditures continued to rise, leading to a budget deficit. In 2024, despite a 9.62% increase in total federal fiscal revenues compared to 2023 (in inflation-adjusted terms), supported by ad hoc measures enacted at the end of 2023, public expenditures grew at a faster pace, resulting in another budget deficit. The Brazilian government continues to navigate a challenging fiscal environment, even after the approval of a new fiscal framework in 2023. Likewise, Brazil’s state governments are facing fiscal pressures due to high debt burdens, declining revenues, rigid expenditures, and extensive federal economic relief programs, alongside additional aid efforts in response to floods in early 2024 in the State of Rio Grande do Sul. In addition, uncertainties relating to the implementation by the new Brazilian government under President Luis Inácio Lula da Silva of changes to monetary, fiscal and social security policy and related legislation (including as a result of the 2024 municipal elections, the relationship between the executive, legislative and judiciary branches and the relationships among the leading political parties) may contribute to economic instability. Specifically, although the tax reform on duties levied on consumption was approved by the Brazilian Congress in 2023, it continues to require the approval of additional legislation by lawmakers in 2025 to be fully implemented by the Brazilian government. On October 3, 2024, the Brazilian government issued Provisional Measure No. 1,262, establishing the implementation of the OECD Pillar Two global minimum tax in Brazil. On December 27, 2024, Law No. 15,079/2024 was enacted, formalizing these requirements and making them definitive for the implementation of the new tax regime in the country. A new round of tax reforms is also expected to be presented to the Brazilian Congress by the Brazilian government in 2025, including the revocation of the income tax exemption on the payment of dividends, which, if enacted, would increase the taxes associated with any dividend or distribution by Brazilian companies and could impact our capacity to receive future dividends or distributions net of taxes from our subsidiaries. The incumbent administration has stated that this proposed reform is among their priorities, along with other economic reforms. Any such new policies or changes to current policies may have a material adverse effect on us. These uncertainties and new measures may increase the volatility of the Brazilian capital markets. A failure by the Brazilian government to implement necessary reforms may result in diminished confidence in the Brazilian government’s budgetary condition and fiscal stance, which could result in downgrades of Brazil’s sovereign foreign credit rating by credit rating agencies, negatively impact Brazil’s economy, and lead to further depreciation of the real and an increase in inflation and interest rates, which could adversely affect our business, financial condition and results of operations. Any of the above factors may harm the Brazilian economy and, consequently, our business and the price of our Class A common shares. 33 Table of Contents Inflation and certain measures by the Brazilian government to curb inflation have historically harmed the Brazilian economy and Brazilian capital markets, and high levels of inflation in the future would harm our business and the price of our Class A common shares. In the past, Brazil has experienced extremely high rates of inflation. Inflation and some of the measures taken by the Brazilian government in an attempt to curb inflation have had significant negative effects on the Brazilian economy generally. Inflation, policies adopted to curb inflationary pressures and uncertainties regarding possible future governmental intervention have contributed to economic uncertainty and heightened volatility in the Brazilian capital markets. According to the National Consumer Price Index (Índice Nacional de Preços ao Consumidor Amplo, or IPCA), which is published by the Brazilian Institute for Geography and Statistics (Instituto Brasileiro de Geografia e Estatística, or IBGE), Brazilian inflation rates were 4.8%, 4.6% and 5.8% as of December 31, 2024, 2023 and 2022, respectively. Brazil may experience high levels of inflation in the future and inflationary pressures may lead to the Brazilian government intervening in the economy and introducing policies that could harm our business and the trading price of our Class A common shares. In the past, the Brazilian government’s interventions included the maintenance of a restrictive monetary policy with high interest rates that restricted credit availability and reduced economic growth, causing volatility in interest rates. For example, the Monetary Policy Committee (Comitê de Política Monetária do Banco Central do Brasil), or COPOM, started raising the official base interest rate (Sistema Especial de Liquidação e Custódia) or the SELIC rate, in mid-March 2021, ultimately reaching 9.25% by the end of 2021. This cycle continued into 2022, with the SELIC rate peaking at 13.75% in August 2022, at which point COPOM opted to maintain that level. The SELIC rate stayed at 13.75% for nearly a year, as inflation hovered near the upper limit of COPOM’s target range pursuant to applicable law (3.25% for 2023 and 3.0% thereafter). In August 2023, as inflationary pressures eased, COPOM began reducing the SELIC rate, which fell to 10.50% by May 2024. Nevertheless, renewed inflationary pressures—driven in part by fiscal concerns stemming from persistent budget deficits and increased government spending—prompted COPOM to reverse course and resume hiking rates in September 2024, with the SELIC rate reaching 12.25% by December 2024. As of the date of this annual report, the SELIC rate stands at 14.25% per annum, reflecting the challenges of controlling inflation amid a strong economy, historically low unemployment levels, and fiscal imbalances requiring tighter monetary policy to maintain economic stability. Exchange rate instability may have adverse effects on the Brazilian economy, us and the price of our Class A common shares. The Brazilian currency has been historically volatile and has been devalued frequently over the past three decades. Throughout this period, the Brazilian government has implemented various economic plans and used various exchange rate policies, including sudden devaluations, periodic mini devaluations (during which the frequency of adjustments has ranged from daily to monthly), exchange controls, dual exchange rate markets and a floating exchange rate system. Although long-term depreciation of the real is generally linked to the rate of inflation in Brazil, depreciation of the real occurring over shorter periods of time has resulted in significant variations in the exchange rate between the real, the U.S. dollar and other currencies. The real/U.S. dollar exchange rate reported by the Central Bank was R$5.580 per US$1.00 on December 31, 2021, which reflected a 7.3% depreciation in the real against the U.S. dollar during 2021. On December 31, 2022, the exchange rate of the U.S. dollar as reported by the Central Bank was R$5.218 per US$1.00, which reflected a 6.5% appreciation in the real against the U.S. dollar since December 31, 2021. The real/U.S. dollar exchange rate reported by the Central Bank was R$4.841 per US$1.00 on December 31, 2023, which reflected a 7.2% appreciation in the real against the U.S. dollar during 2023. The real/U.S. dollar exchange rate reported by the Central Bank was R$6.192 per US$1.00 on December 31, 2024, which reflected a 27.9% depreciation in the real against the U.S. dollar during 2024. As of April 24, 2025, the exchange rate for the sale of U.S. dollars as reported by the Central Bank was R$5.6738 per US$1.00, which reflected an appreciation of 8.4% in the real against the U.S. dollar since December 31, 2024. There can be no assurance that the real will not again depreciate or appreciate against the U.S. dollar or other currencies in the future. 34 Table of Contents A devaluation of the real relative to the U.S. dollar could create inflationary pressures in Brazil and cause the Brazilian government to, among other measures, increase interest rates. Any depreciation of the real may generally restrict access to the international capital markets. It would also reduce the U.S. dollar value of our results of operations. Restrictive macroeconomic policies could reduce the stability of the Brazilian economy and harm our results of operations and profitability. In addition, domestic and international reactions to restrictive economic policies could have a negative impact on the Brazilian economy. These policies and any reactions to them may harm us by curtailing access to foreign financial markets and prompting further government intervention. A devaluation of the real relative to the U.S. dollar may also, as in the context of the current economic slowdown, decrease consumer spending, increase deflationary pressures and reduce economic growth. On the other hand, an appreciation of the real relative to the U.S. dollar and other foreign currencies may deteriorate the Brazilian foreign exchange current accounts. Depending on the circumstances, either devaluation or appreciation of the real relative to the U.S. dollar and other foreign currencies could restrict the growth of the Brazilian economy, as well as our business, results of operations and profitability. Infrastructure and workforce deficiency in Brazil may impact economic growth and have a material adverse effect on us. Our performance depends on the overall health and growth of the Brazilian economy. Brazilian GDP growth has fluctuated over the past few years, notwithstanding a growth of 3.0% in 2022, a growth of 2.9% in 2023, and a growth of 3.4% in 2024. Growth is limited by inadequate infrastructure, including potential energy shortages and deficient transportation, logistics and telecommunication sectors, general strikes, the lack of a qualified labor force, and the lack of private and public investments in these areas, which limit productivity and efficiency. Any of these factors could lead to labor market volatility and generally impact income, purchasing power and consumption levels, which could limit growth and ultimately have a material adverse effect on us. Developments and the perceptions of risks in other countries, including other emerging markets, the United States and Europe, may harm the Brazilian economy and the price of our Class A common shares. The market for securities offered by companies with significant operations in Brazil is influenced by economic and market conditions in Brazil and, to varying degrees, market conditions in other Latin American and emerging markets, as well as the United States, Europe and other countries. There have been concerns over conflicts, unrest and terrorist threats in the Middle East, Europe and Africa, which have resulted in volatility in oil and other markets. Furthermore, after taking office, the U.S. president raised the possibility of imposing tariffs on key trade partners of the United States, such as Mexico and Canada, and also imposed a series of significant economic tariffs on a wide array of goods imported into the United States, including certain imports from China as well as on imports of steel and aluminum from around the world. Brazil, as an exporter of steel and aluminum to the United States, will be adversely affected by these tariffs. There is no guarantee that the United States will not impose additional tariffs on Brazilian exports, whether directly on Brazilian goods more broadly or indirectly through tariffs on other products that incorporate Brazilian inputs. To the extent the conditions of the global markets or economy deteriorate, the business of companies with significant operations in Brazil may be harmed. The weakness in the global economy has been marked by, among other adverse factors, lower levels of consumer and corporate confidence, decreased business investment and consumer spending, increased unemployment, reduced income and asset values in many areas, reduction of China’s growth rate, currency volatility and limited availability of credit and access to capital. Developments or economic conditions in other emerging market countries have at times significantly affected the availability of credit to companies with significant operations in Brazil and resulted in considerable outflows of funds from Brazil, decreasing the amount of foreign investments in Brazil. These developments, as well as potential crises and forms of political instability arising therefrom or any other as of yet unforeseen development, may harm our business and the price of our Class A common shares. Any further downgrading of Brazil’s credit rating could reduce the trading price of our Class A common shares. We and the trading price of our Class A common shares may be harmed by investors’ perceptions of risks related to Brazil’s sovereign debt credit rating. Rating agencies regularly evaluate Brazil and its sovereign credit ratings, which are based on a number of factors, including macroeconomic trends, fiscal and budgetary conditions, indebtedness metrics and the perspective of changes in any of these factors. 35 Table of Contents The rating agencies began to review Brazil’s sovereign credit rating in September 2015. Subsequently, the three major rating agencies downgraded Brazil’s investment-grade status: · In 2015, Standard & Poor’s initially downgraded Brazil’s credit rating from BBB-negative to BB-positive and subsequently downgraded it again from BB-positive to BB, maintaining its negative outlook. On January 11, 2018, Standard & Poor’s further downgraded Brazil’s credit rating from BB to BB-negative, and on December 11, 2019, the agency affirmed the rating at BB- and revised the outlook on Brazil to positive. On April 7, 2020, the rating was reaffirmed as BB- with a stable outlook. On November 30, 2021 and June 15, 2022, Standard & Poor’s further reaffirmed Brazil’s rating at BB- with a stable outlook. On December 19, 2023, the rating was upgraded to BB with a stable outlook, reflecting the rating agency’s expectation that Brazil will make slow progress in addressing fiscal imbalances and that its still weak economic prospects, balanced by a strong external position and monetary policy is helping to re-anchor inflation expectations. · In 2015, Moody’s downgraded Brazil’s Baa3’s issue and bond ratings to below investment grade, at Ba2 with a negative outlook. On April 9, 2018, Moody’s revised the outlook to stable, reaffirming the Ba2 rating. In September 2020, Moody’s maintained Brazil’s credit rating at Ba2 with a stable outlook. In May 2020, Moody’s confirmed Brazil’s long-term foreign currency sovereign credit rating at Ba2 maintaining a stable outlook. On May 25, 2021, April 12, 2022 and October 20, 2023, Moody’s further reaffirmed Brazil’s rating at Ba2 with a stable outlook. On October 1, 2024, Moody’s upgraded Brazil’s credit rating to Ba1 with a positive outlook. · In 2015, Fitch downgraded Brazil’s sovereign credit rating to BB-positive with a negative outlook, citing the rapid expansion of the country’s budget deficit and the worse-than-expected recession. In February 2018, Fitch downgraded Brazil’s sovereign credit rating again to BB-negative. In November 2020, Fitch Ratings affirmed Brazil’s long-term foreign currency sovereign credit rating at BB- with a negative outlook. On December 14, 2021, Fitch further reaffirmed Brazil’s credit rating at BB-negative with a negative outlook. On July 14, 2022, while reaffirming Brazil’s credit rating at BB-negative, Fitch changed its outlook on Brazil’s credit rating to a positive outlook. On July 26, 2023, Fitch upgraded Brazil’s credit rating at BB and changed its outlook on Brazil’s credit rating to a stable outlook. On December 15, 2023 and June 27, 2024, Fitch further reaffirmed Brazil’s rating at BB with a stable outlook. Brazil’s sovereign credit rating is currently rated below investment grade by the three main credit rating agencies. Consequently, the prices of securities offered by companies with significant operations in Brazil have been negatively affected. A prolongation or worsening of the challenging economic conditions currently facing Brazil, along with continued political uncertainty, among other factors, could lead to further ratings downgrades. Any further downgrade of Brazil’s sovereign foreign credit ratings could heighten investors’ perception of risk and, as a result, cause the trading price of our Class A common shares to decline. Certain Risks Relating to Our Class A Common Shares An active trading market for our Class A common shares may not be sustainable. If an active trading market is not maintained, investors may not be able to resell their shares and our ability to raise capital in the future may be impaired. Although our Class A common shares are listed and being traded on the Nasdaq Global Select Market, an active trading market for our shares may not be maintained. The existence of our dual-class share structure could also result in less liquidity for our Class A common shares than if there were only one class of our common shares. If an active market for our Class A common shares is not maintained, it may be difficult for you to sell shares without depressing the market price for the shares or at all. An inactive trading market may also impair our ability to raise capital to continue to fund operations by selling shares and may impair our ability to acquire other companies or technologies by using our shares as consideration. In addition to the risks described above, the market price of our Class A common shares may be influenced by many factors, some of which are beyond our control, including: · announcements by us or our competitors of significant contracts or acquisitions; · technological innovations by us or competitors; 36 Table of Contents · the failure of financial analysts to cover our Class A common shares or changes in financial estimates by analysts; · actual or anticipated variations in our operating results; · changes in financial estimates by financial analysts, or any failure by us to meet or exceed any of these estimates, or changes in the recommendations of any financial analysts that elect to follow our Class A common shares or the shares of our competitors; · future sales of our shares; and · investor perceptions of us and the industries in which we operate. In addition, the stock market in general has experienced substantial price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of particular companies affected. These broad market and industry factors may materially harm the market price of our Class A common shares, regardless of our operating performance. In the past, following periods of volatility in the market price of certain companies’ securities, securities class action litigation has been instituted against these companies. This litigation, if instituted against us, could adversely affect our financial condition or results of operations. If a market is not maintained, the liquidity and price of our Class A common shares could be seriously harmed. The concentration of ownership and voting power in Bertelsmann, our controlling shareholder, limits your ability to influence corporate matters. Bertelsmann, our controlling shareholder, as of the date of this annual report, owns 77.8% of our outstanding Class B common shares, which, together with its ownership of 57.0% of our outstanding Class A common shares, represent approximately 67.1% of our outstanding share capital and 75.8% of the voting power of our outstanding share capital, and, together with the Esteves Family, controls all matters requiring shareholder approval. Our Class B common shares are entitled to 10 votes per share and our Class A common shares, which are the common shares trading on NASDAQ, are entitled to one vote per share. Our Class B common shares are convertible into an equivalent number of Class A common shares and generally convert into Class A common shares upon transfer subject to limited exceptions. As a result, Bertelsmann and the Esteves Family will control the outcome of all of our decisions at our shareholders’ meetings, and Bertelsmann alone is able to elect a majority of the members of our board of directors. The decisions of Bertelsmann and the Esteves Family on these matters may be contrary to your expectations or preferences, and they may take actions that could be contrary to your interests. They are able to prevent any other shareholders, including you, from blocking these actions. For further information regarding shareholdings in our company, see “Item 7. Major Shareholders and Related Party Transactions—A. Major Shareholders.” So long as Bertelsmann and the Esteves Family continue to beneficially own a sufficient number of Class B common shares, even if they beneficially own significantly less than 50% of our outstanding share capital, acting together, they will be able to effectively control the outcome of all decisions at our shareholders’ meetings. For example, if our Class B common shares amounted to 15% of our outstanding common shares, beneficial owners of our Class B common shares (consisting of the Esteves Family and Bertelsmann), would collectively control 63.8% of the voting power of our outstanding common shares. If Bertelsmann sells or transfers any of its Class B common shares, they will generally convert automatically into Class A common shares, subject to limited exceptions, such as transfers to affiliates, to trustees for the holder or its affiliates and certain transfers to U.S. tax exempt organizations. The fact that any Class B common shares convert into Class A common shares if Bertelsmann sells or transfers them means that Bertelsmann will in many situations continue to control a majority of the combined voting power of our outstanding share capital, due to the voting rights of any Class B common shares that it will retain. However, if our Class B common shares at any time represent less than 10% of the total number of shares in the capital of the Company outstanding, the Class B common shares then outstanding will automatically convert into Class A common shares. For a description of our dual class equity structure, see “Item 10. Additional Information—B. Memorandum and Articles of Association—Description of Share Capital.” 37 Table of Contents Class A common shares eligible for future sale may cause the market price of our Class A common shares to drop significantly. The market price of our Class A common shares may decline as a result of sales of a large number of our Class A common shares in the market (including Class A common shares issuable upon conversion of Class B common shares) or the perception that these sales may occur. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate. As of December 31, 2024, we have 49,920,068 Class A common shares and 43,802,763 Class B common shares outstanding, which, except as set forth below, are freely tradable without restriction or further registration under the Securities Act by persons other than our affiliates within the meaning of Rule 144 of the Securities Act. Our shareholders or entities controlled by them or their permitted transferees will be able to sell their shares in the public market from time to time without registering them, subject to certain limitations on the timing, amount and method of those sales imposed by regulations promulgated by the SEC. If any of our shareholders, the affiliated entities controlled by them or their respective permitted transferees were to sell a large number of their shares, including common shares issuable upon conversion of the Series A perpetual convertible preferred shares, the market price of our Class A common shares may decline significantly. In addition, the perception in the public markets that sales by them might occur may also adversely affect the market price of our Class A common shares. Our Articles of Association contain anti-takeover provisions that may discourage a third party from acquiring us and adversely affect the rights of holders of our Class A common shares. Our Articles of Association contain certain provisions that could limit the ability of others to acquire our control, including a provision that grants authority to our board of directors to establish and issue from time to time one or more series of preferred shares without action by our shareholders and to determine, with respect to any series of preferred shares, the terms and rights of that series. These provisions could have the effect of depriving our shareholders of the opportunity to sell their shares at a premium over the prevailing market price by discouraging third parties from seeking to obtain our control in a tender offer or similar transactions. If securities or industry analysts publish inaccurate or unfavorable research, about our business, the price of our Class A common shares and our trading volume could decline. The trading market for our Class A common shares will depend in part on the research and reports that securities or industry analysts publish about us, our business, our market or our competitors. In the event one or more of the analysts who cover us downgrades us or releases negative publicity about our Class A common shares, our share price would likely decline. Further, as we are not required to publish quarterly financial information, if we cease to publish that information, any analysts covering us may not have enough information to compare us to our peers on a regular basis and may choose to cease coverage. If one or more of these analysts ceases to cover us or fails to regularly publish reports on us, interest in our Class A common shares may decrease, which may cause our share price or trading volume to decline. There can be no assurance that we will continue to declare dividends. On March 12, 2025, our board of directors approved the distribution of our first-ever dividends. The payment of any dividends in the future is subject to continued capital availability, market conditions, applicable laws and agreements, and our board of directors continuing to determine that the declaration of dividends are in the best interests of our shareholders. The declaration and payment of any dividend may be discontinued or reduced at any time, and there can be no assurance that we will declare dividends in the future in any particular amounts, or at all. 38 Table of Contents Our Series A perpetual convertible preferred shares have rights, preferences and privileges that are not held by, and are preferential to, the rights of our common shares, which could adversely affect our liquidity and financial condition, and may result in the interests of the holders of our Series A perpetual convertible preferred shares differing from those of our common shareholders. The Series A perpetual convertible preferred shares rank senior to our common shares with respect to dividend rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of our affairs. The holders of Series A perpetual convertible preferred shares have the right to receive a liquidation preference entitling them to be paid out of our assets available for distribution to stockholders before any payment may be made to holders of any other class or series of our share capital, an amount equal to the greater of (a) the sum of the original liquidation preference plus all accrued but unpaid dividends or (b) the amount that such holder would have been entitled to receive upon our liquidation, dissolution and winding up if all outstanding shares of such series of Series A perpetual convertible preferred shares had been converted into common shares immediately prior to such liquidation, dissolution or winding up. In addition, the holders of the Series A perpetual convertible preferred shares are entitled to a cumulative dividend at the rate of 6.5% per annum. The holders of the Series A perpetual convertible preferred shares are also entitled to participate in dividends declared or paid on our common shares on an as-converted basis. The holders of our Series A perpetual convertible preferred shares also have the right, subject to certain exceptions, to require us to repurchase all or any portion of the Series A perpetual convertible preferred shares upon certain change of control events at the repurchase price set forth in the applicable certificate of designations. These dividend and share repurchase obligations could impact our liquidity and reduce the amount of cash flows available for general corporate purposes. Our obligations to the holders of the Series A perpetual convertible preferred shares could also limit our ability to obtain additional financing or increase our borrowing costs, which could have an adverse effect on our financial condition. These preferential rights could also result in divergent interests between the holders of Series A perpetual convertible preferred shares and holders of our common shares. The issuance of Series A perpetual convertible preferred shares reduces the relative voting power of holders of our common stock, and the conversion and sale of those shares would dilute the ownership of holders of common shares and may adversely affect the market price of our common shares. As of December 31, 2024, 150,000 Series A perpetual convertible preferred shares were outstanding, representing approximately 6.6 % of our outstanding common shares, excluding treasury shares and including the Series A perpetual convertible preferred shares on an as-converted basis. Holders of Series A perpetual convertible preferred shares are entitled to a cumulative dividend at the rate of 6.5% per annum. Because holders of our Series A perpetual convertible preferred shares are entitled to vote on certain matters described in “—SoftBank and any other holders of our Series A perpetual convertible preferred shares may exercise influence over us,” the issuance of the Series A perpetual convertible preferred shares, and the subsequent issuance of additional Series A perpetual convertible preferred shares, effectively reduce the relative voting power of the holders of our common shares. In addition, the conversion of the Series A perpetual convertible preferred shares into common shares would dilute the ownership interest of existing holders of our common shares. Furthermore, any sales in the public market of the common shares issuable upon conversion of the Series A perpetual convertible preferred shares would increase the number of our common shares available for public trading and could adversely affect prevailing market prices of our common shares. Sales of a substantial number of our common shares in the public market, or the perception that such sales might occur, could have a material adverse effect on the price of our common shares. SoftBank and any other holders of our Series A perpetual convertible preferred shares may exercise influence over us. As of December 31, 2024, outstanding Series A perpetual convertible preferred shares represented approximately 6.6% of our outstanding common shares, excluding treasury shares and including the Series A perpetual convertible preferred shares on an as-converted basis. The terms of the Series A perpetual convertible preferred shares require the approval of a majority of our Series A perpetual convertible preferred shares by a separate class vote for us to take the following decisions, among others described in the respective certificate of designations: 39 Table of Contents · amend our organizational documents in a manner that would have an adverse effect on the Series A perpetual convertible preferred shares; or · issue securities that are senior to, or equal in priority with, the Series A perpetual convertible preferred shares. Circumstances may occur in which the interests of SoftBank and its affiliates could diverge from, or even conflict with, the interests of our other shareholders. For example, the existence of SoftBank as a significant shareholder may have the effect of delaying or preventing changes in control or management or limiting the ability of our other shareholders to approve transactions that they may deem to be in our best interests. SoftBank and its affiliates may seek to cause us to take courses of action that, in their judgment, could enhance its investment in us but which might involve risks to our other shareholders or adversely affect us or our other shareholders. Our dual class equity structure means our shares will not be included in certain indices. We cannot predict the impact this may have on our share price. In 2017, FTSE Russell, S&P Dow Jones and MSCI announced changes to their eligibility criteria for inclusion of shares of public companies on certain indices to exclude companies with multiple classes of shares of common stock from being added to such indices. FTSE Russell announced plans to require new constituents of its indices to have at least five percent of their voting rights in the hands of public stockholders, whereas S&P Dow Jones announced that companies with multiple share classes, such as ours, will not be eligible for inclusion in the S&P 500, S&P MidCap 400 and S&P SmallCap 600, which together make up the S&P Composite 1500. MSCI also opened public consultations on their treatment of no-vote and multi-class structures and temporarily barred new multi-class listings from its ACWI Investable Market Index and U.S. Investable Market 2500 Index; however, in October 2018, MSCI announced its decision to include equity securities “with unequal voting structures” in its indices and to launch a new index that specifically includes voting rights in its eligibility criteria. We cannot assure you that other stock indices will not take a similar approach to FTSE Russell, S&P Dow Jones and MSCI in the future. Under the announced policies, our dual class equity structure would make us ineligible for inclusion in any of these indices and, as a result, mutual funds, exchange-traded funds and other investment vehicles that attempt to passively track these indices will not invest in our stock. It continues to be somewhat unclear what effect, if any, these policies will have on the valuations of publicly traded companies excluded from the indices, but in certain situations they may depress these valuations compared to those of other similar companies that are included. Exclusion from indices could make our Class A common shares less attractive to investors and, as a result, the market price of our Class A common shares could be adversely affected. The dual class equity structure of our common stock has the effect of concentrating voting control with Bertelsmann; this will limit or preclude your ability to influence corporate matters. Each Class A common share entitles its holder to one vote per share, and each Class B common share entitles its holder to 10 votes per share. Due to the 10-to-one voting ratio between our Class B and Class A common shares, the beneficial owners of our Class B common shares (composed of the Esteves Family and Bertelsmann) collectively will continue to control a majority of the combined voting power of our common shares and therefore be able to control all matters submitted to our shareholders so long as the total number of the issued and outstanding Class B common shares is at least 16.67% of the total number of shares outstanding. However, if our Class B common shares at any time represent less than 10% of the total number of shares in the capital of the Company outstanding, the Class B common shares then outstanding will automatically convert into Class A common shares. In addition, our Articles of Association provide that at any time when there are Class A common shares in issue, additional Class B common shares may only be issued pursuant to (1) a share split, subdivision of shares or similar transaction or where a dividend or other distribution is paid by the issue of shares or rights to acquire shares or following capitalization of profits, (2) a merger, consolidation, or other business combination involving the issuance of Class B common shares as full or partial consideration, or (3) an issuance of Class A common shares, whereby holders of the Class B common shares are entitled to purchase a number of Class B common shares that would allow them to maintain their proportional ownership interests in Afya (following an offer by us to each holder of Class B common shares to issue to such holder, upon the same economic terms and at the same price, such number of Class B common shares as would ensure such holder may maintain a proportional ownership interest in Afya pursuant to our Articles of Association). 40 Table of Contents Future transfers by holders of Class B common shares will generally result in those shares converting to Class A common shares, subject to limited exceptions, such as certain transfers effected to permitted transferees or for estate planning or charitable purposes. The conversion of Class B common shares to Class A common shares will have the effect, over time, of increasing the relative voting power of those holders of Class B common shares who retain their shares in the long term. In light of the above provisions relating to the issuance of additional Class B common shares, the fact that future transfers by holders of Class B common shares will generally result in those shares converting to Class A common shares, subject to limited exceptions as provided in the Articles of Association; as well as the 10-to-one voting ratio of our Class B common shares and Class A common shares, holders of our Class B common shares will in many situations continue to maintain control of all matters requiring shareholder approval. This concentrated control will limit or preclude your ability to influence corporate matters for the foreseeable future. For a description of our dual class equity structure, see “Item 10. Additional Information—B. Memorandum and Articles of Association—Description of Share Capital—Voting Rights.” We are a Cayman Islands exempted company with limited liability. The rights of our shareholders, including with respect to fiduciary duties and corporate opportunities, may be different from the rights of shareholders governed by the laws of U.S. jurisdictions. We are a Cayman Islands exempted company with limited liability. Our corporate affairs are governed by our Articles of Association and by the laws of the Cayman Islands. The rights of shareholders and the responsibilities of members of our board of directors may be different from the rights of shareholders and responsibilities of directors in companies governed by the laws of U.S. jurisdictions. In particular, as a matter of Cayman Islands law, directors of a Cayman Islands company owe fiduciary duties to the company and separately a duty of care, diligence and skill to the company. Under Cayman Islands law, directors and officers owe the following fiduciary duties: (i) duty to act in good faith in what the director or officer believes to be in the best interests of the company as a whole; (ii) duty to exercise powers for the purposes for which those powers were conferred and not for a collateral purpose; (iii) directors should not improperly fetter the exercise of future discretion; (iv) duty to exercise powers fairly as between different sections of shareholders; (v) duty to exercise independent judgment; and (vi) duty not to put themselves in a position in which there is a conflict between their duty to the company and their personal interests. Our Articles of Association have varied this last obligation by providing that a director must disclose the nature and extent of his or her interest in any contract or arrangement, and following such disclosure and subject to any separate requirement under applicable law or the listing rules of the Nasdaq, and unless disqualified by the chairman of the relevant meeting, such director may vote in respect of any transaction or arrangement in which he or she is interested and may be counted in the quorum at the meeting. Conversely, under Delaware corporate law, a director has a fiduciary duty to the corporation and its stockholders (made up of two components) and the director’s duties prohibit self-dealing by a director and mandate that the best interest of the corporation and its shareholders take precedence over any interest possessed by a director, officer or controlling shareholder and not shared by the shareholders generally. See “Item 10. Additional Information—B. Memorandum and Articles of Association—Description of Share Capital—Principal Differences between Cayman Islands and U.S. Corporate Law.” We may need to raise additional capital in the future by issuing securities, use our Class A common shares as acquisition consideration or enter into corporate transactions with an effect similar to a merger, which may dilute your interest in our share capital and affect the trading price of our Class A common shares. We may need to raise additional funds to grow our business and implement our growth strategy going forward through public or private issuances of common shares or securities convertible into, or exchangeable for, our common shares, which may dilute your interest in our share capital or result in a decrease in the market price of our common shares. In addition, we may also use our Class A common shares as acquisition consideration or enter into mergers or other similar transactions in the future, which may dilute your interest in our share capital or result in a decrease in the market price of our Class A common shares. Any fundraising through the issuance of shares or securities convertible into or exchangeable for shares, the use of our Class A common shares as acquisition consideration, or the participation in corporate transactions with an effect similar to a merger, may dilute your interest in our capital stock or result in a decrease in the market price of our Class A common shares. 41 Table of Contents As a foreign private issuer, we have different disclosure and other requirements than U.S. domestic registrants. As a foreign private issuer, we are subject to different disclosure and other requirements than domestic U.S. registrants. For example, as a foreign private issuer, in the United States, we are not subject to the same disclosure requirements as a domestic U.S. registrant under the Exchange Act, including the requirements to prepare and issue quarterly reports on Form 10-Q or to file current reports on Form 8-K upon the occurrence of specified significant events, the proxy rules applicable to domestic U.S. registrants under Section 14 of the Exchange Act or the insider reporting and short-swing profit rules applicable to domestic U.S. registrants under Section 16 of the Exchange Act. In addition, we rely on exemptions from certain U.S. rules which permit us to follow Cayman Islands legal requirements rather than certain of the requirements that are applicable to U.S. domestic registrants. We follow Cayman Islands laws and regulations that are applicable to Cayman Islands companies. However, Cayman Islands laws and regulations applicable to Cayman Islands companies do not contain any provisions comparable to the U.S. proxy rules, the U.S. rules relating to the filing of reports on Form 10-Q or 8-K or the U.S. rules relating to liability for insiders who profit from trades made in a short period of time, as referred to above. Furthermore, foreign private issuers are required to file their annual report on Form 20-F within 120 days after the end of each fiscal year, while U.S. domestic issuers that are accelerated filers are required to file their annual report on Form 10-K within 75 days after the end of each fiscal year. Foreign private issuers are also exempt from Regulation Fair Disclosure, aimed at preventing issuers from making selective disclosures of material information, although we will be subject to Cayman Islands laws and regulations having substantially the same effect as Regulation Fair Disclosure. As a result of the above, even though we are required to file reports on Form 6-K disclosing the limited information which we have made or are required to make public pursuant to Cayman Islands law, or are required to distribute to shareholders generally, and that is material to us, you may not receive information of the same type or amount that is required to be disclosed to shareholders of a U.S. company. As a foreign private issuer, we rely on permitted exemptions from certain Nasdaq corporate governance standards applicable to U.S. issuers, including the requirement that a majority of an issuer’s directors consist of independent directors. This may afford less protection to holders of our Class A common shares. Section 5605 of the Nasdaq equity rules requires listed companies to have, among other things, a majority of their board members be independent, and to have independent director oversight of executive compensation, nomination of directors and corporate governance matters. As a foreign private issuer, however, we are permitted to, and we have, and will continue to, follow home country practice in lieu of the above requirements. See “Item 10. Additional Information—B. Memorandum and Articles of Association—Description of Share Capital—Principal Differences between Cayman Islands and U.S. Corporate Law.” We may lose our foreign private issuer status, which would then require us to comply with the Exchange Act’s domestic reporting regime and cause us to incur significant legal, accounting and other expenses. In order to maintain our current status as a foreign private issuer, either (a) more than 50% of our Class A common shares must be either directly or indirectly owned of record by non-residents of the United States or (b)(i) a majority of our executive officers or directors may not be U.S. citizens or residents, (ii) more than 50% of our assets cannot be located in the United States and (iii) our business must be administered principally outside the United States. If we lose this status, we would be required to comply with the Exchange Act reporting and other requirements applicable to U.S. domestic issuers, which are more detailed and extensive than the requirements for foreign private issuers. We may also be required to make changes in our corporate governance practices in accordance with various SEC and Nasdaq rules. The regulatory and compliance costs to us under U.S. securities laws if we are required to comply with the reporting requirements applicable to a U.S. domestic issuer may be significantly higher than the costs we will incur as a foreign private issuer. Our shareholders may face difficulties in protecting their interests because we are a Cayman Islands exempted company. Our corporate affairs are governed by our Articles of Association, by the Companies Act (As Revised) of the Cayman Islands and the common law of the Cayman Islands. The rights of shareholders to take action against the directors, actions by minority shareholders and the fiduciary responsibilities of our directors to us under Cayman Islands law are to a large extent governed by the common law of the Cayman Islands. The common law of the Cayman Islands is derived in part from comparatively limited judicial precedent in the Cayman Islands as well as that from English common law, which has persuasive, but not binding, authority on a court in the Cayman Islands. The rights of our shareholders and the fiduciary responsibilities of our directors under Cayman Islands law are different from what they would be under statutes or judicial precedent in some jurisdictions in the United States. In particular, the Cayman Islands has a less exhaustive body of securities laws than the United States. In addition, some U.S. states, such as Delaware, have more fully developed and judicially interpreted bodies of corporate law. 42 Table of Contents As a result of all of the above, public shareholders may have more difficulty in protecting their interests in the face of actions taken by management, members of the board of directors or controlling shareholder than they would as shareholders of a corporation incorporated in a jurisdiction in the United States. While Cayman Islands law allows a dissenting shareholder to express the shareholder’s view that a court-sanctioned reorganization by way of a scheme of arrangement of a Cayman Islands company would not provide fair value for the shareholder’s shares, Cayman Islands statutory law does not specifically provide for shareholder appraisal rights in connection with a court sanctioned reorganization by way of a scheme of arrangement. This may make it more difficult for you to assess the value of any consideration you may receive in a merger or consolidation by way of a scheme of arrangement or to require that the acquirer gives you additional consideration if you believe the consideration offered is insufficient. However, Cayman Islands statutory law provides a mechanism for a dissenting shareholder in a statutory merger or consolidation to apply to the Grand Court of the Cayman Islands for a determination of the fair value of the dissenter’s shares if it is not possible for the company and the dissenter to agree on a fair price within the time limits prescribed. Shareholders of Cayman Islands exempted companies (such as us) have no general rights under Cayman Islands law to inspect corporate records and accounts or to obtain copies of lists of shareholders. Our directors have discretion under our Articles of Association to determine whether or not, and under what conditions, our corporate records may be inspected by our shareholders, but are not obliged to make them available to our shareholders. This may make it more difficult for you to obtain information needed to establish any facts necessary for a shareholder motion or to solicit proxies from other shareholders in connection with a proxy contest. United States civil liabilities and certain judgments obtained against us by our shareholders may not be enforceable. We are a Cayman Islands exempted company and substantially all of our assets are located outside of the United States. In addition, the majority of our directors and officers are nationals and residents of countries other than the United States. A substantial portion of the assets of these persons is located outside of the United States. As a result, it may be difficult to effect service of process within the United States upon these persons. It may also be difficult to enforce in U.S. courts judgments obtained in U.S. courts based on the civil liability provisions of the U.S. federal securities laws against us and our officers and directors who are not resident in the United States and the substantial majority of whose assets are located outside of the United States. Further, it is unclear if original actions predicated on civil liabilities based solely upon U.S. federal securities laws are enforceable in courts outside the United States, including in the Cayman Islands and Brazil. The courts of the Cayman Islands are unlikely (i) to recognize or enforce against us judgments of courts of the United States predicated upon the civil liability provisions of the federal securities laws of the United States or any state ; and (ii) in original actions brought in the Cayman Islands, to impose liabilities against us predicated upon the civil liability provisions of the federal securities laws of the United States or any state, so far as the liabilities imposed by those provisions are penal in nature. In those circumstances, although there is no statutory enforcement in the Cayman Islands of judgments obtained in the United States, the courts of the Cayman Islands will recognize and enforce a foreign money judgment of a foreign court of competent jurisdiction without retrial on the merits based on the principle that a judgment of a competent foreign court imposes upon the judgment debtor an obligation to pay the sum for which judgment has been given provided certain conditions are met. For a foreign judgment to be enforced in the Cayman Islands, such judgment must be final and conclusive and for a liquidated sum, and must not be in respect of taxes or a fine or penalty, inconsistent with a Cayman Islands judgment in respect of the same matter, impeachable on the grounds of fraud or obtained in a manner, or be of a kind the enforcement of which is, contrary to natural justice or the public policy of the Cayman Islands (awards of punitive or multiple damages may well be held to be contrary to public policy). A Cayman Islands Court may stay enforcement proceedings if concurrent proceedings are being brought elsewhere. 43 Table of Contents Judgments of Brazilian courts to enforce our obligations with respect to our Class A common shares may be payable only in reais. Most of our assets are located in Brazil. If proceedings are brought in the courts of Brazil seeking to enforce our obligations in respect of our Class A common shares, we may not be required to discharge our obligations in a currency other than the real. Under Brazilian exchange control laws, an obligation in Brazil to pay amounts denominated in a currency other than the real may only be satisfied in Brazilian currency at the exchange rate, as determined by the Central Bank, in effect on the date the judgment is obtained, and such amounts are then adjusted to reflect exchange rate variations through the effective payment date. The then-prevailing exchange rate may not afford non-Brazilian investors with full compensation for any claim arising out of or related to our obligations under the Class A common shares. Our Class A common shares may not be a suitable investment for all investors, as an investment in our Class A common shares presents risks and the possibility of financial losses. The investment in our Class A common shares is subject to risks. Investors who wish to invest in our Class A common shares are thus subject to asset losses, including loss of the entire value of their investment, as well as other risks, including those related to our Class A common shares, us, the sector in which we operate, our shareholders and the general macroeconomic environment in Brazil, among other risks. Each potential investor in our Class A common shares must therefore determine the suitability of that investment in light of its own circumstances. In particular, each potential investor should: · have sufficient knowledge and experience to make a meaningful evaluation of our Class A common shares, the merits and risks of investing in our Class A common shares and the information contained in this annual report; · have access to, and knowledge of, appropriate analytical tools to evaluate, in the context of its particular financial situation, an investment in our Class A common shares and the impact our Class A common shares will have on its overall investment portfolio; · have sufficient financial resources and liquidity to bear all of the risks of an investment in our Class A common shares; · understand thoroughly the terms of our Class A common shares and be familiar with the behavior of any relevant indices and financial markets; and · be able to evaluate (either alone or with the help of a financial adviser) possible scenarios for economic, interest rate and other factors that may affect its investment and its ability to bear the applicable risks. There can be no assurance that we will not be a passive foreign investment company, or PFIC, for any taxable year, which could subject United States investors in our Class A common shares to significant adverse U.S. federal income tax consequences. Under the Internal Revenue Code of 1986, as amended (the “Code”), we will be a PFIC for any taxable year in which, after the application of certain look-through rules with respect to subsidiaries, either (i) 75% or more of our gross income consists of “passive income,” or (ii) 50% or more of the average quarterly value of our assets consists of assets that produce, or are held for the production of, “passive income.” Passive income generally includes dividends, interest, certain non-active rents and royalties, and capital gains. Cash is generally a passive asset for these purposes. Goodwill is an active asset to the extent attributable to activities that produce active income. Based on the composition of our income and assets and the value of our assets, including goodwill (the implied value of which we estimate based on the price of our Class A common shares), we believe that we were not a PFIC for the taxable year of 2024. However, because we hold a substantial amount of cash (relative to the assets shown on our balance sheet) and because our PFIC status for any taxable year will depend on the composition of our income and assets and the value of our assets from time to time (which may be determined, in part, by reference to the market price of our Class A common shares, which could be volatile), there can be no assurance that we will not be a PFIC for any taxable year. If our Class A common share price declines while we continue to hold a substantial amount of cash for any taxable year, our risk of being or becoming a PFIC will increase. In addition, as we continue to expand our business through acquisitions and organically, our risk of becoming a PFIC will increase if we engage in activities that generate substantial passive income. Moreover, the extent to which our goodwill will be treated as an active asset is not entirely clear. If we are a PFIC for any taxable year during which a U.S. investor holds Class A common shares, we generally will continue to be treated as a PFIC with respect to that U.S. investor for all succeeding years during which the U.S. investor holds Class A common shares, even if we ceased to meet the threshold requirement for PFIC status. Such a U.S. investor may be subject to certain adverse U.S. federal income tax consequences. See “Item 10. Additional Information—10.E. Taxation—U.S. Federal Income Tax Considerations—Passive Foreign Investment Company Rules.” 44 Table of Contents
A. History and Development of the Company Afya Limited is a publicly held company listed on the Nasdaq since July 2019, and therefore subject to certain reporting requirements of the Exchange Act. We were incorporated on March 22, 2019, as a Cayman Islands exempted company with…
A. History and Development of the Company Afya Limited is a publicly held company listed on the Nasdaq since July 2019, and therefore subject to certain reporting requirements of the Exchange Act. We were incorporated on March 22, 2019, as a Cayman Islands exempted company with limited liability duly registered with the Cayman Islands Registrar of Companies. Our corporate purposes are unrestricted, and we have the authority to carry out any object not prohibited by law as provided by Section 7(4) of the Companies Act (As Revised) of the Cayman Islands, or the Companies Act. Our affairs are governed principally by (i) our Amended and Restated Memorandum and Articles of Association; (ii) the Companies Act; and (iii) the common law of the Cayman Islands. As provided in our Amended and Restated Memorandum and Articles of Association, subject to Cayman Islands law, we have full capacity to carry on or undertake any business or activity, do any act or enter into any transaction, and, for such purposes, full rights, powers and privileges. Our registered office is c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands. The SEC maintains an internet site (http://www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. Our internet address is https://ir.afya.com.br/. Our History We founded Afya Brazil with the goal of revolutionizing medical education in Brazil by providing a more effective, individualized and intuitive learning experience. In order to achieve that, we have assembled institutions that collectively will help us fulfill our mission. The combination of Afya Brazil, one of the largest Brazilian medical education groups, and Medcel, one of the leaders in residency exams preparatory courses, was the first step toward achieving our goal. 45 Table of Contents Afya benefits from over 25 years of medical education experience through Afya Brazil and Medcel, both of which were founded and managed by physicians, with a focus on academic excellence and deep roots in technology and innovation. We were founded in 1999 with the opening of our first medical school, Centro Universitário ITPAC, by the Esteves Family, a family of medical professionals with a passion for medical education. Since its inception, our focus has been on medical and related health courses. As of December 31, 2024, 22,867 physicians had graduated with us since the founding of our predecessor companies. Over the last decade, Afya Brazil grew into a large medical education group, with several campuses and as of December 31, 2024, had 76,988 undergraduate students, of which 49,825 were health-related students and 27,163 were non-health-related students. Medcel was founded by Dr. Atilio Barbosa in 2004, a pioneer in online medical preparatory courses. In 2007, Medcel launched a proprietary platform to broadcast online classes. Over the years, Medcel evolved from its online platform into an adaptive digital learning environment where students can access digital media, watch medical case studies, listen to podcasts and answer personalized quizzes. In 2018, Medcel began offering its high-quality tech-enabled content in different formats and to other academic institutions. In 2016, the private equity group Crescera Investimentos (formerly Bozano Investimentos) joined forces with Afya Brazil and Medcel, laying out the foundations for the creation of the largest medical education group in Brazil. Crescera has since sold its interest in Afya to Bertelsmann in 2021. See “— Acquisition of Crescera Shares by Bertelsmann” below. The industry expertise of the founders of Afya Brazil and Medcel combined with the governance and financial support of Crescera Investimentos allowed the group to dive deeper into its mission as a thematic educational service provider focused on the lifelong learning career of physicians in Brazil. We achieve this through the production and distribution of high-quality content through technology. In order to achieve our goals, we have laid the foundations of Afya focusing on a four-step process: Management Professionalization Our highly skilled and experienced management team has extensive experience in the education industry and was hired from some of the best health, education and technology institutions in Brazil. Our management team is part of a company-wide strategy to attract and retain the best talent. Our CEO, Virgilio Deloy Capobianco Gibbon, has over 16 years of experience in education. Our CFO, Luis André Blanco, has over 15 years of experience as CFO, and Lélio de Souza Junior, our Vice President of Medical Practice Solutions, has more than 25 years of experience in technology companies. Integration of Processes & Services In order to create synergies, we have developed several initiatives to improve operational efficiency and to integrate processes across all our campuses and operations. Our high standard Shared Services Center and Integrated Systems (ERP + Academic System + Learning Management System) went live in October 2017. These initiatives will help us grow our student base and keep our marginal costs low. In 2017, we began to roll out the integration of the educational curriculum throughout all medical school units. This rollout begins with the new entrants curriculum and will be fully completed as the course matures its students. Accordingly, we have been streamlining the teaching methodology and quality across our undergraduate medical courses. Since the second half of 2019, all undergraduate medical students have access to our fully integrated Educational Curriculum. Continuing Innovation We take a blended approach to our methodology, integrating in-person teaching with online tools and features. By integrating face-to-face and online features through data collection and analysis, we are able to individualize the student experience at all times. Through seven key initiatives, we create a 100% student-centric ecosystem. These initiatives include: Medical content mapping, proprietary methodological assembly, significant learning experiences, comprehensive adaptive learning, daily learning process evaluation, and practical learning and knowledge. 46 Table of Contents Organic Growth and Entry into Adjacent Markets In 2018, the MEC awarded new licenses to Afya Brazil, allowing it, subject to the verification by the MEC of the satisfactory implementation by Afya Brazil of all regulatory requirements, to operate seven new medical schools through the “Mais Médicos II” program, with an aggregate amount of 350 new medical school seats per year. As of December 31, 2024, six of these campuses are already operating, as described below. We expect an additional campus to start operations in 2025. On May 9, 2019, we consummated the acquisition of IPEMED, marking our entry into the medical graduate and specialization segment. IPEMED, a leading medical graduate school founded in 2006, was merged into by Afya Brazil in 2024 and subsequently rebranded as Afya Educação Médica. On October 2, 2020, we announced that the Secretary of Regulation and Supervision of Higher Education of the MEC granted authorization for Afya to operate the undergraduate medicine course in Santa Inês in the State of Maranhão, under the “Mais Médicos II” program. This medical school was the first authorized in connection with the “Mais Médicos” program for Afya and contributed 50 seats to our operating seats base. Santa Inês is one of the seven undergraduate campuses Afya was awarded in 2018 in connection with the “Mais Médicos” program, the largest number awarded to any education group. This campus has been operational since October 2020. On December 30, 2020, the Secretary of Regulation and Supervision of Higher Education of the MEC granted the authorization for Afya to operate the undergraduate medicine course in Cruzeiro do Sul in the State of Acre, under the “Mais Médicos II” program. This medical school is the second authorized school in connection with the “Mais Médicos” program for Afya and contributed 50 seats to our operating seats base. This campus has been operational since the first semester of 2021. On November 5, 2021, the Secretary of Regulation and Supervision of Higher Education of the MEC granted the authorization to Afya to operate the undergraduate medicine course in Garanhuns in the State of Pernambuco, under “Mais Médicos II” program. This medical school contributed 120 seats to our operating seats base. This campus has been operational since the second semester of 2022. On February 23, 2022, we announced that the Secretary of Regulation and Supervision of Higher Education of the Ministry of Education (“MEC”) authorized the operations of the medical schools in Abaetetuba, in the State of Pará, and Itacoatiara, in the State of Amazonas, both under the “Mais Médicos II” program. With the authorizations, Afya reaches its third and fourth authorized schools to start operating under the Mais Medicos II program. Each medical school contributed with 50 seats. These campuses have been operational since February 2022. On March 16, 2022, the Secretary of Regulation and Supervision of Higher Education of MEC authorized the operation of medical schools in Bragança, in the State of Pará, and Manacapuru, in the State of Amazonas, both under the “Mais Médicos II” program (our fifth and sixth authorized schools under the Mais Medicos II program, respectively). Each medical school contributed with 50 seats. These campuses have been operational since March 2022. On March 18, 2022, the Secretary of Regulation and Supervision of Higher Education of MEC authorized 28 seats additional at Centro Universitário São Lucas Ji-Parana in the city of Ji-Parana, located in the state of Rondônia. The earn-out related to the seats approval is R$800,000 per seat, adjusted by the CDI rate from the closing until the payment date, of which 50% was paid in April 2022 and the remaining amount was paid in March 2024. The operation of such additional seats started in June 2022. On December 29, 2022, Afya announced that MEC authorized the increase of 64 medical school seats of Faculdade Santo Agostinho, in the city of Itabuna, located in the state of Bahia. No additional commitment is required regarding this authorization. The operation of such additional seats started in the first semester of 2023. On January 24, 2024, Afya announced that MEC authorized the increase of 40 medical school seats at the Faculdades Integradas Padrão (FIP Guanambi) campus, in the city of Guanambi, located in the state of Bahia, which resulted in an additional payment of R$49.6 million in February 2024. With the authorization, we reached 100 medical school seats on this campus. On July 12, 2024, the MEC authorized the increase of 80 medical school seats at the Centro Universitário Tiradentes Alagoas (UNIMA), campus in the city of Maceió, located in the state of Alagoas, which resulted in an additional payment of R$107.6 million in August 2024 under the DelRey acquisition. With this authorization, Afya reaches 220 medical school seats on this campus. 47 Table of Contents On September 6, 2024, Afya announced that following the conclusion of an administrative procedure, MEC has granted the request for reconsideration submitted by Unigranrio. According to the e-MEC portal, Unigranrio reestablished 10 medical school seats in the city of Rio de Janeiro, reaching 318 medical school seats across both Unigranrio campuses, contributing to Afya´s current 3,593 total approved medical school seats, including 175 seats from Unidom which are subject to a final conclusion of the court proceedings. The continued operation of certain of these campuses was subject to the verification by MEC of the satisfactory implementation by Afya Brazil of all regulatory requirements. See “Item 4. Information on the Company—Business Overview—Our Geographic Presence.” The acquisitions of Medical Harbour, Além da Medicina and CardioPapers strengthened our digital capabilities for our Continuing Education segment, whereas the acquisitions of PEBMED, Medphone, iClinic, Medicinae, Cliquefarma, Shosp, RX PRO and Glic marked our entry into the digital health services sector that now comprises our Medical Practice Solutions, complementing our end-to-end offering to healthcare professionals. For more information on Medical Harbour, Além da Medicina, CardioPapers, PEBMED, Medphone, iClinic, Medicinae, Cliquefarma, Shosp, RX PRO and Glic, see “—B. Business Overview.” Initial Public Offering and Equity Follow-on Offering In July 2019, we completed our initial public offering, in which we sold an aggregate of 15,805,841 of our Class A common shares at a public offering price of US$19.00 per common share. We received approximately US$242.7 million of net proceeds from our initial public offering (i.e., after deducting underwriting discounts, commissions and offering expenses). Our shares began trading on the Nasdaq Global Select Market on July 19, 2019, under the symbol “AFYA.” In February 2020, we completed an equity follow-on offering, in which we sold an aggregate of 3,260,480 of our Class A common shares at a public offering price of US$27.50 per common share. We received approximately US$86.6 million of net proceeds from our follow-on offering (i.e., after deducting underwriting discounts, commissions and offering expenses). SoftBank Investment On April 26, 2021, we announced that the SoftBank Latin America Fund, or SoftBank, agreed to purchase R$822 million, equivalent to US$150 million, of Afya’s Series A perpetual convertible preferred shares. In addition, Crescera Educacional II Fundo de Investimento em Participações Multiestratégia and certain members of the Esteves family agreed to sell 2,270,208 Class A common shares to SoftBank. In connection with such sale, at the time, Paulo Passoni from SoftBank was appointed as a board member of Afya, being replaced by Maria Tereza Azevedo in 2022. The key terms of the Series A perpetual convertible preferred shares, as set forth under the relevant certificate of designations, are: (i) 6.5% per annum cumulative dividend payable quarterly and in Brazilian reais (payable in U.S. dollars in Brazilian reais equivalent); (ii) SoftBank shall have the right at any time, to convert its Series A perpetual convertible preferred shares into 5,917,888 common shares, at an initial conversion price established at US$25.35; (iii) SoftBank shall have the right to redeem any time after the 5th year anniversary at 105% premium; (iv) Afya will have the right to force conversion after the 3rd year anniversary if forced conversion trigger conditions are satisfied; and (v) Afya shall have the right to redeem any time after the 7th year anniversary at 105% premium. For further information, see “Item 5. Operating and Financial Review and Prospects—B. Liquidity and Capital Resources—Indebtedness—Series A Perpetual Convertible Shares” and note 12.2.1 to our audited consolidated financial statements included elsewhere in this annual report. As of December 31, 2024, SoftBank and its affiliates would beneficially own approximately 6.6 % of our outstanding common shares, excluding treasury shares and including the Series A perpetual convertible preferred shares on an as-converted basis. Acquisition of Crescera Shares by Bertelsmann On June 7, 2021, an affiliate of Bertelsmann acquired the entirety of the 23,074,134 Class B Afya’s common shares held by Crescera Educacional II Fundo de Investimento em Participações Multiestrategia, or “Crescera Educacional,” pursuant to a provision in Afya’s amended and restated memorandum and articles of association then in effect and the shareholders agreement between certain members of the Esteves family and Crescera Educacional, which granted Bertelsmann the right to acquire Crescera Educacional’s Class B common shares and become a party to the shareholders’ agreement. 48 Table of Contents Bertelsmann is a media, services and education company that operates in about 50 countries around the world. It includes the entertainment group RTL Group, the trade book publisher Penguin Random House, the music company BMG, the service provider Arvato, the Bertelsmann Printing Group, the Bertelsmann Education Group and Bertelsmann Investments, an international network of funds. Since Afya’s inception, Bertelsmann has indirectly held a stake in Afya through its investment in Crescera Educacional. In connection with and following such transaction, Bertelsmann appointed Kay Krafft, Shobhna Mohn, Christina Krebs and Benedikt Dalkmann as members of our board of directors. Shobhna Mohn later resigned from our board of directors, effective as of June 30, 2024. For more information, see “Item 6. Directors, Senior Management and Employees”. Acquisition of our Corporate Control by Bertelsmann On May 4, 2022, Bertelsmann acquired 6,000,000 of our Class B common shares from the Esteves Family at a purchase price of US$26.90 per share. As a result of the closing of the transaction, Bertelsmann came to beneficially own approximately a 57.5% voting interest in Afya. We also entered into a new CEO executive employment agreement with Virgilio Deloy Capobianco Gibbon, extending its period through May 2027. The extension was made in connection with the increase of Bertelsmann’s stake in Afya to continue to execute the expansion in the medical education business and the deployment of our digital health services strategy. B. Business Overview We are the leading medical education group in Brazil based on the number of private medical school seats, according to a MEC report as of December 31, 2024, delivering an end-to-end physician-centric ecosystem that serves and empowers students to be lifelong medical learners from the moment they join us as medical students through their medical residency preparation, graduate courses, medical graduate courses and continuing medical education activities, or CME, including through digital health services. Our innovative methodological approach combines integrated content, interactive learning, and an adaptive experience for lifelong medical learners. Through our educational content and technology-enabled activities, we focus on effective, personalized learning that mirrors one-on-one tutoring. Based on our number of MEC's approved medical seats, as compared to our main competitors, we have the largest medical education footprint in Brazil. Our undergraduate and graduate campuses are spread across 19 Brazilian states, and our digital medical platform is available across Brazil. As of December 31, 2024, our network of 57 undergraduate and graduate medical school campuses consisted of 20 graduate facilities, 36 undergraduate operating units (i.e., units that have been approved by MEC and that have commenced operations) and one approved unit (i.e., a unit that has been approved by MEC but that has not yet commenced operations), compared to 32 campuses as of December 31, 2023 and 30 campuses as of December 31, 2022. As of December 31, 2024, our network of medical school seats consisted of 3,543 operating seats (seats that have been approved by MEC and that have commenced operations) and 50 approved seats (seats that have been approved by MEC but that have not yet commenced operations), compared to 3,113 operating seats as of December 31, 2023 and 2,773 operating seats as of December 31, 2022. Following our acquisition of Medcel in the first quarter of 2019 and IPEMED in the second quarter of 2019, we also offer residency preparatory courses and medical graduate courses, delivering printed and digital content, an online medical education platform and practical medical training. The acquisitions of Medical Harbour, Além da Medicina and CardioPapers strengthened our digital capabilities for our Continuing Education segment, whereas the acquisitions of PEBMED, Medphone, iClinic, Medicinae, Cliquefarma, Shosp, RX PRO and Glic marked our entry into the digital health services sector that now comprises our Medical Practice Solutions segment, complementing our end-to-end offering to healthcare professionals. Through PEBMED, we have three different products: (i) Whitebook, a mobile and web application that assists doctors and medical professionals in clinical daily decision-making; (ii) Nursebook, a mobile application that assists nurses in clinical decision-making; (iii) Portal PEBMED, a website that offers free content, including opinions, papers and updates in connection with medical news and scientific publications. The acquisition expanded our products and services offerings and offers significant cross-sell and upsell opportunities. As part of our ongoing efforts to enhance our digital platforms, the Portal PEBMED was discontinued in 2024 and replaced by the Afya Portal, which continues to provide high-quality medical content and resources for healthcare professionals. 49 Table of Contents iClinic is a SaaS model physician-focused technology company and one of the leading medical practice management software in Brazil. They seek to empower doctors to be more independent and have more control over their careers by digitalizing their daily routine, so they can increase their productivity and deliver better healthcare services. Their portfolio includes: (i) Electronic Medical Record: the first electronic medical record as a SaaS model in Brazil focused on the physician experience; (ii) Clinical Management System: with this software, doctors can schedule patients online, organize their financial records, use marketing tools to promote their clinics and others; (iii) Telemedicine: a platform to provide online consultations fully integrated with doctor’s schedule and records; and (iv) Physicians Marketplace: a website that connects doctors and patients to schedule consultations. The platform is currently used for almost 27 million medical consultations per year, of which around 187,489 were through telemedicine and prescribed more than 10.8 million electronic medical prescriptions. Medicinae is a healthcare technology company specializing in healthcare payments and financial services. It offers a financial platform that allows healthcare professionals to manage receivables in an efficient and scalable way using FIDC (receivables investment fund). We believe Medicinae relieves a number of challenges in the healthcare payments industry, by reducing long payment cycles for professionals and consolidating financial information, improving the consumer financial experience. Medical Harbour offers educational health and medical imaging solutions through an interactive platform for anatomical study, 3D virtual dissection and analysis of medical images, which allow the exploration, and knowledge of human anatomy with digital resources: (i) educational health solutions: Athena Hub specialized in anatomy was created to support dynamic teaching and allow physicians, teachers and students to interact and manipulate a real human body on a digital platform. Considering the high prices, restriction policies and difficulty on maintaining a human body for anatomy classes, Athena Hub allows students to interact with a digital human body instead of the aged and degenerate bodies for educational purposes. The solution count with virtual body, anatomy modules, and real exam analysis with photorealistic rendering; and (ii) medical imaging solutions: Athena DICOM and MH Cloud specialized in medical imaging with a range of products that simplifies radiology and teleradiology. Allow physicians to visualize, manipulate, share and store medical imaging with the certification of ANVISA (Brazilian Health Agency). Cliquefarma is a healthtech company operating a free-to-use website that tracks prescription drugs, cosmetics and personal hygiene product prices in Brazil. Users of Cliquefarma can search for medications or healthcare products and compare prices from over 9,404 pharmacies in Brazil. The traffic generated is monetized through a cost-per-click model, where drugstores pay for each click on their ads, and a cost-per-acquisition model, where drugstores pay for each concluded sale. In 2024, Cliquefarma generated traffic of 6.6 million visitors. Shosp is a clinical management software that offers all functionalities needed for clinics all over Brazil to manage their financials, patients’ appointments, medical records, marketing, and others. The acquisition of Shosp reinforces the digital prescription digital pillar and creates synergies with iClinic and Medicinae solutions. RX PRO is a digital platform that connects physicians with the pharmaceutical industry, providing specialized and personalized marketing for those companies, in a more convenient way for physicians. RX PRO has already delivered free samples to more than 72,000 physicians with an innovative digital experience, with a Net Promoter Score, or NPS, of 84.6 and as of the date of this annual report has 12 pharmaceutical companies using its platform. RX PRO is monetized by providing a B2B subscription service to the pharmaceutical industry. Além da Medicina is an online medical content platform for physicians and medical students that provides educational tools and technical medical content to assist them throughout their careers. Its robust content includes mentoring for residency, soft skills, finance, accounting, and investment basics for physicians. The platform also has a strong digital presence, with more than 135,000 followers on Instagram. Afya Papers is the main medical content and education platform in the Cardiology, Endocrinology, Dermatology, Gynecology and Obstetrics, Pediatric and Psychiatrist field, offering courses and books developed by physicians and for physicians, covering all phases of the medical career, aligned with Afya’s overall business strategy. The platform was formerly known as CardioPapers and has been rebranded as part of Afya’s identity. Afya Papers had over 500,000 followers on Instagram in 2024. The platform includes medical update courses, such as a cardiology specialist degree preparatory course, cardiological emergencies course, preoperative course, dyslipidemia course, electrocardiogram (EKG) course and diabetes course, exploring the cardiologic medical field and also expanding to other medical areas. 50 Table of Contents Glic is a free diabetes care and management app solution for physicians and patients that uses technology to improve diabetes education and daily routine practices, connecting users, devices and healthcare providers. In addition to health sciences courses, which comprise medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition and biomedicine, we also offer degree programs and courses in other subjects and disciplines across several of our campuses, including undergraduate and graduate courses in business administration, accounting, law, civil engineering, industrial engineering and pedagogy. These non-health courses are not part of our core business, although the number of non-health sciences courses we offer has increased as a consequence of our strategic acquisitions of multi-disciplinary schools with strong health sciences programs, which are our principal focus. Although non-health courses are not part of our growth strategy, we expect to continue to offer them to the extent they generate local demand. Following our acquisition of Medcel in the first quarter of 2019 and IPEMED in the second quarter of 2019, we also offer residency preparatory courses and medical graduate courses, delivering printed and digital content, an online medical education platform and practical medical training. As of December 31, 2024, we had 76,988 enrolled students, compared to 66,034 enrolled students as of December 31, 2023, representing an increase of 16.6% from 2023, and 58,200 enrolled students as of December 31, 2022, representing an increase of 13.5% from 2022. Our business model is characterized by high revenue visibility and operating leverage. Approximately 90% of our revenue for the years ended December 31, 2024, 2023 and 2022 was composed of the monthly tuition fees we charge students enrolled in our undergraduate and graduate courses. Our ability to execute our strategy and business model through acquisitions and organic growth has led to growth, profitability and cash generation: · Our revenue totaled R$3,304.3 million, R$2,875.9 million and R$2,329.1 million in the years ended December 31, 2024, 2023 and 2022, respectively, representing a compound annual growth rate, or CAGR, of 19.1% since 2022; · Medical school’s revenue represented 85.9%, 85.5% and 83.4% of our undergraduate programs revenue in 2024, 2023 and 2022, respectively. The average monthly net ticket for medical school tuition fees was R$8,849 for the year ended December 31, 2024, which represented an increase of 4.6% from R$8,460 for the year ended December 31, 2023, which, in turn, represented an increase of 6.1% from R$7,973 for the year ended December 31, 2022; · Continuing Education and Medical Practice Solutions revenues totaled R$417.2 million, R$376.1 million and R$298.8 million in revenue for the years ended December 31, 2024, 2023 and 2022, respectively; · We generated net income of R$648.9 million, R$405.4 million and R$392.7 million in the years ended December 31, 2024, 2023 and 2022, respectively, representing a CAGR of 28.5% since 2022; · Our Adjusted EBITDA totaled R$1,455.6 million, R$1,165.7 million and R$961.9 million in the years ended December 31, 2024, 2023 and 2022, respectively, representing a CAGR of 23.0% since 2022; · Our Net cash flows from operating activities was R$1,433 million, R$1,044 million and R$844 million for the years ended December 31, 2024, 2023 and 2022, respectively. Our Operating Cash Conversion Ratio was 102.2%, 97.1% and 94.4% for the years ended December 31, 2024, 2023 and 2022, respectively. Quality is a cornerstone of our value proposition. As of the date of this annual report, our average General Course Index score, which is measured and published by MEC, and is based on certain institutional planning and development, academic, and management criteria, was 2.62 on a scale of 1 to 5, in line with the Brazilian average of 2.62. Recent Developments On April 23, 2025, MEC officially announced the launch of the National Medical Education Assessment Exam (Exame Nacional de Avaliação da Formação Médica - Enamed), an annual examination that will be administered to students completing medical school programs in Brazil. The initiative is intended to evaluate the quality of medical education and will be conducted based on a reference framework and theoretical assessment instruments developed by INEP, in accordance with the national curriculum guidelines for medical programs. We believe this initiative will reinforce the importance of consistent academic standards across medical programs in Brazil. The establishment of annual oversight mechanisms, coupled with the exam’s anticipated role as a criterion for admission into medical residency programs, is expected to enhance student engagement and strengthen institutional accountability. 51 Table of Contents Our Recent Acquisitions The entry point to a medical career begins in undergraduate institutions, so part of our mission is to consolidate this market. Accordingly, expanding our operations through acquisitions has been a key component of our growth strategy. We have been able to apply our operating business model to our acquisitions, allowing us to add quality, value and increase profitability. In addition, we have equipped ourselves through key initiatives for strategic and relevant acquisitions to our portfolio, including: the creation of a Shared Services Center dedicated to serving our business units and running our integration processes, the centralization of content creation and the creation of a dedicated sales team for each market we operate in. Our recent acquisitions, which were all made through Afya Brazil, include: Além da Medicina On March 4, 2022, we acquired 100% of the total share capital of Além da Medicina. The aggregate purchase price of R$26.8 million is comprised of: (i) R$14.9 million paid in cash on the transaction closing date; (ii) an earn-out (“contingent consideration”) of up of R$19.2 million is payable in connection with revenue target achievements for 2023 and 2024; and (iii) a price adjustment related to net debt of R$0.8 million in favor of selling shareholders. As of December 31, 2024, the contingent consideration of R$9.6 million was based on the estimated payment considering the facts and circumstances at that date. CardioPapers On April 5, 2022, we acquired 100% of the total share capital of CardioPapers. The aggregate purchase price of R$42 million is comprised of: (i) R$34.9 million paid in cash on the transaction closing date; (ii) an earn-out (“contingent consideration”) of up of R$15 million is payable in connection with revenue target achievements for 2023 and 2024 and other goals relating to market credentials for 2023 and 2024; and (iii) price adjustment related to net debt of R$0.3 million in favor of Afya Brazil. As of December 31, 2024, the contingent consideration of R$10.0 million was based on the estimated payment considering the facts and circumstances at that date. Glic On May 23, 2022, we acquired 100% of the share capital of Glic. Glic is a free diabetes care and management app solution for physicians and patients that uses technology to improve diabetes education and daily routine practices, connecting users, devices and healthcare providers. The aggregate purchase price of R$30.6 million is comprised of: (i) R$21.6 million paid in cash on the transaction closing date; and (ii) an earn-out (“contingent consideration”) of up of R$12.0 million payable in connection with revenue target achievements for 2023 and 2024 and product development goals. We paid R$3.0 million as contingent consideration in 2023 and the remaining balance is no long due and payable given the earn-out targets have not been met. DelRey On January 2, 2023, we acquired 100% of the total share capital of DelRey, which acquisition encompasses the operations of Centro Universitário Tiradentes Alagoas, or UNIMA, and Faculdade Tiradentes Jaboatão dos Guararapes, or FCM Jaboatão. The transaction does not include the “UNIMA” and “FCM Jaboatão” trademarks, which were licensed to Afya during the first year of operation. The aggregate purchase price of R$816.2 million is comprised of: (i) R$575.0 million paid in cash on the transaction’s closing date; and (ii) R$234.0 million to be paid in three annual installments of R$134.0 million in January 2024, R$50.0 million in January 2025 and R$50.0 million in January 2026, as adjusted by the SELIC rate, of which only the last installment remains outstanding. The aggregate purchase also includes R$7.2 million estimated at fair value as of the date of acquisition relating to an offer of our digital solutions free of charge until December 31, 2030 for medical students of universities owned by the sellers but which were not a part of this transaction. On July 12, 2024, MEC authorized the increase of 80 medical school seats of UNIMA, which resulted in an additional payment of R$107.6 million to the former shareholders of UNIMA. 52 Table of Contents Unidom On July 1, 2024, we acquired 100% of the total share capital of Unidom Participações S.A., which acquisition encompasses the operations of Unidompedro and Faculdade Dom Luiz, or “Unidom,” Instituição Baiana de Ensino Superior Ltda., or “IBES,” and SESSA — Sociedade de Educação Superior do Semi-Árido Ltda., or “Sessa.” The aggregate purchase price of R$620.8 million is comprised of: (i) R$340.8 million paid in cash on the transaction’s closing date; and (ii) R$280.0 million to be paid in ten annual installments, adjusted by the CDI (Interbank Certificate of Deposit) rate, and it is conditioned upon the maintenance of the authorization of the 175 medical school seats in each year immediately before payment. The remaining balance will be accelerated if a final and non-appealable ruling of certain court proceedings confirms the authorization for all 175 medical school seats. In turn, if a final ruling does not confirm the authorization for such 175 medical school seats, the outstanding balance will no longer be due. FUNIC On December 19, 2024, we signed a definitive contract for the acquisition 100% of the total share capital of Faculdade Masterclass Ltda., or “FUNIC,” which will add 60 medical school seats to Afya in Contagem, a city in the metropolitan area of Belo Horizonte, the capital of the state of Minas Gerais. The aggregate purchase price is R$100 million, and the Net Debt will be deducted at closing. The purchase consideration of R$60 million will be paid in cash at the closing date, and R$40 million will be paid in three annual installments adjusted by the Brazilian interbank interest rates (“CDI”). Additionally, the acquisition includes a contingent consideration provision for up to 60 additional medical school seats. If approved by MEC within 36 months of the closing date, we will be required to make an additional payment of R$1 million per approved seat, up to a maximum of 60 medical school seats. The closing of the transaction is subject to customary conditions precedent and is expected to be completed in May 2025. Our Competitive Strengths Continuous focus on disrupting traditional medical education · We have an in-depth understanding of medical education and the related issues faced by students in Brazil. As the largest medical education group in Brazil on a per-seat basis, according to MEC, we are able to identify trends and adapt our services accordingly; · We have developed a methodological approach to learning that incorporates individualization and technology in both digital and physical format; · We currently produce content that is centralized, continuously updated and available to all our institutions and students; · We have the largest operating infrastructure in medical education in Brazil on a per-seat basis, according to MEC, with more than 614 partner teaching hospitals and clinics and 313,119 users in Afya's ecosystem; · We believe we have developed the first instructional medical web series created globally, and we have completed the first two seasons and have already begun working on the third season; · We believe we are the first education group in Brazil to offer a fully digital and customized service for medical residency exam preparation; · We believe we are the first player to offer supplemental medical education content to third-party institutions through a business-to-business model; and · We started offering content and clinical tools for healthcare professionals, including mobile and web apps. High-quality standards Quality is a cornerstone of our value proposition. Our operating infrastructure and innovative methodological approach have achieved high levels of satisfaction across our medical schools. Through our digital platforms, we monitor our students’ learning experience using several criteria and variables. Our NPS, a widely known survey methodology that measures the willingness of customers to recommend a company’s products and services, showed a consistent improvement across all groups of medical students in 2024 compared to 2023. Among students from the 1st to the 4th semester, the NPS rose from 40 in 2023 to 46 in 2024. For those in the 5th to the 10th semester, it increased from 25 to 29. Finally, among students in the last two semesters of the program, the score went up from 26 to 31. This gradual improvement in our NPS score shows our continuing commitment to high-quality education and the medical careers of our students. Additionally, according to the latest results released by the Brazilian government on April 2, 2024, our average General Course Index, which is measured and published by MEC, and is based on certain institutional planning and development, academic and management criteria, was 2.62 on a scale of 1 to 5, in line with the Brazilian average of 2.62. See “Item 4. Information on the Company—Business Overview—Regulatory Overview—Regulatory Processes of Post-secondary Education Institutions—Accreditation of Post-secondary Education Institutions and Authorization and Recognition of Courses” for further information on the General Course Index. 53 Table of Contents In addition, through our online medical education platform that offers distance learning residency preparatory courses, we are able to monitor our students’ learning experience using several criteria and variables, including the educational materials they access and use, frequently asked questions, their study hours and schedule, and their attendance record. Furthermore, as a result of the quality of the content and methodology and the differentiated services offered by Medcel, third-party medical schools proactively contact it seeking to adopt Medcel’s medical education content to improve their medical students’ learning experience and academic scores. As of December 31, 2024, 17 third-party schools had adopted Medcel’s medical education content compared to 17 as of December 31, 2023. The nature of our business model Attractive financial model: We have a strong combination of significantly low customer acquisition costs, calculated as the sum of sales and marketing and personnel expenses divided by student additions, which were approximately R$1,576, R$1,415 and R$1,882 per student as of December 31, 2024, 2023 and 2022, respectively, high occupancy rates of approximately 100% of medical school seats in our medical schools as of December 31, 2024, 2023 and 2022, strong net cash flows from operating activities which was R$1,433 million, R$1,044 million and R$844 million for the years ended December 31, 2024, 2023 and 2022, respectively, and operating cash conversion ratio which was 102.2%, 97.1% and 94.4% as of December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, our Life Time Value (LTV) was R$447,647, calculated as the gross profit per student of R$74,602 divided by 17% (to account for one-sixth of the student base graduating every year). As of December 31, 2023, our LTV was R$423,308, calculated as the gross profit per student of R$70,551 divided by 17%. As of December 31, 2022, our LTV was R$425,658, calculated as the gross profit per student of R$70,943 divided by 17%. Contracted growth: We have contracted growth visibility into medical schools that are in the initial six years of operations as a result of the six-year maturation cycle of our medical school seats. This cycle begins when a medical school becomes operational, with a first year medical school class that progresses through the required six years as the next classes begin behind it, and ends when the medical school has six school years of medical students and has therefore reached capacity at maturation (i.e., the maximum number of approved seats). Since the maximum number of medical seats per medical school is set by regulation, the only way to grow our medical school seats, and thus our numbers of enrollments, is through acquisitions or starting new medical schools. As of December 31, 2024, we had 3,593 approved medical school seats, including 175 seats from Unidom which are subject to a final conclusion of the court proceedings, out of an expected total capacity of 25,870 medical school enrollments by 2031, which gives us visibility as to the growth potential of our revenues over the period. See “Item 5. Operating and Financial Review and Prospects—Medical School Regulatory Capacity and Capacity at Maturation.” End-to-end ecosystem: Successfully integrating the businesses we invest in or acquire, allows us to offer an end-to-end physician-centric ecosystem. The point of entry of one business unit is the point of exit from another, which increases cross-selling and upselling opportunities. Difficult to replicate: We believe the combination of regulatory barriers, demand and supply imbalance and our end-to-end physician-centric ecosystem are difficult to replicate and that it would take a significant amount of time for competitors to reach the scale of our operation. Self-reinforcing network effects of our education cycle: As we aim to be the trusted content and knowledge partner for lifelong medical learners in Brazil, we have created and have been nurturing an education cycle that entails differentiation, talented stakeholders and recognition. Our continuous focus on implementing all stages of our cycle has allowed us to continuously expand our footprint. 54 Table of Contents Extensive M&A track record We have extensive capabilities in, and a strong track record of, identifying, negotiating and successfully integrating acquisitions. We have developed an integration model, operated by a dedicated team responsible for analyzing, mapping and integrating the systems of our acquired businesses, that we believe enables us to fully integrate the businesses we acquire in an efficient manner and usually within 12 months of their acquisition. Our integration model is composed of four stages: · Stage 1 (Preliminary Analysis): Preliminary analysis of the available infrastructure, organizational structure and teaching model of the acquired business to identify potential integration issues. · Stage 2 (Detailed Mapping): Detailed migration diagnosis and mapping of the systems, processes and teaching model of the acquired business to be integrated into our centralized shared-services center and academic model. · Stage 3 (Integration/Migration): Centralization and migration of the systems and processes into our shared services center and standardization of the teaching model of the acquired business. · Stage 4 (Ongoing Support): Post migration/integration remote and on-site support and monitoring to stabilize the integrated operations of the acquired business. Our consolidated operating history and our recent acquisitions entail a number of challenges, such as effectively integrating the operations of any acquired company with our existing business and managing a growing number of campuses. See “Item 3. Key Information—D. Risk Factors—Certain Risks Relating to Our Business and Industry—We may face challenges in identifying and acquiring new medical higher education institutions, which could hinder our strategic and financial goals. Additionally, difficulties in effectively integrating and managing an increasing number of acquisitions may adversely affect our strategic objectives.” 55 Table of Contents Purpose driven culture Medical education requires a core human value: compassion. As we endeavor to revolutionize medical education in Brazil, we believe that by training and educating better physicians we are helping people and their communities across Brazil. This mission has united families and entrepreneurs, executives and sponsors with over 20 years of know-how and expertise in the education sector. Our internal satisfaction survey conducted in 2024 showed employee satisfaction levels of 86 out of a possible 100, based on several criteria, such as trust in, and a commitment to, our values, leadership satisfaction, work satisfaction, learning and development, and active participation in our activities, reinforcing our strong commitment to our mission and purpose. Our Growth Strategies We aim to continue to grow organically and through acquisitions and to generate greater shareholder value by implementing the following strategic initiatives: Maturation of current number of authorized medical school seats We benefit from contracted growth visibility in our medical schools that are in the initial six years of operations, which we derive from two main sources: (1) the six-year maturation cycle of our medical school seats, which begins when a medical school becomes operational, with a first year medical school class which progresses through the required six years as the next classes begin behind it, and which ends when the medical school has six school years of medical students and has therefore reached capacity at maturation (i.e., the maximum number of approved seats), and (2) new enrollments from our seven awarded campuses in connection with the “Mais Médicos” program. Since the maximum number of medical seats per medical school is set by applicable regulations, the only way to grow our medical school seats, and thus our number of enrollments, is through acquisitions or starting new medical schools. As of the date of this annual report, assuming full compliance with applicable regulations and that our seven new “Mais Médicos II” campuses mature as expected with 50 medical school seats for each campus, we estimate reaching a total medical student base of 26,302 students by 2031. See “Item 5. Operating and Financial Review and Prospects—Medical School Regulatory Capacity and Capacity at Maturation” and “Item 3. Key Information—D. Risk Factors—Certain Risks Relating to Our Business and Industry—The post-secondary education sector is highly regulated, and our failure to comply with existing or future laws and regulations could significantly impact our business.” Open new campuses in connection with the “Mais Médicos II” program In 2018, we were also awarded seven new undergraduate campuses in connection with the “Mais Médicos II” program, the largest number awarded to any education group, with a total of 350 new medical school seats. The operation of such campuses was subject to the verification by MEC of the satisfactory implementation by Afya Brazil of all regulatory requirements. As of December 31, 2024, MEC had inspected six of the campuses, and the final verification was published in: (i) October 2020 for ITPAC Santa Inês; (ii) December 2020 for ITPAC Cruzeiro do Sul; (iii) February 2022 for ITPAC Abaetetuba; (iv) February 2022 for ITPAC Itacoatiara; (v) March 2022 for ITPAC Bragança; (vi) March 2022 for ITPAC Manacapuru. We expect an additional campus to start operations in 2025. Expand our medical residency preparation enrollments base We expect that competition for medical residencies will increase as the number of graduating physicians grows and the number of available residency seats remains static. We plan to continue to grow our medical residency exam preparation student enrollments, leveraging the academic outcome, scalability and learning experience of our digital platform. Expand our graduate programs enrollments base Due to the shortage of medical residency seats and the growing demand for medical undergraduate courses, we believe we will be able to expand our current offering in the Undergrad segment. 56 Table of Contents We intend to continue developing our business-to-business strategy by increasing the number of partners and student enrollments through increased marketing and sales efforts. Cross-sell across our existing medical student base Because our solutions target the lifelong education journey of medical students, we have identified an opportunity to increase student enrollments at a low marginal cost driven by cross-selling opportunities, such as increasing the number of former undergraduate students subscribing to our medical residency exam solutions and the number of former undergraduate and/or medical residency students applying to our graduate and/or other continuing medical education offerings, such as hard and soft skills courses. Expand our B2B capabilities B2B contracts are effective customer entry points to our products and services. Students are familiar with our platforms, increasing our brand equity and helping us attract more physicians to enroll in preparatory courses, graduate programs, hard and soft skills courses. Expand our distribution channels We plan to continuously expand our distribution network by increasing our presence in direct and third-party channels, launching graduate courses or CME for third-party continuing medical education hubs (including, but not limited to, hospitals, clinics and other medical schools) to grow our graduate medical footprint, through partnerships with such third-party continuing medical education hubs. Leverage infrastructure and extract synergies from acquisitions We believe we have been able to successfully integrate our acquisitions into our ecosystem. We plan to implement several measures to improve the profitability of recent acquisitions, including but not limited to: · Streamlining fee discounts and scholarship policies; · Integrating operations with our shared-services center; · Streamlining faculty training in line with our career plan; and · Integrating teaching models into our academic model. Continue to selectively pursue M&A opportunities We plan to selectively pursue acquisitions that will complement our current medical education services offering and/or enhance our product portfolio, such as digital content platforms, continuing medical education institutions and other medical certification companies, among others. We are currently evaluating possible acquisition opportunities and submit non-binding proposals from time to time. We believe that we have developed a strong capability and track record of acquisitions. In 2024, we acquired Unidom, which increased our number of approved medical school seats by 300 seats authorized, of which 125 are final and 175 are subject to a final conclusion of the court proceedings. In 2023, we acquired or invested in two companies. In 2022, we acquired or invested in three companies. In 2021, we acquired or invested in nine companies, which increased our medical school seats by more than 27.4% over the year. Our acquisition of Medcel enabled us to access the medical residency preparation market, and the acquisition of IPEMED, enabled us to enter the graduate courses market. Our acquisition strategy is mainly focused on expanding our medical school footprint by adding new institutions to our existing portfolio. On December 19, 2024, we signed a definitive contract for the acquisition 100% of the total share capital of FUNIC, which may increase our approved medical school seats from 3,593 to 3,653. The closing of the transaction is subject to customary conditions precedent and is expected to be completed in May 2025. Enter into new markets We believe our end-to-end physician-centric ecosystem is equipped to serve medical students in complementary segments where our innovative, methodological, data-driven approach can continue to disrupt traditional vendors and legacy business models. We believe opportunities exist in new sectors and regions of Brazil. In the future, we intend to focus on expanding further into continuing medical education. We may also seek to grow our business by selectively expanding into international markets with similar fundamentals. 57 Table of Contents Develop new products We plan to continuously evolve our platform and offer solutions that keep up with the growing demands of our students. We have a planned pipeline of new products, including new medical web-series seasons, corporate medical training, new extension health programs, a tutoring suite, a peer-to-peer suite and a virtual reality product. Our Geographic Presence Our headquarters and most of our shared services operations are located in Nova Lima and Belo Horizonte, respectively, in the State of Minas Gerais. Our content creation and dedicated sales team is located in São Paulo, in the State of São Paulo. As of December 31, 2024, our network consisted of a total of 57 undergraduate and graduate campuses: (i) 37 undergraduate campuses, out of which 36 are operating units (units that have been approved by MEC and that have commenced operations), 32 offer a medical course, and one has been approved by MEC but has not yet commenced operations, and (ii) 20 graduate campuses that offer medicine- and health-related courses. We plan to expand our network by opening one approved undergraduate medical school campus we were awarded in connection with the “Mais Médicos” program by 2025. The chart and table below illustrate our current footprint of undergraduate medical schools, as of the date of this annual report. Campus State Brand Year of Acquisition Approved Medical School Seats(1) Semester(2) Porto TO ITPAC Before 2018 120 02.04 Pato Branco PR FADEP 2018 50 02.17 Pato Branco PR FADEP 2018 60 02.19 Itajubá MG CCSI 2018 87 01.68 Parnaíba PI IESVAP 2018 80 02.15 Palmas TO ITPAC 2018 120 02.17 Teresina PI IESP 2018 110 02.04 Teresina PI IESP 2018 61 02.17 São João Del Rei MG IPTAN 2018 38 02.15 São João Del Rei MG IPTAN 2018 11 02.16 Araguaína TO UNITPAC 2018 80 02.06 Ipatinga MG UNIVAÇO 2018 100 01.99 Marabá PA FACIMPA 2019 120 02.19 Vitória da Conquista BA FASA 2019 100 01.15 Itabuna BA FASA 2019 85 02.18 Itabuna BA FASA 2019 64 01.23 Cametá PA ITPAC - Mais Médicos 2019 50 Pre-operational Cruzeiro do Sul AC ITPAC - Mais Médicos 2019 50 01.21 Santa Inês MA ITPAC - Mais Médicos 2019 50 02.20 Manacapuru AM ITPAC - Mais Médicos 2019 50 02.22 Itacoatiara AM ITPAC - Mais Médicos 2019 50 02.22 Abaetetuba PA ITPAC - Mais Médicos 2019 50 02.22 Bragança PA ITPAC - Mais Médicos 2019 50 02.22 Itaperuna RJ UniRedentor 2019 112 02.15 João Pessoa PB FCMPB 2020 24 02.17 João Pessoa PB FCMPB 2020 33 02.18 João Pessoa PB FCMPB 2020 80 02.16 João Pessoa PB FCMPB 2020 20 02.18 Redenção PA FESAR 2020 120 02.18 Porto Velho RO UniSL 2020 52 02.19 Porto Velho RO UniSL 2020 130 02.05 Ji-Paraná RO UniSL 2020 28 02.21 Guanambi BA FIP Guanambi 2021 60 02.18 Guanambi BA FIP Guanambi 2021 40 01.24 Garanhuns PE ITPAC 2021 120 02.21 Montes Claros MG UNIFIPMOC 2021 100 02.07 Duque de Caxias RJ UNIGRANRIO 2021 110 01.97 Duque de Caxias RJ UNIGRANRIO 2021 88 02.17 Rio de Janeiro RJ UNIGRANRIO 2021 110 02.04 Rio de Janeiro RJ UNIGRANRIO 2021 10 02.24 Alagoas AL UNIMA 2023 100 02.14 Alagoas AL UNIMA 2023 40 02.16 Alagoas AL UNIMA 2023 80 02.24 Jaboatão PE FCM Jaboatão 2023 100 01.18 Jaboatão PE FCM Jaboatão 2023 100 01.19 Unidompedro (3) BA UNIDOM 2024 300 01.21 (1) Number of medical school seats presented are estimated. (2) Schools with six or more years of operations are considered fully matured. (3) 300 seats authorized, of which 125 are final and 175 are subject to a final conclusion of court proceedings. 58 Table of Contents Industry Overview Introduction to Brazil’s education environment Brazil’s education environment has become increasingly open to private capital. At the same time, the government has continued to play an important role through the municipalities, states, and federal government. Post-secondary education Higher education in Brazil differs significantly from pre-secondary education. The majority of higher education schools are under private management and account for approximately 88% (both for profit and nonprofit) of all higher education institutions, according to Sinopse Estatística da Educação Superior. Higher education institutions are divided into three categories depending on the number of courses they offer, seniority of the teaching staff, and amount of research they conduct: they can be classified as colleges, university centers or universities. Typical post-secondary programs take between four to six years to complete. While some courses in these programs only occur during a certain period of the day (i.e., morning, afternoon, or evening), others are offered as full day courses. Tuition is paid on a monthly basis, primarily out of pocket by students and their families. Government financing is available, but not easily accessible. The main programs are FIES and PROUNI, which together accounted, in Brazil, for 20.3% of total financing in 2023 prior to more regulated policies in recent years, according to Sinopse Estatística da Educação Superior. Introduction to Brazil’s medical education industry In Brazil, aspiring physicians apply to medical school following graduation from secondary education. Medical school in Brazil is a six-year undergraduate program. Upon graduation, medical students gain a license and can start working as a generalist physician. At this point, they usually consider alternatives to gain a certification for one or more medical specialties. The first and most common path to obtaining a medical specialty certification is through a medical residency program. If a candidate chooses the medical residency path, the student must pass an entrance examination, referred to as R1 exam administered by each institution offering a residency program. After getting approved by a residency institution, the student then starts the first year of residency with the support of a government study grant throughout the specialization period. If the physician wants to pursue a subspecialty, he or she will need additional years of study, which may or may not require incremental entrance tests. 59 Table of Contents Medical professionals that do not choose or fail to be admitted into a residency program can still pursue a medical specialty certification through other alternatives. For instance, a generalist can take the specialist certification exam to become a specialist after meeting a variety of eligibility criteria. Those criteria can include internships, hours of work under the supervision of a medical specialist, or hours of study in a certified graduate program, among other methods. Depending on the desired level of medical specialty, it can take four to 10 years for a generalist to meet the criteria and, in this context, graduate courses can be a shorter path to reach eligibility sooner. As medical science continues to evolve very rapidly, medical professionals must seek ways to stay up to date on those developments. For that purpose, physicians and other medical professionals tend to use numerous sources of continuing medical education, or CME, including short term programs, scientific paper digests, and medical congresses, among others. 60 Table of Contents Regulatory overview and “Mais Médicos” program Medical education in Brazil is subject to regulatory terms that aim to define the supply of medical seats across the country. Since 2013, the Brazilian government put initiatives in place to increase the number of annual medical school and residency vacancies. In 2013, the “Mais Médicos” Law defined the rules for the creation of new medical courses in Brazil to address issues such as the unequal distribution of doctors across Brazilian states. Among the criteria that support the creation of medical school seats, two relevant aspects are (i) the importance of these new openings in a specified region and (ii) the sufficiency of the current medical infrastructure in both public regional hospitals and in the applicant medical institution in order to obtain government authorization. To reduce the shortage of doctors and mitigate the perceived healthcare inequality, the Brazilian federal government implemented a strategic initiative called “Mais Médicos.” The program’s main objectives included addressing the provision of doctors for primary care in municipalities, strengthening health care infrastructure, and allocating medical workforce to underserved areas. Regarding academics, “Mais Médicos” implemented short- and long-term measures to improve the Brazilian medical training system in both quantitative and qualitative ways. Among these measures was the opening of new medical school slots, in both undergraduate courses and residency programs. From its creation in 2013 until the date of this annual report, MEC, through SERES, announced three public calls for the selection of proposals for the authorization of medical courses on a national scale, the “Mais Médicos I” program in 2013, the “Mais Médicos II” program in 2018, and the “Mais Médicos III” program in 2023. “Mais Médicos I” and “Mais Médicos II” jointly authorized the opening of 58 new medicine courses and, initially, 4,971 new seats in medical schools, which may be increased by up to 100 seats, each in accordance with the “Mais Médicos” regulation. With the increase in annual offerings through “Mais Médicos,” on April 5, 2018 MEC announced that the government had decided to freeze the new offering of medical school seats for a period of five years, pursuant to Ordinance No. 328/2018. The decision was based on a need to evaluate the impact of opening new medicine courses in Brazil. However, on April 5, 2023, MEC issued Ordinance No. 650/2023, which revoked the suspension under Ordinance No. 328/2018 and set new rules for the opening of new medicine courses. Following the issuance of Ordinance No. 650/23, on October 4, 2023, MEC, through SERES, exercising its legal powers and based on Article 3 of the “Mais Médicos” Law announced the public call for the selection of proposals for the authorization of medical courses on a national scale. The rules for the new “Mais Médicos III” program set forth the criteria for new undergraduate medical school seats. This new program will allow the opening of up to 5,700 new undergraduate seats, to be distributed across 95 cities with a limit of 60 seats per institution. Although the “Mais Médicos” program requires a public call prior to the authorization of a new medicine course, some educational institutions have been judicially challenging this restriction before Brazilian courts to compel MEC to receive and review requests for new medicine courses outside the “Mais Médicos” program rules by alleging that these rules are an undue restriction on freedom of competition. Certain courts may ultimately compel the MEC to receive and review these requests. For more information, see “Item 3. Key Information—D. Risk Factors—Certain Risks Relating to Our Business and Industry—We face significant competition in each program we offer. If our competition increases or if we fail to compete efficiently, we may lose market share and our profitability may be adversely affected.” 61 Table of Contents In addition, the increase in medical school seats in existing undergraduate courses is regulated by Ordinance No. 1,771, dated September 1, 2023, which allowed educational institutions to request an increase in medical school seats by submitting a request to MEC. As of the date of this annual report, those requests are still under MEC’s analysis. Brazilian medical education quantitative assessment Given the national regulatory framework, expanding medical school seats depends mostly on quality attributes and the need for additional doctors in the given geography. The number of medical school seats remained approximately unchanged between 2005 and 2012, but increased at a faster pace from 2012 to 2014 to mitigate the shortage of physicians in the country. “Mais Médicos I” and “Mais Médicos II” jointly authorized the opening of 58 new medicine courses and, initially, 4,971 new seats in medical schools, which may be subject to an increase of up to 100 seats, each in accordance with the “Mais Médicos” regulation. Furthermore, the new “Mais Médicos III” program will authorize the opening of up to 5,700 new undergraduate seats. From 2012 to 2022, first-year enrollments in private medical schools have increased by 20,386, representing a 10.6% CAGR, compared to an additional 2,901 public medical first-year enrollments during that period. According to the Demografia Médica do Brasil report—which is co-produced by the Brazilian Medical Association (Associação Médica Brasileira) and the University of São Paulo, Brazil, or Demografia Médica—the number of physicians in Brazil increased from 310,800 to 562,200 from 2010 to January 2023, representing an 80.8% increase. With that demand in place, a supply of new healthcare professionals is expected to keep growing to keep up with the increased demand for public and private health services. By January 2023, the total number of physicians in Brazil increased to 562,229 professionals, implying 2.60 doctors per 1,000 inhabitants. Projection of the number of physicians in Brazil (2019 to 2028) Source: Demografia Médica, 2022. 2023-2028 figures are projections 62 Table of Contents Fundamentals of medical education in Brazil The medical education market in Brazil is supported mainly by the higher demand for medical courses than the actual seats offering, the low and uneven medical density when compared to the Organization of Economic Cooperation and Development, or OECD average, Brazil’s fast aging population, and compelling financial rewards for those seeking to pursue a medical career. Brazil’s aging population Brazil’s aging population is expected to drive an increase in demand for physicians and other healthcare service providers. Brazil’s aging ratio is twice that of the United Kingdom and three times that of the United States. Compared to 1995, life expectancy at birth is up from 66 years to 76 years, driven primarily by medical and health improvements. By 2030, 13.5% of the Brazilian population is expected to be older than 65 years, compared to 7.3% in 2010. Furthermore, in 2060, the percentage of the population of 60 years and older is expected to exceed the number of people 19 years and under, according to the Instituto Brasileiro de Geografia e Estatística, or IBGE. Population distribution by age group—Brazil Source: IBGE. Increase in medical services demand The long-suppressed demand for health services in Brazil is expected to continue to increase given demographic changes in Brazil as well as a larger portion of the population being able to access private healthcare services. As of December 31, 2022, Private Health Insurance penetration in Brazil reached 24.7%, according to data from ANS. This is lower than countries such as Germany, Australia and the United States, which according to the OECD have 33.9%, 54.9% and 63.0% penetration, respectively. Even with the expected increase in medical graduation, the demand for healthcare services is expected to surpass the current supply of physicians by medical schools creating a continued demand for medical courses and graduate education. According to Demografia Médica, Brazil had 2.6 doctors per 1,000 inhabitants in 2022, which is considerably below the international average and the average of developed countries, which have been through the demographic changes that are expected to happen in Brazil. For example, according to Demografia Médica, Italy had an average of 4.13 doctors per 1,000 inhabitants in 2022. Considering the projections of a total of 564,363 physicians in 2023 versus Brazil’s population growth over the same period, Brazil would still have approximately 2.6 doctors per 1,000 inhabitants, which is still below the OECD average. 63 Table of Contents Doctors per thousand inhabitants, according to selected OECD countries (2022). Source: OECD. Shortage and distribution of medical professionals in Brazil Brazil’s low medical density and inequality in physician distribution is illustrated in the figure below. São Paulo and Rio de Janeiro have 3.6 and 4.2 doctors per 1,000 inhabitants, respectively, while the states of Pará and Acre have 1.3 and 1.7 doctors per inhabitant, respectively. The north and northeast regions are Brazil’s most underserved areas and have been the focus of governmental physician assignment programs. With the new “Mais Médicos III” program and the increase of physicians in the upcoming years, it is expected that Brazil’s medical density will reach 3.3 doctors per 1,000 inhabitants, which would still be below the OECD average of 3.73 in 2022. 64 Table of Contents Distribution of doctors according to Brazilian states—2023 Source: Demografia Médica, 2023. Compelling financial rewards for pursuing a medical career One of the notable arguments for pursuing a medical career in Brazil is the financial outcome for the future physician, with higher salaries and fast payback. The main points of view that support the increasing demand for medical education analysis are: (i) nearly 100% employability of medical school graduates in Brazil; (ii) significantly higher salaries for medical school graduates than those enrolled in engineering courses (by approximately 77%), and (iii) a four-year post-graduation average payback period. 65 Table of Contents Source: (1) Instituto de Pesquisa Econômica Aplicada—IPEA, CAGED, (2) Demografia Médica 2023, (3) Afya’s Research Center, (4) Third-party consulting firm analysis. Even when considering the comparatively high tuition paid during the six-year medical undergraduate program, its above-average income after graduation results in an average payback period of four years, a relatively short period compared to other undergraduate education majors. Expansion in graduate programs and CME The number of public and private medical graduate courses is not measured by any institution, as it is developing and growing as residency slots become increasingly restricted. Typically, educational institutions partner with hospitals to provide an adequate infrastructure for teaching students. Unlike residencies, students pay out-of-pocket monthly tuition of around R$4,000, according to a third-party consulting firm. These are usually one to two-year courses and there is currently no government student financing for this segment. Underlying Trends of Medical Education in Brazil In addition to a large and underpenetrated total addressable market, we have identified other trends that contribute to the strength of the markets we serve: · Increased life expectancy and demand for medical services: The Brazilian population is aging at the fastest rate in its recent history. Average life expectancy is currently 76.2 years, and the number of people over 65 should double from 7% of the total population in 2012 to 14% of the total population in 2033. This has led to, and is expected to continue to drive, increased demand for healthcare professionals. In addition, private healthcare spending and public healthcare spending in Brazil grew at a CAGR of 14.0% and 11.8%, respectively, from 2010 to 2015, primarily due to an increase in demand for medical services as a result of an aging population and an increase in average household income. These trends have continued since 2015 to date. · Shortage of medical professionals in Brazil: There is a shortage of medical professionals in Brazil, primarily due to the uneven socio-economic environment. On average, Brazilian cities with less than 50,000 inhabitants, which corresponds to approximately 90% of all cities in Brazil, have less than one physician per 1,000 residents. Brazil is expected to have an average of 3.07 physicians per 1,000 inhabitants by 2028, below the average of 3.4 for 2018 Organization for Economic Cooperation and Development, or OECD, countries. 66 Table of Contents · Attractive financial incentives: The medical profession is lucrative. Medical professionals are highly employable, with salaries that are on average more than three times higher than the average salary for other professions such as engineering, nursing and law, and 1.9 to 3.8 times higher than the net present value of engineering, nursing or law programs in Brazil. · Supply and demand imbalance for medical education: The number of available medical course seats in Brazil is controlled by MEC, which has limited medical school intakes to current levels until 2023, resulting in a significant imbalance between supply and demand. In the last three years, medical schools have on average received five applications per available medical course seat, and four applications per available residency program vacancy, and the number of applications are expected to increase. We believe that graduate courses will gradually become a more popular, high-demand destination for physicians that are not admitted into residency programs. · CME expansion: The growing number of physicians in Brazil and the demand for ongoing education on new medical procedures, drugs, technologies and developments will continue to drive demand for CME. · Technological innovation is driving medical education: The current generation of medical students and professionals requires instantly accessible digital content. Over 600,000 biomedical articles have been published globally every year since 2005, and it is critical for lifelong learners to be able to access information and learning methodologies regardless of location and physical availability. · Limited scope of existing product offerings: By generally limiting their focus on individual aspects of a student’s education cycle, traditional education providers have struggled to build comprehensive student track records and profile databases. Consequently, there is a general lack of integrated platforms that apply accumulated student information to efficiently tailor experiences to, or produce bespoke materials for, the particular needs of each student. We believe we are well-positioned to take advantage of this market and its trends, bringing a more effective, personal and diversified service to our students, which will enable us to continue to grow our market share. Our Competition We believe we are the only company in Brazil with a focus on the entire learning career of a physician. However, several companies provide solutions that compete in some of the markets in which we operate. We compete directly or indirectly with other post-secondary institutions that offer medical courses or any of the other higher education courses in our portfolio. This market is very fragmented and currently, there are more than 300 other institutions that offer medical courses in Brazil. The following table sets forth our main competitors and the number of approved medical school seats they had as of December 31, 2024: Number of Approved Medical School Seats Company As of December 31, 2024 Afya Brazil 3,593 Player 1 2,060 Player 2 1,892 Player 3 1,019 Player 4 941 The market for graduate medical courses has been growing rapidly and we have recently experienced increasing competition from traditional education institutions that previously had been limited to providing undergraduate courses and have since begun to offer graduate programs. 67 Table of Contents Our Products and Services We offer the following educational products and services to lifelong medical learners enrolled across our evolving distribution network, as well as to third-party medical schools. Medical Schools · A fully integrated core curriculum is offered to our medical school students across all our campuses. · All our medical students have access to our supplemental instructional platforms as part of the internship module of their medical course, which we implemented for all incoming medical students of the fifth and sixth academic year. · As of December 31, 2024, we had 24,255 students enrolled in medical school programs which represented 31.5% of the total number of students in our Undergrad segment, contributing to a revenue of R$2,487.1 million for the year ended December 31, 2024, which represented 85.9% of our total revenue for our Undergrad segment. As of December 31, 2023, we had 21,446 students enrolled in medical school programs which represented 32.5% of the total number of students in our Undergrad segment, contributing to a revenue of R$2,147.4 million for the year ended December 31, 2023, which represented 85.5% of our total revenue for our Undergrad segment. As of December 31, 2022, we had 17,968 students enrolled in medical school programs which represented 30.9% of the total number of students in our Undergrad segment, contributing to a revenue of R$1,699.2 million for the year ended December 31, 2022, which represented 83.4% of our total revenue for our Undergrad segment. Residency Journey · Instructional content in digital format is offered to medical students and newly graduated physicians to prepare them for medical residency exams. · Supplementary instructional content in digital format is offered to third-party medical schools that adopt our services. · As of December 31, 2024, 2023 and 2022, we had 16,381, 12,170 and 19,986, respectively, enrolled students in our medical residency preparatory courses. Graduate Journey · We offer a wide array of options for doctors pursuing specialization, whether through graduate medical courses or preparatory programs for specialist title exams. These students also have access to some of our supplemental instructional platforms. · Supplemental instructional content for different medical specializations is offered to individual lifelong medical learners in our graduate courses. · As of December 31, 2024, we had 8,527 enrolled students in our graduate courses. As of December 31, 2023, we had 7,722 enrolled students in our graduate courses. As of December 31, 2022, we had 6,058 enrolled students in our graduate courses. Other Courses — B2P and Business to Business Offerings · We provide courses that extend beyond medical practice, focusing on lifelong learning and the development of both technical and interpersonal skills essential for well-rounded medical professionals. · These programs cater to physicians seeking to stay current throughout their careers while enhancing their technical expertise. · As of December 31, 2024, we had 25,613 enrolled students in our other courses. As of December 31, 2023, we had 27,188 enrolled students in our other courses. As of December 31, 2022, we had 17,475 enrolled students in our other courses. 68 Table of Contents Other Programs · Other national core curriculum is offered to all students across all of our undergraduate campuses: healthcare degrees and a subset of non-healthcare degrees, including business and engineering degrees offered by the companies we invested in or acquired. · As of December 31, 2024, we had 52,733 students enrolled in other programs which represented 68.5% of the total number of students in our Undergrad segment, contributing to a revenue of R$408.6 million for the year ended December 31, 2024, which represented 14.1% of our total revenue for our Undergrad segment. As of December 31, 2023, we had 44,588 students enrolled in other programs which represented 67.5% of the total number of students in our Undergrad segment, contributing to a revenue of R$363.6 million for the year ended December 31, 2024, which represented 14.5% of our total revenue for our Undergrad segment. As of December 31, 2022, we had 40,232 students enrolled in other programs which represented 69.1% of the total number of students in our Undergrad segment, contributing to a revenue of R$338.7 million for the year ended December 31, 2022, which represented 16.6% of our total revenue for our Undergrad segment. Medical Practice Solutions · Subscription-based mobile app and website portal focused on assisting health professionals and students with clinical decision-making for 30 medical specializations through tools such as medical calculators, charts and updated content, including prescriptions, clinical scores, medical procedures and laboratory exams, among others. · Free instructional content we offer to physicians, healthcare professionals and students. · As of December 31, 2024, we had approximately 195,018 active paying users, consisting of approximately 161,283 in Clinical Decision and 33,735 in Clinical Management. As of December 31, 2023, we had approximately 183,602 active paying users, consisting of approximately 153,541 in Clinical Decision and 30,061 in Clinical Management. As of December 31, 2022, we had approximately 163,446 active paying users, consisting of approximately 137,767 in Clinical Decision and 25,679 in Clinical Management. Our acquisition of PEBMED represented our initial expansion into the digital health services sector, which we believe adds value to our platform. In particular, our acquisition of PEBMED included the Whitebook product, which added approximately 125,300 active users to our platform and increased our penetration in the segments in which we already operate through digital health services. The following chart sets forth our market share by career aging cohort as of December 31, 2024: 69 Table of Contents Our Lifelong Medical Learner Clients As of December 31, 2024, we had a total of 127,508 students across all our segments, including 24,255 enrolled in our undergraduate medical programs, 16,381 enrolled students in our medical residency preparatory courses, 8,527 enrolled students in our medical graduate courses, and 25,613 enrolled students using our other B2B and B2P offerings. In addition to health sciences courses, which comprise medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition and biomedicine, we also offer degree programs and courses in other non-health sciences subjects and disciplines across several of our campuses, including undergraduate and graduate courses in business administration, accounting, law, civil engineering, industrial engineering and pedagogy. These non-health sciences courses are not part of our core business—the number we offer has increased as a consequence of our strategic acquisitions in recent years of multi-disciplinary schools with strong health sciences programs, which are our principal focus. Although non-health courses are not part of our growth strategy, we expect to continue to offer them to the extent they generate local demand. These non-health sciences programs represented 6.2%, 6.5% and 6.3% of the total revenues of our Undergrad segment in 2024, 2023 and 2022, respectively. The attractive dynamics for medical education in Brazil, including high demand for medical services and low medical density, combined with the exceptional rewards a physician receives (e.g., high wages, fast payback), create the perfect environment for us, with high demand for health sciences programs throughout the entire medical career. This scenario enables us to target a unique student profile during our selection process, capturing the most capable individuals in Brazil. In addition, as of December 31, 2024, we had 16 contracts with other partner companies, which represents our B2B business. These partnerships allow us to increase our distribution outreach to other institutions around the country and help us achieve our mission. Student Financing and Incentive Programs Student financing program—Fundo de Financiamento Estudantil (“FIES”) FIES is a MEC program created by Law No. 10,260/2001 to provide financing to undergraduate students who are unable to finance their own education. After going through several reforms from 2015 onwards, as of the date of this annual report, the FIES program is provided in the following categories: · Public FIES (2018)—Extended to persons with a per capita income of up to three minimum wages, with zero interest rate, with the credit risk being divided between the government and the private Higher Education Institutions, or HEIs; 70 Table of Contents · Private FIES (2018)—Extended to persons with a per capital income of up to five minimum wages, with low interest rates. Regional funds and private financial institutions, provide the financing; and · Social FIES (2024)—Reserves at least 50% of FIES vacancies in each selection process for students with a per capita family income of up to half a minimum wage, with zero interest rate. In the Public FIES and the Social FIES, the financing is provided by federal government funds and contributions from HEIs through the FG-FIES fund. With respect to this fund, on November 1, 2023, Law No. 14,719 was enacted and set a maximum contribution limit to the FG-FIES at 27.5%. This limit applies to contributions made by maintaining entities voluntarily joining the program after the fifth year of their participation. In addition, as part of the conditions and rules of the FIES program, private higher education institutions that apply for the program can immediately increase up to 10% of their authorized vacancies annually. For more information, see “Item 3. Key Information—D. Risk Factors—Certain Risks Relating to Our Business and Industry—Changes to the rules or delays or suspension of tuition payments made through FIES may adversely affect our cash flows and our business” for further information. Incentive program—Programa Universidade Para Todos Programa Universidade Para Todos, or PROUNI, was established in 2005 through Law No. 10,096/2005, which offers full and partial scholarships (50%), in private HEIs for undergraduate and subsequent courses of specific training, to Brazilian students without a higher education diploma. Additionally, the Government offers federal tax exemptions to higher education institutions adhering to PROUNI. Private higher education institutions, whether for profit or not, may join PROUNI by signing a term of adhesion (valid for 10 years), and at least (i) offer a full scholarship for every 10.7 students who pay a regular monthly fee and are regularly enrolled at the end of the previous school year; or (ii) an integral scholarship for every 22 students who pay the regular monthly tuition fees in specific undergraduate and subsequent courses, provided they also offer scholarships of 50%, in amounts necessary so that the sum of the benefits granted is equivalent to 8.5% of its annual revenue. The tax exemptions (in whole or in part) for HEIs that participate in this program are the following: · IRPJ (income tax) and CSLL (social contribution), with respect to the portion of net income in proportion to revenues from traditional and technology undergraduate programs; and · COFINS (Contribution for the Financing of Social Security) and PIS (Program of Social Integration), concerning revenues from traditional and technology undergraduate programs. In addition, as part of the conditions and rules of the PROUNI program, private higher education institutions that apply for the program can immediately increase up to 10% of their authorized vacancies annually, except for law and medicine courses, which are subject to annual approvals by MEC. As of December 31, 2024, our exposure to PROUNI was 9.2% of our student base. Although we fulfilled all required scholarships to receive 100% of tax exemption, PROUNI does not cover our operation outside of our undergraduate programs. Other private financing program In addition to PROUNI and FIES, Afya participates in private financing programs through external partners (Bradesco, BNB, Sicoob, CashMe and Alume) for undergraduate students. Moreover, in 2024 we launched our own financing program for some of its units to support medical students who were not eligible for other types of financing. Key Benefits for our Lifelong Medical Learners We believe the end-to-end physician-centric ecosystem we have been developing for our students sets us apart from our peers, as we deliver content and learning activities that are tailored to each student’s needs. This contributes to a more interactive and enjoyable learning process for our students, breaking away from a teaching system that we perceive as presenting students with an overwhelming amount of content, unengaging classes and scattered information. We achieve this based on three main pillars: innovative data-oriented methodology, a cutting-edge platform and state-of-the-art operating environment. 71 Table of Contents Innovative, Data-oriented Methodology Our proprietary methodology to support our students’ lifelong medical education is based on the following concepts: Standardized medical curricula: The organization of our medical curricula around interdisciplinary macro-medical topics to guide the development of in-person teaching plans and online learning tools, offering a scalable solution for schools through weekly synchronized content; Active learning: Educational strategy to foster independent, critical and creative student thinking, as well as encourage effective teamwork through case-based problem-solving exercises, debates and small-group discussions; Blended learning: Balanced in-person teaching with technology-assisted activities to improve student and teacher efficiency and results; and Adaptive learning: A personalized instruction and assessment tool that provides training and content tailor-made to each student’s individual profile. Students can access real-time feedback on areas in which they can improve, effective learning methods and teaching/study plans that are most suitable for them. Cutting-Edge Digital Platform We deliver modern, bespoke verbal and practical teaching. We continuously invest in creating innovative, technology-enabled activities and features to enhance our platform. We offer our medical school students doing internships or studying for residency exams the following features through our digital platform: Web portal and in-app communication: Online platform combining supplementary instructional content and a personalized communication tool for students, through which they can also access our content offline; 72 Table of Contents Assessment tool: Broad database suite composed of quizzes and problem-solving activities, through which students can choose the subjects they would like to focus on, with additional teacher-led instructional content; Tutoring/mentoring platform: An online monitoring and support platform for both undergraduate and graduate medical students. The platform allows tutors to interact with students through emails, video calls, voice calls and push notifications, and keeps records of such interactions. It also allows students to ask the tutors questions and schedule appointments. The platform also tracks individual student performance and progress; and Digital health services platform: A combination of mobile and web applications focused on helping physicians, nurses, healthcare professionals and medical students in their clinical decision-making and providing medical references and updates for the medical community. State-of-the-Art Operating Environment For us, individualized learning should be used not just when offering content or technology-supported activities, but also during in-person encounters. Our professors can use our resources to approach lessons more objectively, focusing on each student’s needs: Modern teaching facilities: We have designed our classrooms to engage students in active learning. We rely on cutting-edge didactical equipment and simulation labs and state-of-the-art realistic simulation technologies; Medical specializations centers: Our campuses offer simulation centers and clinics where students can practice primary and secondary care, leveraging the learning process and providing medical assistance to the local population; and Practical learning network: Throughout the internship cycle, our students can access over 614 partner teaching hospitals and clinics, the largest network of any education group in Brazil. Evolving Distribution Network We believe that an effective end-to-end physician-centric ecosystem goes beyond offering the largest and most complete operating infrastructure to the students enrolled at our campuses and with access to our digital platforms. Through our evolving distribution model, we also expect to empower lifelong medical learners across our growing network of diversified partner teaching hospitals, clinics and third-party medical schools by increasing our products and services offerings as we continue to expand our business-to-business, or B2B capabilities. Our partnerships include renowned institutions such as the Brazilian Cancer Foundation, which joined our network in January 2020. Seasonality of Operations Undergrad segment revenues are related to the intake process and monthly tuition fees charged to students, and do not significantly fluctuate from quarter to quarter. Continuing Education revenues are mostly related to: (i) monthly intakes and tuition fees on medical education, which generally do not experience significant fluctuations resulting from seasonality and (ii) Medcel’s revenue, derived from the sales of e-books which are recognized at the point in time when control is transferred to the customer, which is generally concentrated in the first and last quarter of the year due to the period of enrollments. Consequently, the Continuing Education segment generally has higher revenues and results of operations in the first and last quarters of the fiscal year than in the second and third quarters of the fiscal year. Medical Practice Solutions revenues derive mainly from Whitebook and iClinic, which do not experience significant fluctuations resulting from seasonality. Marketing and Sales Our marketing strategy is focused on identifying, qualifying and converting potential students into enrollments. We execute our marketing strategy as follows: · Identification: We use online and offline media channels to distribute relevant content for all decision-making phases of current and future physicians, so that they interact with our solutions throughout their learning careers. 73 Table of Contents · Qualification: After we obtain data on a potential student, we identify his/her needs by offering content that matches his/her academic phase. In addition, through our score models, we can identify potential students that are more likely to enroll with us. · Conversion: From that point on, we contact our sales department (online and inside sales) to convert potential students into enrolled students through structured sales campaigns and continuous monitoring of conversion indices. As our business model is end-to-end and physician-centric, we aim to accompany our lifelong learners at each stage of their careers. Therefore, our sales funnels are calibrated according to the segment’s supply-demand curve (graduation, preparatory, etc.), level of competition and other strategic variables. For example, in medical schools, the most challenging task is to identify potential students interested in attending medical school in a given cycle, since conversion typically occurs organically due to the high demand for these courses. Our challenge is to attract and enroll the best ENEM students in our medical schools. With respect to the medical residency preparatory phase and graduate programs, our main focus is to show potential students the benefits of our methodology in terms of results and cost-benefit in order to guide them toward adopting our solutions. Our marketing and sales efforts are supported by Insider, Braze and Active Campaign, as well as other online analytical tools such as Hubspot and Salesforce products (Sales Cloud, Marketing Cloud and Einstein). Our business model, combined with the use of CRM tools gives us a unique competitive advantage: The ability to identify, market and offer products to virtually all medical students and physicians in Brazil. Technology and Intellectual Property Technology In recent years, we have implemented several initiatives to improve operational efficiency and to integrate processes across several campuses and operations. We plan to continue this process in the future to fully consolidate Afya Brazil’s integrated systems with those of our recent acquisitions. Shared Services Center We have invested in a modern Shared Services Center, or SSC, to process back-office and non-student facing transactions that has idle capacity and is expected to enable student-base growth with low marginal costs. Integrated Systems We have adopted third-party systems to handle our internal systems in a fully integrated manner: · Enterprise Resource Planning, or ERP: TOTVS ERP RM is the leading solution in the Education Industry in Brazil and delivers a flexible systemic solution that fits our companies’ processes to improve management and organization. At the same time, it allows high governance of the processes, with complete control of all back-office activities, preventing operational errors and allowing efficient tax-related calculations and control of government obligations. Salesforce optimizes our sales and customer relationship management processes, facilitating streamlined lead management, sales forecasting, and customer engagement. Its robust analytics capabilities offer valuable insights into sales performance and customer behavior, enabling data-driven decision-making and strategic planning. Additionally, ServiceNow enhances internal workflows and IT service management, empowering teams to efficiently handle incidents, changes, and service requests. Its intuitive interface and automation bolster productivity and customer satisfaction. Moreover, ServiceNow’s robust reporting and analytics offer valuable insights, facilitating data-driven decision-making and continuous improvement. · Academic System: TOTVS RM Educacional is a mature platform that allows the configuration of the student payment plan attached to the disciplines enrolled and processes preventing manual financial transactions and making the process more flexible and efficient. This system includes both Student and Faculty Portals, with features that allow mobile frequency monitoring and provide payment solutions to students and also manages the faculties’ timesheet and payroll. 74 Table of Contents · Learning Management System, or LMS: Canvas LMS is a cloud-native, highly scalable system that connects all digital learning tools and evaluation resources accessed nationally by our faculties and students. As of the date of this annual report, iClinic, Medical Harbour, Cliquefarma, Shosp, RX Pro and Glic independently operate their own ERP systems. We are working to migrate the systems from the companies described above in order to fully incorporate them into our integrated systems. Intellectual Property We rely on a combination of copyright, trademark and trade secret laws, as well as employee and third-party non-disclosure, confidentiality and other types of contractual arrangements to establish, maintain and enforce our intellectual property rights, including with respect to our proprietary rights related to our products and services. In addition, we license technology from third parties. As of the date of this annual report, we had no issued patents and one patent application pending in Brazil. As of December 31, 2024, we owned 285 trademark registrations in Brazil and 5 abroad, and we have also sought to register other trademarks in the United States, in the European Union, Portugal, Mexico, China and Colombia. As of the date of this annual report, we have 119 pending trademark applications in Brazil and unregistered trademarks that we use to promote our brand, and also own 364 registered domain names in Brazil and 53 registered international domain names, and have registered three software in Brazil. Insurance We have insurance policies with reputable insurers in amounts considered sufficient by our management to cover potential losses arising from indemnities that we may have to pay to third parties as a result of our operations. The policies for our operating units have an aggregate coverage limit of up to approximately R$382.8 million. The Company and its subsidiaries have a risk management program with the purpose of delimiting the risks, seeking coverage compatible with its size and operations in the market. We seek coverage against risks that are compatible with our scale and type of operations, considering the nature of our activities, the risks we are exposed to, market practices in our industry, and the advice of our insurance consultants. While we believe our insurance contracts reflect standard market practices, there are certain types of risks that may not be covered by the policies (such as war, terrorism, acts of God and force majeure, liability for certain harm or interruption of certain activities). Therefore, if any of these uncovered events occur, we may be obliged to incur additional costs to remedy the situation, reconstitute our assets and/or indemnify our customers, which may adversely affect us. Furthermore, even in the event that we incur a loss that is covered by our policies, we cannot assure that damages awarded by our insurers will be sufficient to cover the losses arising from the insured event. See “Item 3. Key Information—D. Risk Factors—Certain Risks Relating to Our Business and Industry—We may be held liable for extraordinary events that may occur at our campuses, which may have an adverse effect on our image and, consequently, our results of operations.” Regulatory Overview The Brazilian Constitution establishes education as a right for all citizens and a duty of the State and the family. Accordingly, the government is required to provide all Brazilian citizens with access to free primary education with compulsory attendance. Private investment in education is permitted as long as entities providing education services comply with the applicable rules and regulations. The Brazilian education system is organized under a cooperative management among federal, state and municipal governments. The federal branch is required to organize and coordinate the federal educational system in order to guarantee equal opportunity and quality of education throughout Brazil. The states and the Federal District are required to focus on secondary education, while municipalities are responsible for providing pre-primary school and primary education. 75 Table of Contents Private Higher Education Institutions are part of the federal educational system and their activities are regulated by the federal government, and universities have didactic, scientific and administrative autonomy as provided by the Brazilian Constitution. Additionally, Law No. 9,394 of December 20, 1996, named by National Education Guidelines Law (Lei de Diretrizes e Bases da Educação, or LDB) provides the guidelines for the provision of educational services in Brazil and sets forth the federal government’s duty to, among others: (i) coordinate the national education system; (ii) prepare the National Education Plan; (iii) provide technical and financial assistance to the states, the Federal District and municipalities; and (iv) define, in cooperation with other federal entities, the responsibilities and guidelines for primary and secondary education, with the federal government’s priority in post-secondary education, issuing rules and regulations regarding undergraduate and graduate programs, and carrying out the activities relating to the accreditation of institutions, authorization and recognition of courses and monitoring and evaluation of the educational system as a whole. In addition, the federal government, through Law No. 10,172 of January 9, 2001, implemented the first National Education Plan (Plano Nacional de Educação, or PNE), with a duration of 10 years from the date of its publication. The PNE established objectives for post-secondary education to be met by all branches of government. The primary goal was to offer post-secondary education to at least 30% of the population aged 18 to 24 by 2010. After the expiration of the first PNE, a new plan was enacted and the objectives were revised for the period of 2014 to 2024, consolidated by Law No. 13,005 of June 25, 2014. The new goals consist of: (1) increasing post-secondary education enrollment rates to 50% of the population aged 18 to 24; (2) increasing the quality of post-secondary education by raising the proportion of academic staff with master’s degrees and doctorate degrees to 75%, of which at least 35% shall be doctorates; and (3) increasing progressively stricto sensu graduate programs. Such goals apply to each federation territory, and provide orientation for the private education sector. Finally, each of the federal, state and municipal governments are required to prepare a 10-year education plan and to establish policies, guidelines and objectives applicable to the segment of the Brazilian education system over which it has responsibility. Post-secondary Education The post-secondary education sector is subject to comprehensive government regulation. Its purpose is to ensure the quality of educational services, through evaluations of the ability of educational institutions to meet minimum standards established by CNE and approved by MEC. This evaluation includes the analysis of pedagogical projects, the infrastructure of Higher Educational Institutions, or HEIs, and their academic staff, and the results of such evaluations are considered in the proceedings for opening new units and new courses. Therefore, activities and courses offered by HEIs in Brazil depend on authorizations and are subject to ongoing regulation, guided by the results of quality assessments. The federal responsibility to regulate, monitor and evaluate post-secondary education institutions and programs is exercised by MEC, CNE, INEP and CONAES. Ministry of Education The Ministry of Education, or MEC, is the highest authority for post-secondary education within the Brazilian national education system, whose competence consists, among other prerogatives, of the following: (1) confirming CNE’s accreditation decisions for post-secondary education institutions; (2) confirming evaluation systems and criteria adopted by the INEP; (3) confirming opinions and regulation proposals from CNE; (4) issuing rules and instructions for compliance with laws, decrees and regulations pertaining to education issues; and (5) regulating and monitoring the post-secondary education system through its secretariats. National Education Council The National Education Council, or CNE, is a consulting and decision-making body monitored by MEC, collectively comprised of the Chamber of Primary and Secondary Education, or CEB, and the Chamber of Post-secondary Education, or CES, each composed of 12 members appointed by the President of Brazil. 76 Table of Contents CNE is required, among other responsibilities, to: (i) issue regulations to implement MEC’s guidelines, as well as advise and support MEC in its activities and decisions; (ii) decide on accreditation applications and renewals from post-secondary education institutions engaged in distance learning, based on the opinion of the relevant secretariats; (iii) propose guidelines and deliberate on the preparation of the evaluation instruments for accreditation and re-accreditation of institutions to be elaborated by INEP; (iv) issue guidelines to be observed by SERES for accreditation and re-accreditation of universities, university centers and colleges; (v) determine, through CES, the inclusion and exclusion of course designation from the catalog of advanced technology courses; (vi) rule on appeals of decisions issued by SERES, CEB or CES; and (vii) analyze and propose questions regarding the application of post-secondary education legislation to MEC. Anísio Teixeira National Institute for Educational Research The Anísio Teixeira National Institute for Educational Research, or INEP, is a federal body linked to MEC whose main responsibilities are, among others, to: (i) design, plan, coordinate and operationalize actions for the evaluation of HEIs, undergraduate courses and government schools, as well as the National Student Performance Examination, or ENADE, the examinations and assessments of undergraduate students; (ii) design, plan, coordinate, operationalize and evaluate indicators related to post-secondary education resulting from examinations and inputs from official databases, the establishment and maintenance of databases of specialized evaluators and collaborators, including the appointment of evaluation committees; (iii) prepare and submit to MEC the instruments for external evaluation (in loco), in accordance with the guidelines proposed by the SERES and by other competent bodies; (iv) design, plan, evaluate and update the indicators for the external evaluation instruments in place, in accordance with the guidelines proposed by CONAES; (v) chair the Technical Committee for Evaluation Monitoring; and (vi) plan, coordinate, operationalize and evaluate the actions necessary to achieve its objectives. National Higher Education Evaluation Commission The National Higher Education Evaluation Commission, or CONAES, is a coordination and monitoring body of the National Higher Education Evaluation System, or SINAES, monitored by MEC, composed of a President and 13 members, including one representative of the INEP, one representative of the Fundação de Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Foundation for the Coordination of Improvement of Post-secondary Education Personnel, or CAPES), three representatives of MEC (one of which must come from the body responsible for the regulation and monitoring of post-secondary education), one representative of the student body of post-secondary education institutions, one representative of the academic staff of post-secondary education institutions, one representative of the administrative body of post-secondary education institutions, and five members appointed by the Minister of Education, with distinguished scientific, philosophic and artistic knowledge and proven expertise in post-secondary evaluation or management. Among other activities CONAES is required to: (i) propose and evaluate the dynamics, procedures and mechanisms for institutional evaluation, courses and student performance; (ii) establish guidelines for the organization of evaluation committees, analyze reports, prepare opinions and submit recommendations to the competent bodies; (iii) formulate proposals for the development of HEIs, based on the analysis and recommendations produced in the evaluation processes; (iv) communicate with the state educational systems, with the aim to establish common actions and criteria for the evaluation and supervision of post-secondary education; and (v) annually submit for approval by the Minister of Education the list of courses for which students will apply for the ENADE. Organization of Post-secondary Education Institutions In order to allow post-secondary education institutions to fulfill their objectives, the LDB also provides that post-secondary education includes the following programs: · Undergraduate courses, including traditional and technological undergraduate courses, offering specific training and diplomas to students, open to candidates who have completed high school or equivalent and who have been approved in the respective selection or entrance examinations; · Graduate courses, including master’s and doctoral degrees, specialization courses, further training courses and others, open to candidates who hold a diploma in an undergraduate course and who meet the requirements laid down by educational institutions; and 77 Table of Contents · Extension courses, understood as any academic, technical or cultural activity that is not included as an integral and compulsory part of the undergraduate and graduate curriculum, in which the students receive certificates. Such courses are open to candidates who meet the requirements established in each case by educational institutions. According to the LDB, post-secondary education can be provided by public or private institutions. A private post-secondary education institution must be controlled, managed and supported by an individual or a legal entity with responsibility for financing its supported entities. Post-secondary education institutions may be supported by for-profit or not-for-profit private institutions, or supporting entities, as follows: · Private in the strict sense: private for-profit institutions created and maintained by one or more private individuals or legal entities; · Community: incorporated by groups of individuals or by one or more legal entities and that include representatives of the community in their organizational structure; · Confessional: incorporated by groups of individuals or by one or more legal entities that meet the specific confessional and ideological orientation and that include representatives of the community in their organizational structure; or · Philanthropic, in the form of the applicable regulations. According to their organization and academic prerogatives, post-secondary education institutions can be: · Colleges: colleges are public or private HEIs offering post-secondary programs in one or more areas, maintained by a single supporting entity and with isolated management and direction. Colleges are allowed to offer programs along several levels, namely bachelor’s, associate’s, specialization and graduate programs (master’s and doctorate degrees). Colleges have minimum requirements with regard to the qualification of faculty members and their labor practices, and cannot establish new campuses, courses, or spots without prior authorization from MEC; · University Centers: university centers are public or private education institutions offering several bachelor’s, associate’s and graduate programs, and are expected to provide appropriate work conditions, education and qualification opportunities for their professors. To be considered a university center, the institution shall comply with such requirements: (i) at least one-fifth of the faculty members of a university center must hold a master’s or doctorate degree; (ii) at least 20% of the faculty members must work on a full-time basis; (iii) at least eight undergraduate courses shall be recognized and have obtained a satisfactory concept in the on-site external evaluation carried out by INEP; (iv) have an institutionalized extension program in the areas of knowledge covered by their undergraduate courses; (v) have a scientific initiation program with a project supervised by doctoral or masters professors, which may include programs of professional or technological initiation and initiation to teaching; (vi) have obtained an Institutional Concept, or CI, greater than or equal to four in the on-site external evaluation performed by INEP; and (vii) have not been penalized as a result of an administrative supervision process in the last two years; or · Universities: universities are public or private education institutions offering several post-secondary programs, continuing education and research development. Like University Centers, certain requirements for university re-accreditation must be observed, namely: (i) one-third of the academic staff is hired on a full-time basis; (ii) one-third of the faculty members must have a master’s or doctoral degree; (iii) at least 60.0% of the undergraduate courses shall be recognized and have a satisfactory concept obtained in the evaluation proceedings carried out by INEP; (iv) have an institutionalized extension program in the areas of knowledge covered by their undergraduate courses; (v) have a scientific initiation program with a project supervised by master’s or doctoral professors, which may include programs of professional or technological initiation and initiation to teaching; (vi) have obtained CI greater than or equal to four in the external evaluation carried out by INEP; (vii) regularly offer four master’s degree courses and two PhD courses recognized by MEC; and (viii) have not been penalized as a result of an administrative supervision process in the last two years. 78 Table of Contents The LDB provides that the following powers are granted to universities and university centers in the exercise of their autonomy, amongst others: (i) to create, organize and discontinue post-secondary education programs on their premises, subject to the applicable regulation; (ii) to establish the curricula for programs, subject to the applicable general guidelines; (iii) to establish plans, programs and projects in connection with scientific research, artistic production and extra-curricular activities; (iv) to establish the number of student offerings available; and (v) to create and change their bylaws in accordance with the applicable general rules, as well as to award degrees, diplomas and other certificates. Distance Learning Distance learning in Brazil is regulated by article 80 of the LDB, by Decrees 9,057 and 9,235, both of 2017, by Ordinances No. 11 and 23, both of 2017, and CNE’s Resolution No. 1, of 2016. Distance learning is defined as the educational method in which didactic and pedagogic processes are conducted through information and communication media and technologies, with students and teachers interacting in educational activities while located in different locations or at different times. Pursuant to the applicable regulations, distance learning is subject to different factors compared to traditional methods, including: (i) reduced transmission costs in commercial channels of sound and audiovisual broadcasting; (ii) concession of channels with exclusive educational purposes; and (iii) minimal time reservation, with no onus on the public authorities, by the concessionaries of commercial channels. Distance learning can be offered at the following levels and as part of the following educational methods: (i) primary and secondary education, as long as it is used only to supplement learning processes or in emergency situations; (ii) education for young people and adults, according to specific legal criteria; (iii) special education, according to specific legal criteria; (iv) professional education, covering technical programs at the secondary level and technological programs at the post-secondary level; and (v) post-secondary education, covering graduate, master’s programs, specializations, and doctorate studies. Undergraduate courses (bachelor’s, licentiate and technological) may be offered using distance learning methods whenever a post-secondary institution is regularly accredited by MEC for this purpose. Pursuant to Decree No. 9,057, 2017, institutional accreditation and reaccreditation, as well as the authorization and recognition of courses and their renewal will be subject to on-site evaluation, with the aim to verify the existence and suitability of the method, infrastructure, technology and personnel that may enable the execution of the activities provided in the Institutional Development Plan or PDI and the Pedagogical Project of the Course, or PPC. HEIs accredited for the offering of post-secondary education in the distance modality that hold autonomy prerogatives (universities and university centers) do not require authorization for operation of the post-secondary course in the distance modality, but shall inform MEC about the offering of the course within 60 days of the date of creation of such course, for the purposes of supervision, evaluation and recognition. Also, accredited HEIs must inform MEC about the creation of distance learning supporting units and the alteration of their addresses. Although distance learning is defined by the absence of direct contact between students and teachers, there are activities that must be conducted on-site, such as tutorials, evaluations, internships, professional practice, laboratory and dissertation defense, which are to be provided in the educational and development projects of the institution and the course. Accordingly, distance learning institutions must provide the necessary infrastructure for the students to conduct those activities, using the headquarters of the education institution or smaller supporting units throughout the country. Distance learning supporting units are no longer subject to on-site evaluation or required to obtain prior authorization from MEC in order to be set up or operated. Pursuant to Ordinance No. 11/2017, such units can be created by a unilateral decision of the institution itself. Distance courses and programs must be projected with the same defined duration for the respective on-site courses. The evaluation of the performance of students for the purposes of promotion, conclusion of the course and obtainment of diplomas and certificates must be conducted through the conclusion of the programmed activities and on-site exams by the accredited HEIs, following procedures and criteria defined in respective PPC. 79 Table of Contents The evaluation of the distance learning courses is performed in a very similar manner as the evaluation of on-site courses. In the event of any irregularity or non-compliance to any of the previously established conditions set by MEC, the competent body may initiate an administrative proceeding that may result in one or more penalties, such as: (i) forfeiture of accreditation or reaccreditation to operate as a distance learning institution; (ii) intervention; (iii) temporary suspension of autonomy prerogatives; (iv) initiate reaccreditation proceedings; (v) reduction of available vacancies within courses; (vi) temporary suspension of new students admissions; and (vii) temporary suspension of courses offered. Diplomas and certificates for distance learning courses and programs from accredited institutions are valid throughout the national territory and institutions are not entitled to set different criteria for diplomas issued for distance learning courses and those issued for on-site courses. Distance learning courses may be offered only by HEIs that hold specific accreditations for this purpose. It is MEC’s responsibility to promote the accreditation acts of post-secondary institutions. To act outside the institution’s local geographic reach, the institution shall require an extraterritorial accreditation to MEC. Distance learning courses or programs require periodic renewal. Also, the accredited institution must initiate the authorized coursework within 24 months from the accreditation, and if the institution does not implement the authorized activities in such time frame, it will be subject to an administrative proceeding that may result in the canceling of the given authorization. Pursuant to Decree No. 9,057/2017, post-secondary courses may be offered in the distance learning modality through a partnership between an accredited distance HEI and another company. In this case, applicable regulations establish that educational activities must be conducted in the facilities of the accredited HEI, which will be responsible before MEC for the regularity of the teaching and learning processes. Accordingly, the HEI must inform MEC of its partnerships, describing their purpose and most relevant aspects, in order for MEC to be able to assess eventual irregularities. In any case, distance learning courses and programs are subject to the evaluation rules of the SINAES in the same manner that on-site courses are. Regulatory Processes of Post-secondary Education Institutions Accreditation of Post-secondary Education Institutions and Authorization and Recognition of Courses A post-secondary education institution is initially accredited as a college. The accreditation as a university or university center is only granted after the institution has operated as a college and met satisfactory quality standards, including positive assessments in the SINAES. In addition, the HEI must fulfill other legal requirements that could vary according to the respective category, such as the requirement that a certain percentage of faculty members meet minimum graduation standards (i.e., a doctorate or master’s degree), and specific types of labor regimes. The application for qualification of a post-secondary education institution must be supported by various documents, including: · Supporting entity: (i) incorporation documents, duly registered with the competent body, evidencing its existence and legal capacity, in accordance with civil legislation; (ii) proof of registration in the National Taxpayer’s Registry or, CNPJ; (iii) certificates of tax and social security compliance; (iv) proof of ownership of assets capable of supporting the education institution; (v) financial statements; and (vi) consent form executed by the supporting entity’s legal representative, vouching for the veracity and regularity of the provided information and the financial capability of the supporting entity; and · Post-secondary education institution: (i) proof of payment of the on-site evaluation fee related to the external evaluation to be performed by INEP; (ii) PDI; (iii) bylaws and internal regulations; (iv) identification and qualification of managers, with a description of their academic and administrative experience; (v) receipt of regularity and availability of the teaching facilities; (vi) plan of accessibility assurance, pursuant to the regulation and followed by a technical report by a competent professional or public body; and (vii) compliance with the legal requirements related to the safety of the building, including having an escape route in case of fire, proved by a specific report issued by the competent public body. 80 Table of Contents In relation to the accreditation process of a new post-secondary educational institution and linked course authorizations, MEC may issue a temporary accreditation act to expedite the operation, pursuant to article 24 of Decree No. 9,235/2017, as long as the supporting entity complies with all the following requirements: · all self-supporting post-secondary education institutions have been reaccredited in the last five years obtaining an average Institutional Score (Conceito Institucional) greater or equal to “4”; · none of its post-secondary education institutions have been subject to administrative penalties by MEC in the last two years; and · the courses to be offered by the new post-secondary institution, which are limited to a maximum of five courses, must already be offered by other institutions supported by the same supporting entity and duly recognized by MEC in the last five years with a Program Score (Conceito de Curso) greater or equal to “4.” Following the initial accreditation as a post-secondary education institution, colleges depend on an authorization issued by MEC to offer post-secondary education courses. Within their autonomy, universities and university centers do not depend on authorization by MEC to create the majority of post-secondary education courses and campuses in the same city as its headquarters, except for medicine, dentistry, psychology, nursery and law courses, which necessarily must be previously authorized by MEC. In any other cases, institutions are required to inform MEC about the programs they offer for purposes of monitoring, evaluation and further recognition. In the authorization for post-secondary on-site courses of the federal education system, the external in loco evaluation can be waived after documentary analysis if the following requirements are met: (i) having an Institutional Score (Conceito Institucional) greater than or equal to “3”; (ii) absence of a supervision process; and (iii) the institution offers other courses in the same area of knowledge which meet the minimum evaluation standards. Requesting authorization for a course must be supported by the following documents, among others: (i) proof of payment of the on-site evaluation fee; (ii) the PPC, outlining the number of students, classes, description of the program and other relevant academic elements, and describing the facilities, technology and staff for the distance learning support units, if applicable; (iii) list of faculty members, together with the relevant agreements entered into with the education institution, together with their respective titles, working hours and work regime; and (iv) proof of availability of the teaching facilities. Universities and university centers may also apply for the accreditation of a campus not located in the same city as its headquarters, provided that it is located in the same state. Such campuses and programs must integrate the same set of universities or university centers and will only enjoy autonomous prerogatives if there is compliance with the same headquarters requirements and if a high quality degree is shown, through an average Institutional Score (Conceito Institucional) greater or equal to “4.” Therefore, even in the case of universities or university centers, prior authorization from MEC is necessary to create any courses on campuses not located in the same city as the university’s headquarters. Once authorization for a given program has been issued, post-secondary education institutions, including university centers and universities, must also file a request for the recognition of the program as a condition for the national validation of the respective diploma. The requirement must be filed with MEC after the midway point of the term established for the completion of the corresponding program and three-quarters completion of such term, and must include the following documents, among others: (i) PPC, including the number of students, schedules and other pertinent academic information, (ii) list of faculty members, listed in the national registry of instructors, and (iii) proof of availability of the teaching facilities. Authorization and recognition of courses, as well as accreditation of post-secondary education institutions must have a limited term and be renewed periodically following the regular evaluation process, currently established according to the evaluation cycles of the SINAES. Our post-secondary education institutions are accredited by MEC and their courses are duly authorized. We also make every effort to comply with all applicable regulations to maintain our institutions and courses compliant with MEC regulations. 81 Table of Contents Modification of Supporting Entity Pursuant to Decree No. 9,235/2017 and Ordinance No. 23/2017, modification of a supporting entity occurs whenever there is a change in the supporting entity or its controlling shareholder, affecting the decision-making process. Although it no longer depends on the approval of MEC, MEC must be informed within 60 days of the consummation of the event for the purposes of updating the registration with MEC. Such notice must be followed by all the legal documents related to the alteration, duly registered and the term of commitment executed by the legal representatives of both the current and new supporting entities. The new supporting entity or controlling shareholder must meet the requirements necessary for the accreditation of a post-secondary education institution, which will be assessed by MEC in the context of the institution’s reaccreditation proceedings. Additionally, the LDB also provides that educational institutions must inform MEC of any change in their bylaws, which must be registered with the competent bodies. The transfer of programs or courses between HEIs is strictly prohibited and may subject the involved entities to penalties such as: (i) suspension of new students’ admission; (ii) suspension of the offering of undergraduate or graduate lato sensu courses; (iii) suspension of the institution’s autonomy to, among others, create new post-secondary courses and establish course curricula, if applicable; (iv) suspension of the license to establish new distance-learning programs; (v) override any ongoing regulatory requests filed by the institution and prohibit the filing of any new regulatory requests; (vi) suspension of the participation in the FIES; (vii) suspension of the participation in PROUNI; and (viii) suspension or restriction to participate in other federal educational programs. Financing Alternatives for Students: Incentive Programs Programs providing public funding to students enrolled in private higher education institutions have been a major public policy to expand access to post-secondary education in Brazil, especially for the low-income segment of the population. The most important programs are the following. University for All Program The University for All Program, or PROUNI is a tax incentive program created through the Provisional Measure No. 213, of September 10, 2004, later converted into Law No. 11,096, of January 13, 2005, that addresses the exemption of certain federal taxes imposed to post-secondary institutions that grant scholarships to low-income students enrolled in undergraduate courses and technology graduate courses. By granting tax incentives to IES, PROUNI has played an important role in inciting the growth and private investment in the post-secondary education sector. Private post-secondary institutions may adhere to PROUNI by the execution of a specific agreement with MEC, valid for 10 years and renewable for the same period. Such agreement must be emended every semester with an additional term establishing the number of scholarships to be offered in each course, unit and class, and what percentage of scholarships shall be granted to indigenous and afro-Brazilians. In order to participate in PROUNI, an educational institution must: · be up to date with its tax obligations; and · comply with the following requirements: (1) offer at least one full-time scholarship to every 10.7 regularly paying students enrolled at the end of the past school year, excluding the full-time scholarships granted through PROUNI or by the institution; or (2) offer one full-time scholarship to every 22 regularly paying students enrolled in traditional and technological graduation courses, provided that it also offers scholarships (50% of the tuition) with a value equal to 8.5% of the paying students’ annual revenue, available to students enrolled in traditional and technological graduation courses at the school year. The ratio between the number of scholarships and the number of regularly paying students must be complied with annually. If the entity does not comply with the ratio during a school year because of the withdrawal of students, the institution must adjust the number of scholarships in a proportionate matter for the subsequent school year. 82 Table of Contents Pursuant to Normative Ruling No. 1,394, of September 12, 2013, issued by the Brazilian Federal Revenue Office, a post-secondary education institution that has adhered to the PROUNI is exempt, totally or partly, from the following taxes for the duration of the adherence period: · Income Tax (“IRPJ”) and Social Contribution on Net Income (“CSLL”), with respect to the net income proportionate to the revenue derived from the Undergraduate Degree Programs and Extension courses; and · Contribution for Social Security Financing (“Cofins”) and Contribution to the Social Integration Plan (“PIS”), with respect to the revenue derived from the traditional and technological graduation courses. In case a post-secondary education institution requires its exclusion from the PROUNI, its tax incentives will be suspended from the date of the solicitation and will not be applicable for the entire period of the basis of calculation. Normative Ruling No. 1,394, of September 12, 2013, introduced new provisions regarding the tax exemptions granted by PROUNI, in particular the form to calculate the extension of the benefits. According to this Normative Ruling, in addition to the tax exemptions obtained by HEI signatories to PROUNI, tax exemptions are calculated based on the Proportion of Effective Occupation of the Scholarships, or POEB, and the exemption related to IRPJ would be calculated without taking into account the additional 10%. According to Article 7, II, amended by Normative Ruling No. 1,417, dated September 6, 2013, the calculation of the exemption also includes the additional 10% of IRPJ, in addition to the CSLL rate. The amount calculated is the amount of the IRPJ and CSLL exemption, respectively, which may be deducted from the IRPJ and CSLL in relation to the totality of our activities. Accordingly, with the issuance of Normative Ruling No. 1,417, of September 6, 2013, the IRPJ and CSLL exemption on our operating income proportionate to the POEB will also include the additional 10% of IRPJ. Moreover, considering that Normative Ruling No. 1,417, dated September 6, 2013, creates a potential limit to the amount of the tax exemption, the application of these new provisions will result in a reduction in value of the tax exemption obtained. Nevertheless, the legality of the provisions introduced by Normative Ruling No. 1,417, of September 6, 2013, is being discussed before the judiciary, with several motions still pending. Other modifications of the fiscal incentive granted by PROUNI were established by Normative Ruling No. 1,476, of July 1, 2014, which also amends the aforementioned Normative Ruling No. 1,417, of September 6, 2013, in order to (i) exclude several amounts from the concept of profit of the holding, which impacts the enjoyment of the exemption related to CSLL and IRPJ; and (ii) exclude the POEB from the applicable calculation, specifically for HEI with terms of adherence to PROUNI signed up to June 26, 2011, which also affects the calculation of the exemption specifically enjoyed for the terms of adhesion celebrated in the period prior to that date. Student Financing Program The Programa de Financiamento Estudantil (Student Financing Program, or FIES), created by Law No. 10,260, of July 12, 2001, is a MEC program to finance students that cannot bear the total costs of their education. FIES has been the most important program for the expansion of access to higher education in Brazil during the last decade, and it is currently responsible for a significant part of the revenues of the majority of private higher education institutions. FIES consists of funding granted by the National Fund for Educational Development, or FNDE to students regularly enrolled in an on-site course of a post-secondary private HEI registered in the FIES that has been positively evaluated by MEC. After a specific selection proceeding, students may be partially or wholly funded by FIES and, in that case, FNDE will be responsible for crediting the corresponding amount due by the student to the private higher education institution. Payments are made with government bonds whose primary purpose is to compensate tax debts from the private higher education institution. In case there are no debts to be compensated, the institution can resell the bonds to the government by means of a specific proceeding that currently occurs on a monthly basis. The frequency of these proceedings could vary according to public financial constraints and the discretion of FNDE. FIES has been substantially reshaped by Law No 13,530, dated December 7, 2017, and currently the program is not as broad as it used to be. According to applicable regulations, in order to enroll students that have been selected by FIES, private higher education institutions are required to contribute to the fund 13% of the amount due by the student to the institution as consideration for the educational services rendered in the first year of studies. This amount is subject to change in the following years and could vary between 10% and 25% of the consideration due, depending on specific circumstances. 83 Table of Contents On March 1, 2024, MEC issued Ordinance No. 167/2024, establishing the Social FIES program. This program reserves at least 50% of FIES vacancies in each selection process for students with a per capita family income of up to half a minimum wage, registered in the Central Registry of Social Programs of the Federal Government (CadÚnico). These eligible students can receive 100% financing for tuition fees at universities, subject to the availability of the FIES budget. National Higher Education Evaluation System The National Higher Education Evaluation System, or SINAES was created by Law No. 10,861 of April 14, 2004, with the purpose of evaluating post-secondary education institutions, undergraduate courses and measuring student academic performance. The main objective of this evaluation system is to assess the quality of education in the country, providing guidelines for MEC to decide upon institutional reaccreditation, recognition and renewal of recognition of courses. Additionally, SINAES is responsible for improving the quality of post-secondary education in Brazil given that MEC can identify deficiencies and establish specific conditions for institutions to remedy their issues and resume their operations. The SINAES is monitored and coordinated by the CONAES and INEP has a very important role in all processes. The results of the evaluation of post-secondary education institutions and their programs are public and represented on a five-level scale as follows: · Level 5 indicates excellent conditions; · Level 4 indicates more than satisfactory conditions; · Levels 3 indicates satisfactory conditions; and · Levels 1 and 2 indicate unsatisfactory conditions. Pursuant to applicable regulations, evaluation processes consist of a preliminary assessment of several conditions relating to the institution and its courses, such as infrastructure, titles of faculty members, work schedule of faculty members and student performance. Every year INEP establishes a method to evaluate those elements and for them to correspond to a number in the five level scale. The preliminary assessment is a complex process based on quality indicators as follows: (a) National Student Performance Examination The National Student Performance Examination, or ENADE, is a test applied to a number of students that are completing courses. It evaluates students’ knowledge regarding the content provided in the curricular guidelines of the respective undergraduate course, their skills and competencies. ENADE’s results are considered in the composition of quality indexes for courses and institutions. (b) Preliminary Course Concept The Preliminary Course Concept, or CPC, is a compound of the ENADE score, the Difference Indicator between Observed and Expected Performance, or IDD, and factors that include teacher titles, the work schedule of faculty staff and infrastructure of the institution. It is an indicator of the state of undergraduate courses in the country. CPC 1 and 2 courses are automatically included in the INEP examiner’s visit schedule for on-site verification of teaching conditions. Courses with a concept equal to or greater than 3 can choose not to receive the visit of the evaluators and, thus, transform the CPC into a permanent concept (the Course Concept). The CPC is released every year for a specific group of courses along with the results of ENADE. 84 Table of Contents (c) General Course Index The General Course Index, or IGC, of the institution summarizes in a single indicator the results of CPC and the evaluation of master’s and doctorate courses of each educational institution. With regard to undergraduate courses, CAPES indexes are used and adapted to the scale according to a methodology provided by INEP, given that they are organized in a different manner. IGC also goes from 1 to 5 and is published by INEP/MEC, after the release of the results of ENADE and CPC. The IGC is a criterion in the accreditation and re-accreditation processes of institutions and also in the authorization process for new courses: institutions with IGCs less than 3, for example, may have their applications for new courses rejected by MEC. Similarly, the indicator is used to guide the expansion of quality education: institutions with good performance are exempted from the authorization of MEC to open courses. (d) Indicator of Difference Between Observed and Expected Performance The Indicator of Difference Between Observed and Expected Performance, or IDD, is aimed at providing a reference of the contribution of the course to the learning of each student. For that purpose, it compares the results of the ENADE with the performance of the same student in the ENEM. The indicator has a scale of 1 to 5. Following preliminary assessments, all institutions are typically subject to an on-site evaluation to confirm the results. However, given the size of the system, MEC gives institutions the option to convert the results of the preliminary assessments into final results and, therefore, forgo on-site evaluations. For institutions that obtain unsatisfactory levels, MEC on-site evaluations are mandatory. Even before the on-site evaluation, MEC is entitled to apply precautionary measures when preliminary assessments of the institution or course are not considered satisfactory, such as: (i) suspension of new enrollments within the respective course or the entire institution; (ii) reduction of vacancies; and (iii) suspension of all regulatory proceedings for institutional reaccreditation, new authorizations, recognitions or renewals of recognitions. Should the level be confirmed as less than three by the on-site evaluation, MEC may propose a term of commitment to the institution, in order for it to correct the unsatisfactory conditions within a specific deadline. Failure to uphold, in full or in part, the conditions established in the term of commitment may result in one or more penalties to be applied by MEC, such as: (i) temporary suspension of the opening of a selection process of graduation courses; (ii) disqualification from the operating authorization of the higher education institution or recognition of courses offered; and (iii) warning, suspension or cancellation of the mandate of the officer responsible for the action not executed, in the case of public HEI. After the on-site evaluations, institutions and courses obtain definitive quality concepts, as follows: (a) Institutional Concept, which is the result of the on-site evaluation of the institution performed by INEP; and (b) Course Concept, which is the result of the on-site evaluation of the course performed by INEP. Accreditation for Graduate programs Lato sensu Post-secondary HEIs accredited for offering undergraduate courses and that have at least one regular undergraduate course or a stricto sensu graduate course can offer lato sensu graduate courses in the subjects in which they are accredited, either on-site or through distance learning. The offering of graduate programs does not require an authorization to operate, even if it is offered by a college. However, it must be notified to MEC, through MEC’s system (e-MEC), within 60 days of the date of creation of such course. The lato sensu graduate courses are aimed at students who hold a diploma in an undergraduate course and satisfy the criteria of the institution that is offering the graduate course. The graduate courses must meet the following requirements: (i) curriculum with a minimum study load of 360 hours; and (ii) a teaching staff composed of at least 50% masters- or doctorate-level graduates of stricto sensu graduate courses. 85 Table of Contents Stricto sensu The authorization and recognition of stricto sensu graduate courses (masters and doctorates) must be evaluated by CAPES, submitted to CNE’s deliberation and approved by MEC. The HEIs can only initiate masters and doctorate courses activities following the publication of the homologation of CNE’s favorable opinion by MEC in the Official Gazette. As part of its analysis, CAPES must consider the general requirements and the specific parameters of the subject area to which each course is linked. The general requirements are: (i) alignment of the proposal with the graduate planning of the institution; (ii) suitability and justification of the proposal for the regional or national development and its economic and social importance; (iii) clarity and consistency of the proposal with detailed information on its objectives, area of concentration, lines of research, curricular structure, discipline and bibliographic references; (iv) clarity of the criteria adopted to select the students, justifications for the profile of the aimed formation and profile of the egress; (v) proof that the teaching staff has academic, didactic, technical and scientific competence and qualifications related to the purpose of the course; (vi) a permanent teaching staff to ensure the regularity and quality of teaching, research and orientation activities; (vii) indication of up to five intellectual productions of each permanent teacher; and (viii) physical and technological infrastructure of teaching and research adequate for the development of the proposed activities. Authorizations of new stricto sensu graduate courses must be requested at specific dates, as defined by CAPES and published in the Official Gazette. The “Mais Médicos” program The “Mais Médicos” Law established the “Mais Médicos” program, an initiative designed to address medical professional shortages in certain municipalities and underserved regions of Brazil and improve healthcare infrastructure and services, implementing short- and long-term measures to improve the Brazilian medical training system in both quantitative and qualitative ways. This law establishes specific regulations for medical courses, including criteria for approving the creation of new courses in Brazil involving the definition of its location, the mandatory contribution to the public health infrastructure according to the specific categories established by Ordinance No. 16/2014 issued by MEC (i.e., training of health professionals, building or reforming of health service structure, purchasing of medical equipment and supplies and study grant to the medical residency program) and also the conditions for public-private partnerships to implement the course. Within the “Mais Médicos” program, supporting entities are no longer able to choose the location of their courses or establish all conditions of supply, which have been transferred to MEC. The proceedings to implement a medical course, therefore, are more bureaucratic and time-consuming. MEC publishes a public auction notice to select municipalities that will receive medical courses. After this selection, it issues another public auction notice with the criteria for private higher institutions to compete for the right to implement courses in the municipalities previously selected. From its creation in 2013 until the date of this annual report, MEC, through SERES, announced three public calls for the selection of proposals for the authorization of medical courses on a national scale, the “Mais Médicos I” program in 2013, the “Mais Médicos II” program in 2018, and the “Mais Médicos III” program in 2023. “Mais Médicos I” and “Mais Médicos II” jointly authorized the opening of 58 new medicine courses and, initially, 4,971 new seats in medical schools, which may be increased by up to 100 seats, each in accordance with the “Mais Médicos” regulation. With the increase in annual offerings through “Mais Médicos,” on April 5, 2018 MEC announced that the government had decided to freeze the new offering of medical school seats for a period of five years, pursuant to Ordinance No. 328/2018. The decision was based on a need to evaluate the impact of opening new medicine courses in Brazil. However, on April 5, 2023, MEC issued Ordinance No. 650/2023, which revoked the suspension under Ordinance No. 328/2018 and set new rules for the opening of new medicine courses. Following the issuance of Ordinance No. 650/23, on October 4, 2023, MEC, through SERES, exercising its legal powers and based on Article 3 of the “Mais Médicos” Law announced the public call for the selection of proposals for the authorization of medical courses on a national scale. The rules for the new “Mais Médicos III” program set forth the criteria for new undergraduate medical school seats. This new program will authorize the opening of up to 5,700 new undergraduate seats, to be distributed across 95 cities with a limit of 60 seats per institution. 86 Table of Contents C. Organizational Structure All of our subsidiaries are incorporated in Brazil. The following is a chart of our current corporate structure as of the date of this annual report: Medcel, IPEMED, PEBMED, Cardiopapers and Além da Medicina were merged into Afya Brazil in 2024 and UNIDOM was merged into Afya Brazil in 2025 and therefore they do not appear in our current corporate structure chart. D. Property, Plant and Equipment As of the date of this annual report, our corporate headquarters are located in Nova Lima, State of Minas Gerais. We also have branches of the headquarters located in Belo Horizonte, State of Minas Gerais, São Paulo, State of São Paulo and Rio de Janeiro, State of Rio de Janeiro. All of the corporate headquarters are under lease agreements. In addition to our corporate headquarters and as of December 31, 2024, we leased almost all of our operational, sales, and administrative facilities. We believe that our facilities are suitable and adequate for our business as presently conducted, however, we periodically review our facility requirements and may acquire new space to meet the needs of our business or consolidate and dispose of facilities that are no longer required.
A. Operating Results Overview We are the leading medical education group in Brazil based on the number of medical school seats, as published by MEC as of December 31, 2024, delivering an end-to-end physician-centric ecosystem that serves and empowers students to be lifelong medi…
A. Operating Results Overview We are the leading medical education group in Brazil based on the number of medical school seats, as published by MEC as of December 31, 2024, delivering an end-to-end physician-centric ecosystem that serves and empowers students to be lifelong medical learners from the moment they join us as medical students through their medical residency preparation, graduation program, and CME. Our innovative methodological approach combines integrated content, interactive learning, and an adaptive experience for lifelong medical learners. Through our educational content and technology-enabled activities, we focus on effective, personalized learning that mirrors one-on-one tutoring. As of December 31, 2024, we had 76,988 enrolled students, compared to 66,034 enrolled students as of December 31, 2023, representing an increase of 16.6% for the period, and compared to 58,200 enrolled students as of December 31, 2022, representing an increase of 13.5% for the period. In 2018, we were also awarded seven new undergraduate campuses in connection with the “Mais Médicos II” program, the largest number awarded to any education group, with a total of 350 new medical school seats. The operation of such campuses is subject to the verification by MEC of the satisfactory implementation by us of all regulatory requirements. As of the date of this annual report, MEC already inspected six of these campuses and already issued the authorization to operate. Accordingly, we plan to expand our network, and expect to open an additional campus starting in 2025, taking our total to 37 campuses in 19 Brazilian states and 3,653 available medical school seats per year. Our Growth Our revenue growth and increased profitability have been driven by: · Maturation of current number of authorized medical school seats — Anticipated and contracted growth visibility until 2030 from new medical school seats awarded to our schools, that are in the process of maturing, and new seats from our awarded campuses in connection with the “Mais Médicos” program and which became operational in 2022; · Expansion of medical residency preparation and graduate programs enrollments — Increase in the number of students adopting our digital platform, as well as partners and students enrolling in our medical graduate courses; · Deepening of relationships across lifelong medical learners base — Cross-selling opportunities such as increasing the number of former undergraduate students subscribing to our medical residency preparation solutions and the number of former undergraduate and/or medical residency preparation students applying to our graduate and CME courses; · M&A — Acquisition or investment in businesses that complement our medical education services offering. In 2024, we acquired Unidom. In 2023, we acquired DelRey and an additional 15% of CCSI, consolidating our ownership of 75% of its total share capital. In 2022, we acquired or invested in three companies, Além da Medicina, CardioPapers, and Glic. In 2021, we acquired or invested in nine companies, UnifipMoc, Unigranrio and Garanhuns, medical schools which increased our medical school seats by more than 37% when compared to December 31, 2020, and iClinic, Medicinae, Medical Harbour, Cliquefarma, Shosp and RX PRO, digital health services companies that strengthened our digital business strategy; and · Synergies extraction — Successful implementation of several measures to improve the profitability of recent acquisitions, such as streamlining fee discounts and scholarship policies, integrating operations with our shared-services center; and aligning newly acquired faculty teams with our career plan. 88 Table of Contents Key Business Metrics We review the following key metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate business plans and make strategic decisions: Contribution of Medicine to total undergraduate programs revenue We believe the metric that best demonstrates our focus on medical education and its relevance to our products and services offering is undergraduate programs revenue from medicine as a percentage of our total undergraduate programs revenue. We have previously presented this metric based on our “historical undergraduate programs combined tuition fees,” which referred to the sum of the total tuition fees charged to undergraduate students, as recorded in the historical operating information of Afya Brazil and the acquired companies, since the consummation of their respective acquisition. Now that all revenue from our Undergrad segment is consolidated in our financial statements, we refer only to undergraduate programs revenue as presented in our financial statements. For the years ended December 31, 2024, 2023 and 2022, undergraduate programs revenue from medicine were 85.9%, 85.5% and 82.7%, respectively, of total undergraduate programs revenue. The following table sets forth the detailed information of our revenue derived from the different programs within our Undergrad segment: 2024 2024 2023 2022 (in US$ millions (1)) (in R$ millions) (except percentages) Medical school programs 401.6 2,487.1 2,147.4 1,699.2 Other undergraduate health sciences programs 37.2 230.4 200.6 209.7 Other undergraduate programs(2) 28.8 178.1 163.0 129.0 Undergrad segment revenue 467.6 2,895.7 2,511.0 2,037.9 % Medicine(3) 85.9% 85.9% 85.5% 83.4% (1) For convenience purposes only, amounts in reais for the year ended December 31, 2024 have been translated to U.S. dollars using an exchange rate of R$6.1923 to US$1.00, the commercial selling rate for U.S. dollars as of December 31, 2024, as reported by the Central Bank. These translations should not be considered representations that any such amounts have been, could have been or could be converted at that or any other exchange rate. (2) Represents all non-health sciences undergraduate programs. (3) Calculated as medical school programs divided by the undergraduate programs revenue. Medical School Regulatory Capacity and Capacity at Maturation Medical school regulatory capacity and capacity at maturation are operating metrics that provide visibility into our medical school enrollments contracted growth given the supply and demand imbalance in the medical school market and the fact that our medical schools have historically operated very close to their regulatory capacity. Accordingly, the gradual increase in our capacity helps explain the increase in our medical school enrollments, which in turn helps explain our medical school enrollments contracted growth. Contracted growth refers only to schools that are in the initial six years of operation. In addition, since the maximum number of medical seats per medical school is set by applicable regulations, the only way to grow our medical school seats, and therefore our number of enrollments, is through acquisitions or starting new medical schools. Medical school regulatory capacity is defined by the number of medical school seats available per year awarded by MEC plus the additional seats associated with PROUNI and FIES, multiplied by the number of years of operations since the seats were awarded, up to the sixth year of operations (maturation). Capacity at maturation represents the maximum number of approved seats at a medical school six years after becoming operational. Our medical schools have a six-year maturation cycle because medical school programs in Brazil are for a duration of six years. A maturation cycle represents the period starting when a medical school commences its operations with a first year medical school class of students which progresses through the required six years as the next classes begin behind it, and ends when the medical school has six school years of medical students and has therefore reached capacity at maturation (i.e., the maximum number of approved seats). 89 Table of Contents For illustration, a medical school that is awarded 100 seats from MEC has the opportunity to add up to 20 additional seats: · 10 more seats by adhering to PROUNI (one seat for every 10.7 seats awarded by MEC); and · 10 more seats by adhering to FIES (10% of the seats awarded by MEC). Illustrative evolution of regulatory capacity per medical school Our medical school regulatory capacity by seats was 3,593, 3,163 and 2,823 seats and our capacity at maturation was 25,870, 22,774 and 20,325, as of December 31, 2024, 2023 and 2022, respectively. Assuming our medical schools continue to operate at full capacity, we estimate reaching a total medical student base of 25,870 students by 2031. Medical School Occupancy Rate The occupancy rate of our medical schools is the ratio of the number of students effectively enrolled divided by the regulatory capacity in a given period. While we believe retention rates are an important measure of quality and customer satisfaction, we believe that occupancy rate is a more meaningful metric as it captures not only our ability to retain students but also to find new students to compensate for eventual dropouts. Our management does not separately measure retention rates to make decisions about our business. The following table sets forth our medical seats occupancy rate as of the dates indicated. As of December 31, 2024 2023 2022 Occupancy rate ~100.0% ~100.0% ~100.0% Non-GAAP Financial Measures This annual report presents our Revenue (ex-Acquisitions), Adjusted EBITDA and Operating Cash Conversion Ratio information for the convenience of investors, which are non-GAAP financial measures. A non-GAAP financial measure is generally defined as one that purports to measure financial performance but excludes or includes amounts that would not be so adjusted in the most comparable GAAP measure. Although Revenue (ex-Acquisitions), Adjusted EBITDA and Operating Cash Conversion Ratio are used by investors and securities analysts in their evaluation of companies, these measures have limitations as analytical tools, and you should not consider them in isolation or as substitutes for the IFRS measures of earnings. Additionally, our calculations of Revenue (ex-Acquisitions), Adjusted EBITDA and Operating Cash Conversion Ratio may be different from the calculations used by other companies, including our competitors in the education services industry, and therefore, our measures may not be comparable to those of other companies. We present Revenue (ex-Acquisitions) because we believe this measure provides investors with a supplemental measure of the financial performance of our operations without the impact of the acquisition occurred in the last financial year, which facilitates comparisons with the previous periods presented considering the organizational structure as of the beginning of the year ended December 31, 2024. We calculate our Revenue (ex-Acquisitions) as revenue less the revenue received by our acquired companies after the date of their acquisition, i.e. for a period of less than 12 months. The comparability of our Revenue (ex-Acquisitions) between periods was impacted by the acquisition of Unidom in 2024 described under “Item 4B Business Overview—Our Recent Acquisitions” above. 90 Table of Contents We present Adjusted EBITDA because we believe this measure provides investors with a supplemental measure of the financial performance of our core operations that facilitates period-to-period comparisons on a consistent basis. We calculate our Adjusted EBITDA as net income plus/minus finance result plus income taxes expense plus depreciation and amortization plus interest received on late payments of monthly tuition fees, minus income share associate, plus share-based compensation expense plus/minus non-recurring expenses. We also present Operating Cash Conversion Ratio because we believe this measure provides investors with a measure of how efficiently we convert our EBITDA into cash. We calculate our Operating Cash Conversion Ratio as the cash flows from operations plus/minus income taxes paid divided by Adjusted EBITDA plus/minus non-recurring expenses. The following tables set forth the Adjusted EBITDA reconciliation to our net income and the Operating Cash Conversion Ratio reconciliation to our cash flow from operations for the years ended December 31, 2024, 2023 and 2022, in each case, our most recent directly comparable financial measures calculated and presented in accordance with IFRS. Reconciliation between Revenue and Revenue (ex-Acquisition) For the Year Ended December 31, 2024 2024 2023 2022 (in US$ millions (1)) (in R$ millions) Revenue 533.6 3,304.3 2,875.9 2,329.1 Acquired companies’ revenue after acquisition 10.3 63.6 - - Revenue (ex-Acquisition)(2) 523.3 3,240.7 2,875.9 2,329.1 (1) For convenience purposes only, amounts in reais for the year ended December 31, 2024 have been translated to U.S. dollars using an exchange rate of R$6.1923 to US$1.00, the commercial selling rate for U.S. dollars as of December 31, 2024, as reported by the Central Bank. These translations should not be considered representations that any such amounts have been, could have been or could be converted at that or any other exchange rate. See “—Exchange Rates” for further information about recent fluctuations in exchange rates. (2) “Ex-Acquisitions” figures account for revenue recorded by our acquired companies in the last financial period presented (i.e., December 31, 2024) after the date of their acquisitions. For the year ended December 31, 2024, “ex-Acquisitions” excludes revenues from Unidom, (July to December 2024) which was acquired on July 1, 2024. For more information See “—Non-GAAP Financial Measures.” 91 Table of Contents Reconciliation between Net Income and Adjusted EBITDA For the Year Ended December 31, 2024 2024 2023 2022 (in US$ millions (1)) (in R$ millions) Net income 104.8 648.9 405.4 392.8 Finance result 56.1 347.5 347.0 247.9 Income taxes expense 4.4 27.5 24.2 35.7 Depreciation and amortization 53.8 333.3 289.5 206.2 Interest received(2) 7.0 43.4 33.5 27.2 Share of income of associate (1.9) (11.7) (9.5) (12.2) Share-based compensation expense 5.2 32.4 31.5 31.3 Non-recurring expenses(3): 5.5 34.4 44.1 33.1 Integration of new companies(4) 4.1 25.7 28.1 24.8 M&A advisory and due diligence(5) 0.6 3.6 12.6 2.5 Gain on tax amnesty(6) — — (16.8) — Expansion projects(7) 0.5 3.0 4.4 3.4 Restructuring expenses(8) 0.3 2.1 12.0 12.4 Mandatory discounts in tuition fees(9) — — 3.8 (9.9) Adjusted EBITDA 235.1 1,455.6 1,165.7 961.9 (1) For convenience purposes only, amounts in reais for the year ended December 31, 2024 have been translated to U.S. dollars using an exchange rate of R$6.1923 to US$1.00, the commercial selling rate for U.S. dollars as of December 31, 2024, as reported by the Central Bank. These translations should not be considered representations that any such amounts have been, could have been or could be converted at that or any other exchange rate. See “—Exchange Rates” for further information about recent fluctuations in exchange rates. (2) Consists of interest received on late payments of monthly tuition fees. (3) We believe these adjustments are appropriate to provide additional information to investors about certain material non-cash or non-recurring items, not directly associated with our core business, that we do not expect to continue at the same level in the future. (4) Consists of expenses related to the integration of recently acquired companies, such as expenses with personnel and third-party consulting firms. (5) Consists of expenses related to professional and consultant fees in connection with due diligence services for our M&A transactions. (6) On August 10, 2023, Unigranrio entered into a tax amnesty program on interest and penalties to settle a tax proceeding with respect to ISS (tax on services) with the municipality of Rio de Janeiro, which resulted in a payment of R$14.9 million to settle the claim. The selling shareholders of Unigranrio agreed to pay R$5.4 million regarding this matter. We had a provision of R$53.3 million and an indemnification asset from the selling shareholders of R$20.0 million (in light of the indemnification clauses as defined at the acquisition of Unigranrio), with respect to such tax proceeding. The difference between the provision, indemnification asset and the actual paid amount was recorded in Other income (expenses), net on the consolidated statement of income and comprehensive income. (7) Consists of expenses related to professional and consultant fees in connection with the opening of new campuses. (8) Consists of expenses related to employee redundancies in connection with the organizational restructuring of our acquired companies. (9) Consists of mandatory discounts in tuition fees granted by state decrees and individual/collective legal proceedings and public civil proceedings due to COVID-19 on-site class restriction, and excludes any recovery of these discounts that were invoiced based on a decision by the Brazilian Supreme Court with respect to this matter that deemed such discounts to be unconstitutional. 92 Table of Contents Reconciliation between Cash Flow from Operations and Operating Cash Conversion Ratio For the Year Ended December 31, 2024 2024 2023 2022 (in US$ millions (1)) (in R$ millions) (except percentages) Net cash flows from operating activities 231.4 1,432.7 1,043.6 843.9 Income taxes paid 3.3 20.5 45.1 33.1 Net cash flows from operating activities, before income taxes paid 234.7 1,453.2 1,088.8 877.0 Adjusted EBITDA 235.1 1,455.6 1,165.7 961.9 Integration of new companies(2) 4.1 25.7 28.1 24.8 M&A advisory and due diligence(3) 0.6 3.6 12.6 2.5 Gain on tax amnesty(4) — — (16.8) — Expansion projects(5) 0.5 3.0 4.4 3.4 Restructuring expenses(6) 0.3 2.1 12.0 12.4 Mandatory discounts in tuition fees(7) — — 3.8 (9.9) Adjusted EBITDA ex. non-recurring expenses 229.5 1,421.3 1,121.6 928.8 Operating Cash Conversion Ratio 102.2% 102.2% 97.1% 94.4% (1) For convenience purposes only, amounts in reais for the year ended December 31, 2024 have been translated to U.S. dollars using an exchange rate of R$6.1923 to US$1.00, the commercial selling rate for U.S. dollars as of December 31, 2024, as reported by the Central Bank. These translations should not be considered representations that any such amounts have been, could have been or could be converted at that or any other exchange rate. See “—Exchange Rates” for further information about recent fluctuations in exchange rates. (2) Consists of expenses related to the integration of recently acquired companies, such as expenses with personnel and third-party consulting firms. (3) Consists of expenses related to professional and consultant fees in connection with due diligence services for our M&A transactions. (4) On August 10, 2023, Unigranrio entered into a tax amnesty program on interest and penalties to settle a tax proceeding with respect to ISS (tax on services) with the municipality of Rio de Janeiro, which resulted in a payment of R$14.9 million to settle the claim. The selling shareholders of Unigranrio agreed to pay R$5.4 million regarding this matter. We had a provision of R$53.3 million and an indemnification asset from the selling shareholders of R$20.0 million (in light of the indemnification clauses as defined at the acquisition of Unigranrio), with respect to such tax proceeding. The difference between the provision, indemnification asset and the actual paid amount was recorded in Other income (expenses), net on the consolidated statement of income and comprehensive income. (5) Consists of expenses related to professional and consultant fees in connection with the opening of new campuses. (6) Consists of expenses related to employee redundancies in connection with the organizational restructuring of our acquired companies. (7) Consists of mandatory discounts in tuition fees granted by state decrees and individual/collective legal proceedings and public civil proceedings due to COVID-19 on-site class restriction, and excludes any recovery of these discounts that were invoiced based on a decision by the Brazilian Supreme Court with respect to this matter that deemed such discounts to be unconstitutional. 93 Table of Contents Operating Data Key Revenue Drivers - Undergrad Segment As of and For the Year Ended December 31, 2024 2023 2022 UNDERGRAD SEGMENT Medical School Approved Seats 3,593 3,163 2,823 Operating Seats 3,543 3,113 2,773 Total Students (end of period) 24,255 21,446 17,968 Average Total Students 23,440 21,154 17,761 Average Total Students (ex-Acquisitions)(1) 22,863 21,154 17,761 Revenue (Total) (in R$ thousands) 2,487,103 2,147,448 1,699,202 Revenue (ex-Acquisitions) (in R$ thousands)(1) 2,427,630 2,147,448 1,699,202 Medical School Net Avg. Ticket (ex-Acquisitions) (R$/month)(1)(2) 8,849 8,460 7,973 Undergraduate Health Science Total Students (end of period) 25,570 21,117 17,967 Average Total Students 25,154 21,365 19,441 Average Total Students (ex-Acquisitions)(1) 24,830 21,365 19,441 Revenue (Total) (in R$ thousands) 230,449 200,613 209,690 Revenue (ex-Acquisitions) (in R$ thousands)(1) 228,879 200,613 209,690 Other Undergraduate Total Students (end of period) 27,163 23,471 22,265 Average Total Students 27,542 24,336 23,376 Average Total Students (ex-Acquisitions)(1) 26,878 24,336 23,376 Revenue (Total)(in R$ thousands) 178,140 162,957 129,008 Revenue (ex-Acquisitions) (in R$ thousands)(1) 175,540 162,957 129,008 Revenue Revenue (Total) (in R$ thousands) 2,895,692 2,511,018 2,037,889 Revenue (ex-Acquisitions) (in R$ thousands)(1) 2,832,049 2,511,018 2,037,889 (1) “Ex-Acquisitions” figures account for revenue recorded by our acquired companies in the last financial period presented (i.e., December 31, 2024) after the date of their acquisitions. For the year ended December 31, 2024, “ex-Acquisitions” excludes revenues from Unidom, (July to December 2024) which was acquired on July 1, 2024. For more information See “—Non-GAAP Financial Measures.” (2) Medical School Net Average Ticket (ex-Acquisitions) is calculated as Revenue (ex-Acquisitions) divided by the Average Total Students (ex-Acquisitions), divided by the number of months in a given period. Key Revenue Drivers — Continuing Education Segment As of and For the Year Ended December 31, 2024 2023 2022 CONTINUING EDUCATION SEGMENT Total Students (end of period) Residency Journey - Business to Physicians B2P (1) 16,381 12,170 19,986 Graduate Journey - Business to Physicians B2P 8,527 7,722 6,058 Other Courses - B2P and Business to Business Offerings 25,613 27,188 17,475 Total Students 50,521 47,080 43,519 Revenue Business to Physician - B2P (in R$ thousands) 237,379 215,504 170,887 Business to Business - B2B (in R$ thousands) 18,060 20,325 12,457 Revenue (Total) (in R$ thousands) 255,438 235,830 183,344 (1) “Content & Technology for Medical Education” which was previously reported in 2023 and 2022 in the Medical Practice Solutions, has been transferred to the Continuing Education segment under “Residency Journey - Business to Physicians B2P.” 94 Table of Contents Key Revenue Drivers — Medical Practice Solutions As of and For the Year Ended December 31, 2024 2023 2022 MEDICAL PRACTICE SOLUTIONS SEGMENT(1) Active Paying Users (end of period) Clinical Decision 161,283 153,541 137,767 Clinical Management 33,735 30,061 25,679 Total Active Paying Users (end of period) 195,018 183,602 163,446 Monthly Active Users (MAU) Total Monthly Active Users (MaU) - Medical Practice Solutions (1)(2) 238,343 247,702 167,286 Revenue (Total) (in R$ thousands) 161,787 140,282 115,446 Revenue - B2P (in R$ thousands) 135,278 119,847 98,244 Revenue - B2B (in R$ thousands) 26,509 20,435 17,202 (1) “Content & Technology for Medical Education” was transferred to the Continuing Education segment. (2) “Monthly Active Users (MaU)” represents the number of unique individuals that consumed digital services content in each one of our products in the last 30 days of a specific period Revenue For the Year Ended December 31, 2024 2024 Ex Acquisitions(1) 2023 % Change % Change Ex Acquisitions(1) (in R$ millions) Revenue (2) Undergrad 2,895.7 2,832.0 2,511.0 15.3% 12.8% Continuing Education 255.4 255.4 235.8 8.3% 8.3% Medical Practice Solutions 161.8 161.8 140.3 15.3% 15.3% Inter-segment eliminations (8.6) (8.6) (11.2) (23.4%) (23.4%) Total 3,304.3 3,240.7 2,875.9 14.9% 12.7% (1) For the year ended December 31, 2024, “ex-Acquisitions” excludes revenues from Unidom, (July to December 2024) which was acquired on July 1, 2024. For more information See “—Non-GAAP Financial Measures.” (2) In 2024, we restructured our reporting segments so that all products and services related to medical education, excluding medical undergraduate courses, are now managed and reported under the Continuing Education segment. Certain entities previously accounted for and reported under “Content and Technology for Medical Education” (Medcel, Além da Medicina, CardioPapers, and Medical Harbour) within the Medical Practice Solutions segment are now accounted for and reported under the Continuing Education segment. Accordingly, the information relating to the year ended December 31, 2023, has been retroactively adjusted for comparison purposes. The comparability of our revenues between periods was impacted by the acquisitions of DelRey in 2023 and Unidom in 2024 described under “Item 4B Business Overview—Our Recent Acquisitions.” 95 Table of Contents Exchange Rates The Brazilian foreign exchange system allows the purchase and sale of foreign currency and the international transfer of reais by any person or legal entity, regardless of the amount, subject to certain regulatory procedures. The real/U.S. dollar exchange rate reported by the Central Bank was R$5.580 per US$1.00 on December 31, 2021, which reflected a 7.3% depreciation in the real against the U.S. dollar during 2021. On December 31, 2022, the exchange rate of the U.S. dollar as reported by the Central Bank was R$5.218 per US$1.00, which reflected a 6.5% appreciation in the real against the U.S. dollar since December 31, 2021. The real/U.S. dollar exchange rate reported by the Central Bank was R$4.8413 per US$1.00 on December 31, 2023, which reflected a 7.2% appreciation in the real against the U.S. dollar during 2023. On December 31, 2024, the exchange rate for the sale of U.S. dollars reported by the Central Bank was R$6.1923 per US$1.00, which reflected a 27.9% depreciation in the real against the U.S. dollar during 2024. As of April 24, 2025, the exchange rate for the sale of U.S. dollars as reported by the Central Bank was R$ 5.6738 per US$1.00, which reflected an appreciation of 8.4% in the real against the U.S. dollar since December 31, 2024. There can be no assurance that the real will not again depreciate or appreciate against the U.S. dollar or other currencies in the future. The Central Bank has intervened occasionally in the foreign exchange market to attempt to control instability in foreign exchange rates. We cannot predict whether the Central Bank or the Brazilian government will continue to allow the real to float freely or will intervene in the exchange rate market by re-implementing a currency band system or otherwise. The real may depreciate or appreciate substantially against the U.S. dollar in the future. Furthermore, Brazilian law provides that, whenever there is a serious imbalance in Brazil’s balance of payments or there are serious reasons to foresee a serious imbalance, temporary restrictions may be imposed on remittances of foreign capital abroad. We cannot assure you that the Brazilian government will not place restrictions on remittances of foreign capital abroad in the future. The following table sets forth, for the periods indicated, the high, low, average and period-end exchange rates for the purchase of U.S. dollars expressed in Brazilian reais per U.S. dollar. The monthly and annual average rates are calculated by using the average of reported exchange rates by the Central Bank on each day during a monthly period and on the last day of each month during an annual period, respectively. Year Period-end Average(1) Low(2) High(3) 2020 5.196 5.158 4.021 5.937 2021 5.580 5.395 4.920 5.839 2022 5.218 5.165 4.618 5.704 2023 4.841 4.995 4.720 5.446 2024 6.192 5.392 4.854 6.199 Source: Central Bank. (1) Represents the average of the exchange rates on the closing of each day during the year. (2) Represents the minimum of the exchange rates on the closing of each day during the year. (3) Represents the maximum of the exchange rates on the closing of each day during the year. Month Period-end Average(1) Low(2) High(3) October 2024 5.7779 5.6241 5.4305 5.7801 November 2024 6.0535 5.8071 5.6624 6.0535 December 2024 6.1923 6.0970 5.9408 6.1991 January 2025 5.8301 6.0218 5.8301 6.2086 February 2025 5.8488 5.7656 5.6979 5.8687 March 2025 5.7422 5.7468 5.6628 5.8346 April 2025 (through April 24, 2025) 5.6738 5.8133 5.6067 6.0605 Source: Central Bank. (1) Represents the average of the exchange rates on the closing of each day during the month. (2) Represents the minimum of the exchange rates on the closing of each day during the month. (3) Represents the maximum of the exchange rates on the closing of each day during the month. 96 Table of Contents Significant Factors Affecting Our Results of Operations We believe that our results of operations and financial performance will be driven by the following trends and factors: Regulatory Environment and “Mais Médicos” Program Our business is significantly influenced by the regulatory environment of the educational industry in Brazil. We are subject to various federal laws and extensive government regulations by MEC, CNE, INEP, FIES and CONAES, among others. In particular, medical education in Brazil is subject to regulations that aim to control the supply of medical school seats across Brazil and their geographic allocation including, but not limited to the “Mais Médicos” Law, which created the “Mais Médicos” program, whose main objectives include addressing the provision of doctors for primary care in municipalities, strengthen health care infrastructure and allocate medical workforce to vulnerable areas. With the increase in annual offerings through “Mais Médicos,” on April 5, 2018, MEC issued Ordinance No. 328/2018, pursuant to which, among other measures, MEC imposed a five-year suspension on the granting of authorizations for the creation of new medical education courses. However, on April 5, 2023, MEC issued Ordinance No. 650/2023, which revoked the suspension under Ordinance No. 328/18 and set new rules for the opening of new medicine courses. In particular, MEC will be required to conduct a public call for new courses, i.e., through the Mais Médicos program pursuant to the “Mais Médicos” Law, and subject any such courses to the prior review by the Interministerial Commission for Health Education Management (Comissão Interministerial de Gestão da Educação na Saúde). On October 4, 2023, the Ministry of Education, through SERES, exercising its legal powers and based on Article 3 of the “Mais Médicos” Law, announced the public call and set the rules, procedures, decision-making standards and the calendar in connection with the fulfillment of medicine course vacancies, this will result in the creation of new medical education courses or medicine course vacancies, which will in turn increase competition. As a result, we may be required to reduce our tuition fees or increase our operating expenses (including our costs per student) in order to retain or attract students or to pursue new market opportunities and reduce our ability to fill all our medical school seats capacity. For further information, see “Item 4. Information on the Company—Business Overview—Regulatory Overview,” “Item 3. Key Information—D. Risk Factors—Certain Risks Relating to Our Business and Industry—The post-secondary education sector is highly regulated, and our failure to comply with existing or future laws and regulations could significantly impact our business,” “Item 3. Key Information—D. Risk Factors—Certain Risks Relating to Our Business and Industry—We are subject to supervision by MEC and, consequently, may suffer sanctions as a result of non-compliance with any regulatory requirements” and “Item 3. Key Information—D. Risk Factors—We face significant competition in each program we offer. If our competition increases or if we fail to compete efficiently, we may lose market share and our profitability may be adversely affected.” Scholarships, Student Financing and Tax Benefits A large number of our students fund their tuition fees through financing from FIES. In addition, we participate in the PROUNI scholarship program, and we benefit from tax benefits in return. For more information on our students enrolled in these programs, see “Item 4. Information on the Company—Business Overview—Regulatory Overview—Financing Alternatives for Students: Incentive Programs—University for All Program” “Regulatory Overview—Financing Alternatives for Students: Incentive Programs—Student Financing Program (FIES),” “Item 3. Key Information—D. Risk Factors—Certain Risks Relating to Our Business and Industry—Changes to the rules or delays or suspension of tuition payments made through FIES may adversely affect our cash flows and our business,” and “Item 3. Key Information—D. Risk Factors—Certain Risks Relating to Our Business and Industry—If we lose the benefits of federal tax exemptions provided under the PROUNI program, our business, financial condition and results of operations may be materially adversely affected.” In addition to PROUNI and FIES, Afya participates in private financing programs through external partners (Bradesco, BNB, Sicoob, CashMe and Alume) for undergraduate students. Moreover, in 2024 Afya launched its own financing program for some of its units to support medical students who were not eligible for other types of financing. 97 Table of Contents Brazilian Macroeconomic Environment All of our operations are located in Brazil. As a result, our revenues and profitability are affected by political and economic developments in Brazil and the effect that these factors have on the availability of credit, disposable income, employment rates and average wages in Brazil. Our operations, and the industry in general, may be affected changes in economic conditions. Brazil is the largest economy in Latin America, as measured by gross domestic product, or GDP. The following table shows data for real GDP, inflation and interest rates in Brazil and the U.S. dollar/real exchange rate at the dates and for the periods indicated. For the Year Ended December 31, 2024 2023 2022 Real growth (contraction) in gross domestic product 3.4% 2.9% 2.9% Inflation (IGP-M)(1) 6.5% (3.2)% 5.5% Inflation (IPCA)(2) 4.8% 4.6% 5.8% Long-term interest rates—TJLP (average)(3) 7.4% 5.7% 7.2% CDI interest rate(4) 12.15% 13.2% 13.7% Period-end exchange rate—reais per US$1.00 6.192 4.841 5.218 Average exchange rate—reais per US$1.00(5) 5.392 4.995 5.165 Appreciation (depreciation) of the real vs. US$ in the period(6) (27.9)% 7.2% 6.5% Unemployment rate(7) 6.2% 7.4% 7.9% Source: FGV, IBGE, Central Bank and Bloomberg. (1) Inflation (IGP-M) is the general market price index measured by the FGV. (2) Inflation (IPCA) is a broad consumer price index measured by the IBGE. (3) TJLP is the Brazilian long-term interest rate (average of monthly rates for the period). (4) The CDI (Certificado de Depósito Interbancário) interest rate is an average of interbank overnight rates in Brazil. (5) Average of the exchange rate on each business day of the year. (6) Comparing the US$ closing selling exchange rate as reported by the Central Bank at the end of the period’s last day with the day immediately prior to the first day of the period discussed. (7) Average unemployment rate for the year as measured by the IBGE. Inflation directly affects our current operating costs and expenses, adjusted by reference to indexes that reflect the inflation rate such as the IGP-M or IPCA, primarily as a result of annual adjustments to faculty member and employee salaries. Historically, inflation has been more than offset by the tuition fees we charge our students. Our financial performance is also marginally tied to fluctuations in interest rates, such as the CDI rate, because such fluctuations affect the value of our financial investments. We are also exposed to fluctuations in interest rates on our accounts payable to selling shareholders and loans and financing which are indexed to the CDI, IPCA and SELIC. Pillar Two Global Minimum Tax On December 27, 2024, Law 15,079/2024 was enacted, establishing the implementation of the OECD Pillar Two global minimum tax in Brazil, effective as of January 1, 2025. Law 15,079/2024 aligns the Brazilian tax legislation to the OECD’s Global Anti-Base Erosion (GloBE) rules by introducing a minimum effective taxation of 15% through an additional Social Contribution tax on Net Profit (Contribuição Social sobre o Lucro Líquido, or “CSLL”). This regulation applies to multinational groups that fall within the scope of the OECD’s GloBE rules, specifically those whose ultimate parent entity reported annual consolidated revenues of at least €750 million in at least two of the four fiscal years immediately preceding the year under review. 98 Table of Contents The rules are designed to ensure that the additional CSLL qualifies as a Qualified Domestic Minimum Top-up Tax (QDMTT) under the OECD Inclusive Framework, subjecting Brazilian entities to a minimum tax rate of 15%. As a result, this new regulation is expected to impact our effective tax rate and may have an adverse effect on our results of operations. Although these rules do not apply to the fiscal year ended December 31, 2024, we are currently assessing their potential effects on our consolidated financial statements. While the financial impact has not yet been quantified, we are taking steps to ensure compliance with the new tax requirements. On March 28, 2025, we filed a writ of mandamus with the Brazilian Federal Courts challenging the enforceability of the newly enacted additional CSLL. The action is grounded on constitutional and statutory arguments, and we are seeking a preliminary injunction in the Federal Court of Appeals of the Sixth Region (TRF6), to prevent the collection of the additional CSLL, which is scheduled to disburse in 2026 with respect to the 2025 fiscal year. Acquisitions We may face significant challenges in the process of integrating the operations of our acquired companies. If we are not able to manage these integrations effectively, our results of operations may be affected. See “Item 3. Key Information—D. Risk Factors—Certain Risks Relating to Our Business and Industry—We may face challenges in identifying and acquiring new medical higher education institutions, which could hinder our strategic and financial goals. Additionally, difficulties in effectively integrating and managing an increasing number of acquisitions may adversely affect our strategic objectives” and “Item 4. Information on the Company—B. Business Overview—Our Recent Acquisitions.” Business Segments Our three operating segments are as follows: · Undergrad, which provides educational services through undergraduate courses related to medicine, other health sciences and other non-health-related undergraduate programs; · Continuing Education, which includes our medical education programs (including preparatory courses for residency and specialization tests, as well as other medical capabilities), medical specializations and graduate courses in medicine, each offered through digital and in-person means; and · Medical Practice Solutions (previously denominated Digital Services), which provides digital solutions (i) to assist physicians with clinical decision, clinical management and doctor-patient relationships and (ii) to assist other healthcare players with access, demand and efficiency for their businesses. Segment information is presented consistently with the internal reports provided to our chief executive officer, who is our chief operating decision maker (CODM) and is responsible for allocating resources, assessing the performance of our operating segments, and making our strategic decisions. No operating segments have been aggregated to form the above reportable operating segments. There is only one geographic region and the results are monitored and evaluated as a single business. In 2024, in connection with a restructuring project occurred across the Continuing Education and Medical Practice Solutions segments, the Pillar 1 entities (Medcel, Além da Medicina, CardioPapers and Medical Harbour), which offer residency preparation programs, specialization test preparation and other medical capabilities, were moved from the Medical Practice Solutions segment into the Continuing Education segment. This strategic project integrated all Continuing Education capabilities into a single structure that will be responsible for services that address physicians education and continuous needs from graduation throughout their careers, while exploring the potential synergies among those operations. 99 Table of Contents This restructuring project took place in 2024 and represents how the segments are monitored internally. Due to changes in operating segments, the segment information as of December 31, 2023 and for the years ended December 31, 2023 and 2022 has been retroactively adjusted for comparison purposes. Description of Principal Line Items Revenue Our revenue consists primarily of tuition fees charged for medical courses. We also generate revenue from tuition fees for other undergraduate and graduate courses, student fees, certain education-related activities, digital education content and subscription of digital services. Cost of services Cost of services includes expenses related to payroll, rent, hospital agreements, utilities and depreciation and amortization. Cost of services amounted to 36.8%, 38.6% and 36.9% of our revenue in the years ended December 31, 2024, 2023 and 2022, respectively. Operating expenses Our operating expenses includes expenses for personnel, general and administrative, management and officer compensation, marketing and other income (expenses), net. Personnel. Personnel expenses consist of wages, overtime, benefits (meal vouchers, transportation vouchers and medical and dental insurance, among others), profit sharing, social contribution and payroll taxes. In Brazil, social contribution and payroll taxes consist of the Brazilian Social Security Institute (Instituto Nacional do Seguro Social) contribution, or INSS, and the Brazilian Unemployment Severance Fund (Fundo de Garantia do Tempo de Serviço) contribution, or FGTS. Selling, general and administrative. Selling, general and administrative expenses mainly consist of: (i) building infrastructure expenses, such as leases and property maintenance; (ii) utilities expenses; (iii) expenses for computer system maintenance and office automation, such as software licenses, as well as for integrated accounting, treasury, financial planning and cost management systems; (iv) sales and marketing expenses; (v) allowance for expected credit losses; and (vi) amounts paid for professional services, such as consultants, auditors and outside counsel. Other income (expenses), net. Other income (expenses), net, consists mainly of miscellaneous income and/or expense items. Finance result Our finance result includes finance income and finance expenses. Our finance income consists mainly of income from interest earned on financial investments and interest received on late payments from students. Our finance expenses consist mainly of interest expenses from accounts payable to selling shareholders, loans and financing, lease liabilities, and banking fees. We also have cash and cash equivalents denominated in U.S. dollars, and accordingly, we have foreign exchange gain or losses from the changes in U.S. dollars against the Brazilian real. Income taxes expenses Income taxes expenses includes current income taxes and social contribution. Consolidated Results of Operations Year Ended December 31, 2024 Compared to the Year Ended December 31, 2023 The following table sets forth our consolidated income statement data for the years ended December 31, 2024 and 2023: 100 Table of Contents For the Year Ended December 31, 2024 2023 Change (%) (in R$ millions, except for percentages) Revenue 3,304.3 2,875.9 14.9% Cost of services (1,215.6) (1,109.8) 9.5% Gross profit 2,088.7 1,766.1 18.3% Selling, general and administrative expenses (1,069.3) (1,014.7) 5.4% Other income (expenses), net (7.3) 15.6 n.m. Operating income 1,012.1 767.1 31.9% Finance income 111.3 110.6 0.6% Finance expenses (458.7) (457.6) 0.2% Finance result (347.5) (347.0) 0.1% Share of income of associate 11.7 9.5 23.5% Income before income taxes 676.4 429.6 57.4% Income taxes expenses (27.5) (24.2) 0.1% Net income 648.9 405.4 60.1% n.m. = not meaningful Revenue Revenue for the year ended December 31, 2024 was R$3,304.3 million, an increase of R$428.4 million, or 14.9%, from R$2,875.9 million for the year ended December 31, 2023. The increase in our revenue was primarily affected by the following: · In our Undergrad segment, revenue for the year ended December 31, 2024 was R$2,895.7 million, an increase of 15.3%, or R$384.7 million, from R$2,511.0 million for the year ended December 31, 2023. This increase was primarily attributable to: (i) an increase of 13.8% in our total number of operating seats, from 3,113 seats in 2023 to 3,543 seats in 2024, as a result of the Unidom acquisition; and (ii) increase of 4.6% in the medical school net average ticket, from an average ticket of R$8,460 in 2023 to R$8,849 in 2024; · In our Continuing Education segment, revenue for the year ended December 31, 2024 was R$255.4 million, an increase of 8.3%, or R$19.6 million, from R$235.8 million for the year ended December 31, 2023. This increase was primarily attributable to a 7.3% increase in average total students from 47,080 paying students in 2023 to 50,521 paying students in 2024; and · In our Medical Practice Solutions segment, revenue for the year ended December 31, 2024 was R$161.8 million, an increase of 15.3%, or R$21.5 million, from R$140.3 million for the year ended December 31, 2023. This increase was primarily attributable to an increase of 6.2% in Medical Practice Solutions total active paying users from 183,602 active paying users in 2023 to 195,018 active paying users in 2024, and as a result of price adjustments. Cost of services Cost of services for the year ended December 31, 2024 was R$1,215.6 million, an increase of R$105.8 million, or 9.5%, from R$1,109.8 million for the year ended December 31, 2023. As a percentage of revenue, our cost of services decreased to 36.8% for the year ended December 31, 2024, compared to 38.6% for the year ended December 31, 2023. The increase in our cost of services was primarily affected by the following: · In our Undergrad segment, cost of services for the year ended December 31, 2024 was R$1,086.1 million, an increase of R$88.1 million, or 8.8%, from R$998.0 million for the year ended December 31, 2023. This increase was primarily attributable to: (i) the consolidation of the results of operations for the year ended December 31, 2024 of Unidom in 2024, resulting in an increase of R$16 million in our Undergrad segment’s cost of services; (ii) an increase of R$6.8 million applied to salaries and wages, both related to increase in the number of personnel and yearly readjustment of wages; and (iii) other cost-related effects, such as an increase in costs from hospital and medical agreements and facilities and utilities; 101 Table of Contents · In our Continuing Education segment, cost of services for the year ended December 31, 2024 was R$96.2 million, an increase of R$4.3 million, or 4.6%, from R$91.9 million for the year ended December 31, 2023. This increase was primarily attributable to (i) an increase in costs associated with the opening of new IPEMED units in 2024, and (ii) a general increase in expenses with salaries across our operating units as a result of an increase in the number of personnel and annual readjustment of wages; and · In our Medical Practice Solutions segment, cost of services for the year ended December 31, 2024 was R$41.9 million, an increase of R$10.8 million, or 34.6%, from R$31.1 million for the year ended December 31, 2023. This increase was primarily attributable to an increase in costs with consultancy and third-party services in the amount of R$7.8 million, mostly as a result of the hiring of consultancy services for projects aiming to increase the efficiency of operations of companies in our Medical Practice Solutions segment. Gross profit As a result of the foregoing, gross profit for the year ended December 31, 2024 was R$2,088.7 million, an increase of R$322.6 million, or 18.3%, from R$1,766.1 million for the year ended December 31, 2023. Our gross profit by segment was the following: · In our Undergrad segment, gross profit for the year ended December 31, 2024 was R$1,809.6 million, an increase of R$296.6 million, or 19.6%, from R$1,513.0 million for the year ended December 31, 2023; · In our Continuing Education segment, gross profit for the year ended December 31, 2024 was R$159.3 million, an increase of R$15.3 million, or 10.7%, from R$143.9 million for the year ended December 31, 2023; and · In our Medical Practice Solutions segment, gross profit for the year ended December 31, 2024 was R$119.9 million, an increase of R$10.7 million, or 9.8%, from R$109.1 million for the year ended December 31, 2023. Selling, general and administrative expenses Selling, general and administrative expenses for the year ended December 31, 2024 was R$1,069.3 million, an increase of R$54.6 million, or 5.4%, from R$1,014.7 million for the year ended December 31, 2023. This increase was primarily attributable to: (i) an increase of R$28.5 million in payroll expenses as a result of an increase in the total number of personnel and yearly readjustment of wages, (ii) an increase of R$23.6 million in maintenance expenses, mostly related to periodic conservation procedures on equipment and furniture of educational institutions, and (iii) an increase of R$13.7 million in sales and marketing expenses, mostly related to rebranding efforts, marketing campaigns and advertising expenses, which was partially offset by a reduction of R$16.6 million in consulting fees. Other income (expenses), net Other expense, net for the year ended December 31, 2024 was R$7.3 million, a variation of R$22.9 million from other income, net of R$15.6 million in the year ended December 31, 2023, which was primarily due to the settlement in 2023 of Unigranrio’s tax proceeding in respect to ISS (tax on services) with the municipality of Rio de Janeiro. Operating income For the reasons discussed above, operating income for the year ended December 31, 2024 was R$1,012.1 million, an increase of R$245.0 million, or 31.9%, from R$767.1 million for the year ended December 31, 2023. Finance result Finance result for the year ended December 31, 2024 was a net finance expense of R$347.5 million, compared to a net finance expense of R$347.0 million for the year ended December 31, 2023, for the reasons described below. 102 Table of Contents Finance income. Finance income for the year ended December 31, 2024 was R$111.3 million, remaining stable year over year when compared to R$110.6 million for the year ended December 31, 2023. Finance expenses. Finance expenses for the year ended December 31, 2024 was R$458.7 million, remaining stable year over year when compared to R$457.6 million for the year ended December 31, 2023. Income before income taxes As a result of the foregoing, income before income taxes for the year ended December 31, 2024 was R$676.4 million, an increase of R$246.8 million, or 57.4%, from R$429.6 million for the year ended December 31, 2023. Income taxes expenses Income taxes expenses for the year ended December 31, 2024 was R$27.5 million, remaining stable year over year when compared to R$24.2 million for the year ended December 31, 2023, and the effective tax rate decreased from 5.62% for the year ended December 31, 2023, to 4.10% for the year ended December 31, 2024. This decrease in our effective tax rate was primarily attributable to the effects of: (i) an increase in the amount of PROUNI fiscal incentives received, from R$310.0 million in 2023 to R$379.7 million in 2024. Net income As a result of the foregoing, our net income for the year ended December 31, 2024 was R$648.9 million, an increase of R$243.5 million, or 60.1%, from R$405.4 million for the year ended December 31, 2023. Year Ended December 31, 2023 Compared to the Year Ended December 31, 2022 The following table sets forth our consolidated income statement data for the years ended December 31, 2023 and 2022: For the Year Ended December 31, 2023 2022 Change (%) (in R$ millions, except for percentages) Revenue 2,875.9 2,329.1 23.5% Cost of services (1,109.8) (859.6) 29.1% Gross profit 1,766.1 1,469.5 20.2% Selling, general and administrative expenses (1,014.7) (798.2) 27.1% Other income (expenses), net 15.6 (7.3) n.m. Operating income 767.1 664.1 15.5% Finance income 110.6 102.0 8.4% Finance expenses (457.6) (349.9) 30.8% Finance result (347.0) (247.9) 40.0% Share of income of associate 9.5 12.2 (22.1)% Income before income taxes 429.6 428.4 0.3% Income taxes expenses (24.2) (35.7) (32.2)% Net income 405.4 392.8 3.2% n.m. = not meaningful Revenue Revenue for the year ended December 31, 2023 was R$2,875.9 million, an increase of R$546.8 million, or 23.5%, from R$2,329.1 million for the year ended December 31, 2022. The increase in our revenue was primarily affected by the following: · In our Undergrad segment, revenue for the year ended December 31, 2023 was R$2,511.0 million, an increase of 23.2%, or R$473.1 million, from R$2,037.9 million for the year ended December 31, 2022. This increase was primarily attributable to: (i) an increase of 12.3% in our total number of operating seats, from 2,773 seats in 2022 to 3,113 seats in 2023, as a result of the DelRey acquisition; and (ii) increase of 6.1% in the net average ticket of Medical programs, from an average ticket of R$7,973 in 2022 compared to R$8,460 in 2023; 103 Table of Contents · In our Continuing Education segment, revenue for the year ended December 31, 2023 was R$235.8 million, an increase of 28.6%, or R$52.5 million, from R$183.3 million for the year ended December 31, 2022. This increase was primarily attributable to an 8.2% increase in total students (from 43,519 paying students in 2022 compared to 47,080 paying students in 2023); and · In our Medical Practice Solutions segment, revenue for the year ended December 31, 2023 was R$140.3 million, an increase of 21.5%, or R$24.8 million, from R$115.5 million for the year ended December 31, 2022. This increase was primarily attributable to an increase of 12.3% in Medical Practice Solutions total active paying users (from 163,446 active paying users in 2022 to 183,602 active paying users in 2023). Cost of services Cost of services for the year ended December 31, 2023 was R$1,109.8 million, an increase of R$250.2 million, or 29.1%, from R$859.6 million for the year ended December 31, 2022. As a percentage of revenue, our cost of services increased to 38.6% for the year ended December 31, 2023, compared to 36.9% for the year ended December 31, 2022. The increase in our cost of services was primarily affected by the following: · In our Undergrad segment, cost of services for the year ended December 31, 2023 was R$998.0 million, an increase of R$234.8 million, or 30.8%, from R$763.2 million for the year ended December 31, 2022. This increase was primarily attributable to: (i) the consolidation of the results of operations for the year ended December 31, 2023 of DelRey in 2023, resulting in an increase of R$106.9 million in our Undergrad segment’s cost of services; (ii) an increase of R$57.9 million applied to salaries and wages, both related to increase in the number of personnel and yearly readjustment of wages; and (iii) other cost-related effects, such as an increase in costs from hospital and medical agreements and facilities and utilities; · In our Continuing Education segment, cost of services for the year ended December 31, 2023 was R$91.9 million, an increase of R$14.5 million, or 18.7%, from R$77.4 million for the year ended December 31, 2022. This increase was primarily attributable to (i) an increase in costs associated with the opening of new IPEMED units in 2023, and (ii) a general increase in expenses with salaries across our operating units as a result of an increase in the number of personnel and annual readjustment of wages; and · In our Medical Practice Solutions segment, cost of services for the year ended December 31, 2023 was R$31.1 million, an increase of R$4.5 million, or 16.9%, from R$26.6 million for the year ended December 31, 2022. This increase was primarily attributable to an increase in costs with consultancy and third-party services, mostly as a result of the hiring of consultancy services for projects aiming to increase the efficiency of operations of companies in our Medical Practice Solutions segment. Gross profit As a result of the foregoing, gross profit for the year ended December 31, 2023 was R$1,766.1 million, an increase of R$296,6 million, or 20.2%, from R$1,469.5 million for the year ended December 31, 2022. Our gross profit by segment was the following: · In our Undergrad segment, gross profit for the year ended December 31, 2023 was R$1,513.0 million, an increase of R$238.3 million, or 18.7%, from R$1,274.7 million for the year ended December 31, 2022; · In our Continuing Education segment, gross profit for the year ended December 31, 2023 was R$143.9 million, an increase of R$38.0 million, or 35.9%, from R$105.9 million for the year ended December 31, 2022; and · In our Medical Practice Solutions segment, gross profit for the year ended December 31, 2023 was R$109.1 million, an increase of R$20.2 million, or 22.7%, from R$88.9 million for the year ended December 31, 2022. 104 Table of Contents Selling, general and administrative expenses Selling, general and administrative expenses for the year ended December 31, 2023 was R$1,014.7 million, an increase of R$216.5 million, or 27.1%, from R$798.2 million for the year ended December 31, 2022. This increase was primarily attributable to: (i) the consolidation of the results of operations of DelRey in 2023, resulting in an increase of R$38.3 million in our selling, general and administrative expenses in 2023; (ii) an increase of R$25.9 million in sales and marketing expenses, mostly related to rebranding efforts, marketing campaigns and advertising expenses; (iii) an increase of R$29.4 million in maintenance expenses, mostly related to periodic conservation procedures on equipment and furniture of educational institutions; and (iv) an increase of R$76.5 million in payroll expenses as a result of an in the total number of personnel and yearly readjustment of wages. Other income (expenses), net Other income, net for the year ended December 31, 2023 was R$15.6 million, a variation of R$22.9 million from other expenses, net of R$7.3 million in the year ended December 31, 2022, which was primarily due to the tax amnesty program on interest and penalties entered into by Unigranrio in order to settle a tax proceeding in respect to ISS (city tax on services) with the municipality of Rio de Janeiro. Operating income For the reasons discussed above, operating income for the year ended December 31, 2023 was R$767.1 million, an increase of R$103.1 million, or 15.5%, from R$664.0 million for the year ended December 31, 2022. Finance result Finance result for the year ended December 31, 2023 was a net finance expense of R$347.0 million, compared to a net finance expense of R$247.9 million for the year ended December 31, 2022, for the reasons described below. Finance income Finance income for the year ended December 31, 2023 was R$110.6 million, an increase of R$8.6 million, from R$102.0 million for the year ended December 31, 2022. This increase was primarily attributable to (i) an increase in interest received of R$6.3 million, and (ii) an increase in income from financial investments of R$5.9 million. Finance expenses Finance expenses for the year ended December 31, 2023 was R$457.6 million, an increase of R$107,7 million, from R$349.9 million for the year ended December 31, 2022. This increase was primarily attributable to (i) an increase in interest expenses on lease liabilities of R$12.3 million, as a result of the companies acquired and new lease agreements in the period (including those associated with the acquired company); and (ii) an increase in interest expense of R$85.4 million, mainly as a result of debentures issued in December 2022. Income before income taxes As a result of the foregoing, income before income taxes for the year ended December 31, 2023 was R$429.6 million, an increase of R$1.2 million, or 0.3%, from R$428.4 million for the year ended December 31, 2022. Income taxes expenses Income taxes expenses for the year ended December 31, 2023 was R$24.2 million, a decrease of R$11.5 million, from R$35.7 million for the year ended December 31, 2022, and the effective tax rate decreased from 8.33% for the year ended December 31, 2022, to 5.62% for the year ended December 31, 2023. This decrease in our effective tax rate was primarily attributable to the effects of: (i) an increase in the amount of PROUNI fiscal incentives received, from R$270.1 million in 2022 to R$310.0 million in 2023; and (ii) an increase in our unrecognized deferred tax assets from R$117.4 million in 2022 to R$154.1 million in 2023. 105 Table of Contents Net income As a result of the foregoing, our net income for the year ended December 31, 2023 was R$405.4 million, an increase of R$12.6 million, or 3.2%, from R$392.8 million for the year ended December 31, 2022. Critical Accounting Estimates and Assumptions Our consolidated financial statements are prepared in conformity with IFRS. In preparing our audited consolidated financial statements, we make assumptions, judgments and estimates that can have a significant impact on amounts reported in our consolidated financial statements. We base our assumptions, judgments and estimates on historical experience and various other factors that we believe to be reasonable under the circumstances. Actual results could differ materially from these estimates under different assumptions or conditions. We regularly reevaluate our assumptions, judgments and estimates. Our material accounting policies are described in note 2 and our critical accounting estimates and assumptions are described in note 2.5 to our audited consolidated financial statements included elsewhere in this annual report. Recent Accounting Pronouncements The new and amended standards and interpretations that were applied for the first time in 2024 did not have a significant impact on our consolidated financial statements. We have not adopted new and amended standards and interpretations that are not yet effective. B. Liquidity and Capital Resources As of December 31, 2024, we had R$911.0 million in cash and cash equivalents. We believe that our current available cash and cash equivalents and the cash flows from our operating activities will be sufficient to meet our working capital requirements and capital expenditures in the ordinary course of business for the next 12 months. Future cash needs in the short and long term will be funded by our operating cash flow and from funds raised in the debt or equity capital markets. The following table shows the cash flows for the years ended December 31, 2024, 2023 and 2022: For the Year Ended December 31, 2024 2023 2022 (in R$ millions) Cash Flow Data Net cash flows from operating activities 1,432.7 1,043.6 843.9 Net cash flows used in investing activities (1,091.6) (1,143.0) (591.5) Net cash flows (used in) from financing activities 24.0 (439.9) 92.9 Operating Activities We had net cash flows from operating activities of R$1,432.7 million in 2024, an increase of R$389.1 million, or 37.3%, as compared to R$1,043.6 million in 2023, mainly due to: the acquisition of Unidom in July 2024 which increased our medical school seats approved, which led to an increase in our operating results, partially offset by a reduction of R$40 million in working capital balances and a reduction of R$24.6 million in income taxes paid. Investing Activities We had net cash flows used in investing activities of R$1,091.6 million in 2024, as compared to net cash flows used in investing activities of R$1,143.0 million in 2023 mainly as a result of a decrease of R$187.4 million in the acquisition of subsidiaries, net of cash acquired, from R$815.0 million in 2023 to R$627.6 million in 2024, which was partially offset by an increase of R$128.7 million in cash used in the acquisition of intangibles assets from R$127.0 million in 2023 to R$255.7 million in 2024. Financing Activities We had net cash flows generated in financing activities of R$24.0 million in 2024, as compared to a net cash used from financing activities of R$439.9 million in 2023, mainly as a result of an increase from a new loan granted by the IFC of R$500 million in 2024. The payments of principal and interest of loans and financing and lease liabilities increased R$34.8 million in 2024 compared to 2023. 106 Table of Contents For a discussion of changes in our consolidated cash flows in the year ended December 31, 2023 compared to the year ended December 31, 2022, see our annual report on Form 20-F for the fiscal year ended December 31, 2023, filed with the SEC on April 26, 2024. Liquidity Our management has responsibility for monitoring liquidity risk. In order to achieve the Company’s objective, our management regularly reviews the risk and maintains appropriate reserves, including bank credit facilities with first tier financial institutions. Our management also continuously monitors projected and actual cash flows and the combination of the maturity profiles of the financial assets and liabilities. The main requirements for financial resources used by the Company arise from the need to make payments for suppliers, operating expenses, labor and social obligations, loans and financing and accounts payable to selling shareholders. Our total liquidity, which we calculate as the sum of cash and cash equivalents, increased by 64.7%, from R$553.0 million as of December 31, 2023 to R$911.0 million as of December 31, 2024. Indebtedness As of December 31, 2024, we had outstanding debt, comprised of our loans and financings, in the aggregate amount of R$2,195.2 million. The following table summarizes our loans and financings as of December 31, 2024 and 2023: Financial institution Currency Interest rate Maturity 2024 2023 (in R$ thousands) Banco Itaú Unibanco S.A. Brazilian real CDI + 1.90% p.y. 2025 309,496 412,880 FINEP Brazilian real TJLP p.y. 2027 8,209 11,193 Banco Itaú Unibanco S.A. Brazilian real CDI + 1.75% p.y. 2024 - 21,405 Softbank Brazilian real 6.5% p.y. 2026 845,492 825,957 Debentures Brazilian real CDI + 1.80% p.y. 2028 526,946 529,340 IFC Brazilian real CDI + 1.20% p.y. 2030 505,018 - Total Loans and Financing 2,195,161 1,800,775 Current 363,554 179,252 Non-current 1,831,607 1,621,523 Loans On October 1, 2020 (as amended on September 28, 2022), Afya Brazil entered into a loan with Banco Itaú Unibanco S.A. in the principal amount of R$500.0 million. The loan incurs interest at the CDI rate plus 1.62% per year, through September 28, 2022, and 1.90% per year from September 28, 2022. The loan is repayable in three installments in October 2023, April 2024 and October 2025. The loan is subject to certain obligations including financial covenants. Under the terms of the loan, we are required to maintain our EBITDA at certain levels so that our EBITDA is not reduced by 50% or more year over year during the term of the loan. On July 23, 2019, Medcel entered into a loan of R$16.2 million with Financiadora de Estudos e Projetos (“FINEP”), a governmental agency focused on financing investments on R&D, which has an interest rate based on TJLP (Long term interest rate), and maturity in 2027. The first and second tranches of R$6.7 million and R$4.1 million, respectively, were drawn down in October 2019 and December 2020, respectively, in order to develop the Medical web series and other digital content. There are no financial covenants under this agreement. The total loan balance is guaranteed by a bank warranty. On October 28, 2020, UnifipMoc entered into a loan with Banco Itaú Unibanco S.A. in the amount of R$30.0 million. On June 30, 2021 this agreement was amended and so that interest would be adjusted by the CDI rate plus an interest rate of 1.75% per year. The loan was fully paid in three installments in July 2023, January 2024 and July 2024. On August 7, 2024, Afya Brazil and certain other guarantors party thereto, including Afya Limited, entered into a loan agreement with the International Finance Corporation (IFC) in the principal amount of R$500.0 million. This financing represents IFC’s first sustainability-linked loan based on social targets in the education sector and provides for a potential interest rate reduction as Afya Brazil meets predefined performance targets in selected social key performance indicators ("Sustainability Performance Targets"). The loan incurs interest at the Brazilian CDI rate plus a spread of 1.2% per year, which may be reduced by up to 0.15% if the Sustainability Performance Targets are achieved. The loan is repayable in seven equal semi-annual installments starting in April 2027. The Sustainability Performance Targets are defined based on two key performance indicators (KPIs), each capable of reducing the spread by 0.075% if met. KPI 1 relates to the number of free medical consultations delivered by students, reinforcing Afya Brazil’s commitment to expanding access to healthcare in underserved communities. KPI 2 is linked to the academic quality of Afya Brazil’s medical courses and is measured by the percentage of courses that achieve a quality grade of 4 or 5 in the Brazilian Ministry of Education’s evaluation system. 107 Table of Contents The loan is subject to certain obligations including financial covenants. Under the terms of the loan, we are required to: (i) maintain an Adjusted Net Debt to EBITDA ratio of not more than 3.0x, on a consolidated basis, as of the last day of each quarter until maturity. Adjusted Net Debt for purposes of the agreement means, as of any date of calculation, (a) the aggregate amount of our consolidated financial debt (whether classified as current or not current liabilities), including accounts payable with respect to acquisitions in which the seller finances a portion of the sale price owed by us, excluding, for the avoidance of doubt, lease liabilities and without double counting, any financial debt with affiliates, minus (b) Afya Brazil’s cash and cash equivalents (including earnings thereon) and the aggregate outstanding balance of the Series A perpetual convertible preferred shares calculated on the basis of the most recently quarterly financial statements (ii) ensure that as of June 30th and December 31st of each financial year, the Aggregate EBITDA Amount for the relevant period is at least equal to the 60% of our consolidated EBITDA. Aggregate EBITDA Amount for purposes of the agreement means the sum of (a) Afya Brazil’s unconsolidated EBITDA for the relevant period, plus (b) the unconsolidated EBITDA of each of the guarantors under the agreement, for the relevant period, plus (c) any cash received by Afya Brazil, during the relevant period, as cash dividend (or capital reduction), from any entity other than the guarantors. Debentures On December 16, 2022, Afya Brazil issued 500,000 simple, non-convertible, unsecured debentures in a single series, each with a par value of R$1.00, totaling an aggregate amount of R$500.0 million, in a public distribution with restricted placement efforts in the Brazilian market, under the terms of the Brazilian Securities Commission (Comissão de Valores Mobiliários) Rule No. 476. We expect to use the proceeds of the offering for general corporate purposes, strengthening our cash position, and extending our debt maturity profile. The debentures were issued with a maturity date of January 15, 2028, with the principal to be amortized in two equal installments payable on January 15, 2027 and January 15, 2028, corresponding to the fourth and fifth years of the transaction, respectively. The debentures bear interest at 100% of the CDI rate plus 1.80% per year, payable semi-annually on January 15 and July 15 of each year, until the maturity date. The debentures are subject to certain obligations including financial covenants. Under the terms of the debentures, we are required to maintain a net debt (excluding our Series A perpetual convertible preferred shares and our lease liabilities) to Adjusted EBITDA ratio of below or equal to 3.0x, as of the end of each fiscal year, until the maturity date. Adjusted EBITDA considers, for purposes of this ratio, is calculated as net income plus (i) income taxes expenses, (ii) net financial result (excluding interest expenses on lease liabilities), (iii) depreciation and amortization expenses (excluding right-of-use depreciation expenses), (iv) share-based compensation expenses, (v) share of income of associate, (vi) interest received and (vii) non-recurring expenses. As of December 31, 2024, we were in compliance with all obligations set forth under the terms of the debentures. Series A Perpetual Convertible Shares On April 26, 2021, we issued and sold 150,000 perpetual convertible preferred shares designated as Series A perpetual convertible preferred shares, with a par value of U.S.$0.00005 per share, for US$150.0 million, equivalent to R$821.8 million, on the issuance date. The Series A perpetual convertible preferred shares is a class of equity security that ranks senior to the common shares with respect to dividend rights or rights upon liquidation. Each Series A perpetual convertible preferred share is entitled to a dividend of 6.5% per annum and is convertible, at the holder’s discretion, into our Class A common shares at an initial conversion price of US$25.35. We may require mandatory conversion of any or all of the Series A perpetual convertible preferred shares at any time on or after the three-year anniversary of the original issuance date if certain conditions set forth in the certificate of designation are met (if for 20 out of 30 consecutive trading days prior, Afya’s stock price is equal or above 150% of the conversion rate). We may also redeem any or all of the Series A perpetual convertible preferred shares for cash, common shares or a combination thereof at its election, at any time on or after the seven-year anniversary of the original issuance date as determined in the certificate of designation at 105% premium. On or after the five-year anniversary of the original issuance date, the holders of the Series A perpetual convertible preferred shares shall have the right to redeem all of the outstanding Series A perpetual convertible preferred shares for cash, our common shares or a combination thereof (at our election, subject to certain conditions) to be determined in the certificate of designation at 105% premium. Upon the occurrence of a change of control, the holders will have the right to redeem their Series A perpetual convertible preferred shares for cash at a price set forth in the certificate of designation. The Series A perpetual convertible preferred shares will be entitled to the same voting rights as the common shares only when converted into common shares. 108 Table of Contents We determined that the Series A perpetual convertible preferred shares should be classified as a financial liability at amortized cost upon their issuance since they are redeemable primarily according to the decision of the holder and there is a contractual obligation to deliver assets (cash, common shares or a combination thereof) that could not be avoided by us in an event of redemption. The financial liability is denominated in Brazilian Reais and thus not subject to foreign exchange changes. In addition, as the entire instrument is classified as a liability, the embedded put option to redeem the Series A perpetual convertible preferred shares for cash is an embedded derivative. The embedded derivative will not be treated separately once the exercise price of the option is closely related to the host contract. For further information on our loans and financing, see note 12.2.1(d) to the audited consolidated financial statements, included elsewhere in this annual report. Share Buyback Program For further information on our share buyback program, see note 15 to the audited consolidated financial statements, included elsewhere in this annual report, Exhibit 2.1, “Description of Securities Registered Under Section 12 of the Exchange Act - Share Repurchases” and “Item 16E. Purchases Of Equity Securities By The Issuer And Affiliated Purchasers.” Tabular Disclosure of Contractual Obligations The following is a summary of our contractual obligations, based on contractual undiscounted amounts, as of December 31, 2024: Payments Due by Period as of December 31, 2024 Total Less than 1 year 1 — 3 years 3 — 5 years More than 5 years (in R$ millions) Trade payables 128.1 128.1 - - - Loans and financing (1) 2,714.3 526.7 1,494.3 617.8 75.5 Lease liabilities 2,115.2 158.7 303.2 293.2 1,360.1 Accounts payable to selling shareholders 828.5 205.3 150.6 99.1 373.5 Total 5,786.1 1,018.8 1,948.1 1,010.1 1,809.1 (1) Loans and financing include the obligations related to our Series A perpetual convertible preferred shares discussed in note 12.2.1(d) to our audited consolidated financial statements included elsewhere in this annual report. Future cash needs in the short and long term will be funded by our operating cash flows and from proceeds raised in the debt or equity capital markets. As of December 31, 2024, we did not have any off-balance sheet arrangements. Principal Capital Expenditures We made capital expenditures (consisting of the purchase of property and equipment and intangible assets) of R$392.6 million, R$218.4 million and, R$318.2 million in 2024, 2023 and 2022, respectively. During these years, our capital expenditures mainly included expenditures related to R$157.2 million regarding the earn-out of Guanambi and UNIMA, due to the expansion of medical school seats, the expansion and maintenance of our campuses and headquarters including leasehold improvements, the implementation of our shared services center, development of new solutions in the Medical Practice Solutions segment and the development of the project that led to the certification of seven new greenfield medical schools as part of the “Mais Médicos II” program. For 2025, we have budgeted capital expenditures of R$267.9 million, mostly to support the growth in our business and operations. We expect to meet our capital expenditure needs for the foreseeable future from our operating cash flow and our existing cash and cash equivalents. Our future capital requirements may be adjusted from time to time as they depend on several factors, including our growth rate, the expansion of our research and development efforts, employee headcount, marketing and sales activities, the introduction of new features to our existing products, the continued market acceptance of our products. 109 Table of Contents C. Research and Development, Patents and Licenses As of December 31, 2024, we owned 285 trademark registrations in Brazil and 5 trademark registrations abroad. We have also filed 9 international trademark applications, covering a total of 7 classes. Out of these, three applications are still under examination — namely, the Afya application in the United States, the BioAtlas applications in the United States and Whitebook application in Mexico. We have a pending registration request for the Afya trademark in the United States. We have registered the BioAtlas (a Medical Harbour product) trademark in the European Union and have a pending registration request in the United States. We have two registered trademarks for Whitebook (a PEBMED product) in Mexico, and in Colombia and one in Portugal, and have a pending registration request in Mexico. Our request to register trademarks in China was rejected on November 22, 2022 by the Chinese Trademark Office of the National Intellectual Property Administration due to similarities with other trademarks and to the logo allegedly representing the content characteristics of the service. As of the date of this annual report, we have 119 pending trademark applications in Brazil and unregistered trademarks that we use to promote our brand, and also own 364 registered domain names in Brazil and 53 registered international domain names, and have registered three software programs in Brazil. See “Item 4. Information on the Company—Technology and Intellectual Property.” D. Trend Information Other than as disclosed elsewhere in this annual report, we are not aware of any other trends, uncertainties, demands, commitments or events for the year ended December 31, 2024 that are reasonably likely to have a material and adverse effect on our revenues, income, profitability, liquidity or capital resources, or that would cause the disclosed financial information to be not necessarily indicative of future results of operations or financial conditions. E. Critical Accounting Estimates Our consolidated financial statements have been prepared in accordance with IFRS, as issued by the IASB. In preparing our audited consolidated financial statements, we make assumptions, judgments and estimates that can have a significant impact on amounts reported in our consolidated financial statements. We base our assumptions, judgments and estimates on historical experience and various other factors that we believe to be reasonable under the circumstances. Actual results could differ materially from these estimates under different assumptions or conditions. We regularly reevaluate our assumptions, judgments and estimates, presenting our critical accounting estimates in note 2.5 of our audited consolidated financial statements included elsewhere in this annual report.